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Abstract
When developing a new drug product for children, it is important to provide safe
and effective medicines whilst minimising the experimental burden where possible.
Extrapolating data from clinical trials in adults or other relevant populations has
the potential to reduce the number or size of clinical trials required to obtain a
licence for a new drug in the paediatric population. The ethical and practical ben-
efits extrapolation can provide, such as speeding up access to medicines, reducing
drug development costs and avoiding replication of existing information, have to
be balanced against potential risks i.e. if extrapolation from adults is incorrectly
deemed to be appropriate, children could be exposed to a harmful or ineffective
treatment. Extrapolation is therefore a challenging but important aspect for future
paediatric medicine development.
The work presented in this thesis is broadly interested in approaches for reducing
the experimental burden in the paediatric population by leveraging external infor-
mation, such as existing adult data or the opinion of clinical experts. The concept
of extrapolation, especially in the context of paediatric clinical trials, is explored
over the thesis, beginning with a literature review of extrapolation methodology
in Chapter 3, particularly aiming to identify potentially relevant methods for per-
forming extrapolations to children.
i
Extrapolation can be a potentially controversial approach to take in drug develop-
ment, so the opinion of experts within a target clinical setting is incredibly valu-
able. Chapters 4 and 5 describe the process and outcome of seeking the opinion of
clinical experts regarding extrapolation in epilepsy drug development. Based on
this expert opinion, an outline for a new drug development paradigm is presented
allowing for simultaneous recruitment of adults and paediatric patients aged 2
years and older, from Phase II onwards.
In order for the extrapolation of efficacy data from adult trials to the paediatric
population to be plausible and appropriate, strong assumptions regarding similar-
ity between these populations are required. One important assumption is whether
adults and children can be said to have similar pharmacokinetic-pharmacodynamic
(PK-PD) relationships. In Chapter 6, an approach is developed to use data from
existing studies of adults and adolescents, along with expert opinion, to quantify
prior uncertainty regarding the similarity of PK-PD relationships in adults and
younger children. A bias-adjusted meta-analysis of existing adult and adolescent
data allows the derivation of prior distributions quantifying our uncertainty about
the extrapolation assumption and calculation of the prior probability that the
extrapolation assumption holds. This approach could be extended to quantify-
ing prior uncertainty in other contexts; here we consider PK-PD relationships in
adults and younger children to provide a clear focus.
Within the paediatric population itself, there may exist distinct age groups with
different PK-PD relationships requiring separate dosing rules to account for phar-
macological differences. Chapter 7 considers model-based approaches to quantify
how parameters of PK-PD models differ over age. Based on this, an approach




I would like to thank Dr. Lisa Hampson and Prof. Thomas Jaki for the invaluable
supervision, advice and encouragement throughout my PhD and for giving me
such a fantastic opportunity. I have learned a great deal from both over the last
four years, not only with what I have found a very interesting PhD topic, but also
generally about research, academia and that I am more capable than I thought!
The work presented in this thesis was funded by two grants: the National Institute
for Health Research (NIHR) grant NIHR-RMOFS-2013-03-05; and the Medical
Research Council (MRC) grant MR/M013510/1. I am thankful for this funding
and all of the hard work Lisa (as PI) and everyone else involved put into those grant
applications. Thanks also to Prof. Anne Whitehead who, along with Jack, gave
me my first research job and convinced me that I could do a PhD at Lancaster.
Lancaster University has given me a great deal over the last decade and I have
achieved much more here than I ever thought I could.
Thanks also to Dr. Graeme Sills, whose clinical input and discussions have been
a huge help, as has the support from Prof. Tony Marson, Dr. Richard Appleton
and all epilepsy experts that have taken time to contribute their knowledge and
experience. Visiting Dr. Bjo¨rn Bornkamp at the Novartis campus in Basel was a
very valuable experience and his support has been a great help. Thanks also to
the useful discussions had with Dr. Linh Van, also of Novartis.
I would also like to thank all of my friends for their support (especially Dr. Amanda
Minter who read over part of this thesis) and my parents for always being there
whenever I need them. Finally, thanks to my wife Lucy for all of her love and
iii
support over the last seven years.
iv
Declaration
I declare that this thesis is my own work and has not been submitted elsewhere




This thesis includes the following four papers:
• I. Wadsworth, L. V. Hampson, and T. Jaki. Extrapolation of efficacy and
other data to support the development of new medicines for children: A
systematic review of methods. Statistical Methods in Medical Research,
2016. Published online ahead of print. DOI: 10.1177/0962280216631359.
• I. Wadsworth, T. Jaki, G. J. Sills, R. Appleton, J. H. Cross, A. G. Marson,
T. Martland, A. McLellan, P. E. Smith, J. M. Pellock, and L. V. Hamp-
son. Clinical drug development in epilepsy revisited: a proposal for a new
paradigm streamlined using extrapolation. CNS Drugs, vol. 30, no. 11, pp.
1011–1017, 2016.
• I. Wadsworth, L. V. Hampson, T. Jaki, G. J. Sills, A. G. Marson, R. Apple-
ton. A quantitative framework to inform extrapolation decisions in children.
Under review
• I. Wadsworth, L. V. Hampson, B. Bornkamp, T. Jaki. Exposure-response
modelling approaches for determining optimal dosing rules in children. Un-
der review
The Statistical Methods in Medical Research paper is reproduced under SAGE’s
Green Open Access policy which allows up to one full article in an unpublished
dissertation or thesis. The CNS Drugs paper is reproduced under Springer’s Open
Choice policy, the paper is published open access under the Creative Commons
vi
Attribution Non-Commercial 4.0 International (CC BY-NC) license. The first two
papers are as similar as possible to their original printed form and are given in
Chapters 3 and 5, respectively. The final two papers are as similar as possible to
the manuscript submission and are given in Chapters 6 and 7, respectively.
vii
Contents
List of Tables xiv
List of Figures xviii
1 Introduction 1
1.1 Decision making in clinical research . . . . . . . . . . . . . . . . . . 1
1.2 Paediatric clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Extrapolation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.4 Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.5 Meta-analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.6 Elicitation of expert opinion . . . . . . . . . . . . . . . . . . . . . . 17
2 Thesis Summary 24
3 Extrapolation of efficacy and other data to support the devel-
opment of new medicines for children: A systematic review of
methods 26
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.4 Thematic analysis of methods for extrapolation . . . . . . . . . . . 34
viii
3.4.1 Bayesian methods . . . . . . . . . . . . . . . . . . . . . . . . 34
3.4.2 Frequentist methods . . . . . . . . . . . . . . . . . . . . . . 46
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4 Background to ‘Clinical drug development in epilepsy revisited’
paper 57
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
4.2 One-day meeting outline . . . . . . . . . . . . . . . . . . . . . . . . 58
5 Clinical drug development in epilepsy revisited: A proposal for a
new paradigm streamlined using extrapolation 60
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.2 Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5.2.1 Are paediatric patients just small adults? . . . . . . . . . . . 62
5.2.2 Are all paediatric patients the same? . . . . . . . . . . . . . 63
5.2.3 If a drug is safe in adults, is it safe in paediatrics? . . . . . . 64
5.2.4 When is it reasonable to use therapies in paediatrics that
are licensed only for adults? . . . . . . . . . . . . . . . . . . 65
5.2.5 Can we extrapolate efficacy data from adjunctive therapy to
monotherapy? . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5.3 An alternative paradigm for developing medicines for focal epilepsies 67
5.3.1 Phase I trials . . . . . . . . . . . . . . . . . . . . . . . . . . 67
5.3.2 Phase IIa and IIb trials . . . . . . . . . . . . . . . . . . . . . 67
5.3.3 Phase III trials . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.3.4 Licensing of treatments . . . . . . . . . . . . . . . . . . . . . 68
5.3.5 Shift in research culture . . . . . . . . . . . . . . . . . . . . 69
ix
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
6 A quantitative framework to inform extrapolation decisions in
children 73
6.1 Chapter background . . . . . . . . . . . . . . . . . . . . . . . . . . 73
6.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
6.3 Using existing data to inform an extrapolation decision . . . . . . . 78
6.3.1 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
6.3.2 Extrapolation criterion . . . . . . . . . . . . . . . . . . . . . 81
6.3.3 Bayesian bias adjusted meta-analytic model for existing data 82
6.3.4 Effective sample size . . . . . . . . . . . . . . . . . . . . . . 85
6.4 Eliciting prior opinion on external biases . . . . . . . . . . . . . . . 87
6.4.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
6.4.2 Rationale for the elicitation scheme . . . . . . . . . . . . . . 88
6.4.3 Elicitation protocol . . . . . . . . . . . . . . . . . . . . . . . 91
6.5 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
6.5.1 Epilepsy application extrapolation criterion . . . . . . . . . 97
6.5.2 Simulating historical PK-PD data in adults and adolescents 98
6.5.3 Meta-analysis of simulated historical PK-PD studies . . . . . 101
6.6 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
6.6.1 Meta-analysis of historical data . . . . . . . . . . . . . . . . 102
6.6.2 ESS of the approximate joint posterior for βA and βI . . . . 102
6.6.3 Prior probability that PK-PD curves are similar in adults
and younger children . . . . . . . . . . . . . . . . . . . . . . 104
6.7 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
x
6.8 Appendix: OpenBUGS code . . . . . . . . . . . . . . . . . . . . . . 113
7 Exposure-response modelling approaches for determining optimal
dosing rules in children 114
7.1 Chapter background . . . . . . . . . . . . . . . . . . . . . . . . . . 114
7.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
7.3 Motivating example . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
7.4 Exposure-Response models . . . . . . . . . . . . . . . . . . . . . . . 118
7.5 Estimating the exposure-response relationship . . . . . . . . . . . . 120
7.5.1 Linear model fit with categorical age covariates . . . . . . . 120
7.5.2 MOB and PALM trees . . . . . . . . . . . . . . . . . . . . . 121
7.5.3 Bayesian penalised B-splines . . . . . . . . . . . . . . . . . . 122
7.6 Dosing recommendations . . . . . . . . . . . . . . . . . . . . . . . . 125
7.6.1 Optimisation criterion . . . . . . . . . . . . . . . . . . . . . 125
7.6.2 Identifying an optimal number of age groups in our dosing
rule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
7.7 Design of the simulation study . . . . . . . . . . . . . . . . . . . . . 127
7.7.1 Evaluating different approaches to modelling the E-R rela-
tionship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
7.7.2 Measuring the accuracy of dosing rules . . . . . . . . . . . . 131
7.8 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
7.9 Extension to Emax model . . . . . . . . . . . . . . . . . . . . . . . 137
7.9.1 Bayesian penalised B-splines . . . . . . . . . . . . . . . . . . 139
7.9.2 Bootstrapped MOB . . . . . . . . . . . . . . . . . . . . . . . 140
7.9.3 Deriving dosing rules . . . . . . . . . . . . . . . . . . . . . . 140
xi
7.10 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
8 Discussion 146
8.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
8.2 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
8.3 Further work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
8.4 Wider application . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
Bibliography 155
Appendices 172
A Supplementary material to accompany Chapter 3. 173
A.1 Systematic review search strategy . . . . . . . . . . . . . . . . . . . 174
A.2 Data extraction form used to record relevant information from ar-
ticles identified by the systematic review . . . . . . . . . . . . . . . 176
A.3 Search strategy for software implementing methods identified by the
systematic review. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
B Online supplementary material to accompany Chapter 6. 183
B.1 Prior elicitation scheme screenshots . . . . . . . . . . . . . . . . . . 184
B.2 Additional plots of the probability of the extrapolation assumption
holding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
B.3 Supplementary tables . . . . . . . . . . . . . . . . . . . . . . . . . . 196
C Online supplementary material to accompany Chapter 7. 210
C.1 Worked example of methods . . . . . . . . . . . . . . . . . . . . . . 211
C.2 Simulation scenarios in detail . . . . . . . . . . . . . . . . . . . . . 217
xii
C.3 Inclusion of additional covariate . . . . . . . . . . . . . . . . . . . . 218
C.4 Supplementary tables . . . . . . . . . . . . . . . . . . . . . . . . . . 223
C.5 Supplementary plot . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
xiii
List of Tables
6.1 Population means of the effects of age (γA) and the interaction be-
tween age and exposure (γI) for adults and adolescents in the six
PK-PD simulation models, with the interpretation of each model.
The population median PD response refers to exp{mY }−110, where
mY =M(Y ) is calculated setting PK-PD model parameters equal
to their population means. . . . . . . . . . . . . . . . . . . . . . . . 99
6.2 Standard deviations for the intercept (σ0) and effects of exposure
(σC), age (σA) and the interaction between age and exposure (σI)
chosen to reflect low, moderate, high and very high levels of between-
trial heterogeneity. . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6.3 Prior distributions placed on unknown model parameters defined in
Section 6.3.3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
B.1 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for the
effects of age and the interaction between age and exposure - Low
between-trial heterogeneity 1 of 2 . . . . . . . . . . . . . . . . . . . 197
B.2 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for the
effects of age and the interaction between age and exposure - Low
between-trial heterogeneity 2 of 2 . . . . . . . . . . . . . . . . . . . 198
xiv
B.3 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for
the effects of age and the interaction between age and exposure -
Moderate between-trial heterogeneity 1 of 2 . . . . . . . . . . . . . 199
B.4 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for
the effects of age and the interaction between age and exposure -
Moderate between-trial heterogeneity 2 of 2 . . . . . . . . . . . . . 200
B.5 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for the
effects of age and the interaction between age and exposure - High
between-trial heterogeneity 1 of 2 . . . . . . . . . . . . . . . . . . . 201
B.6 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for the
effects of age and the interaction between age and exposure - High
between-trial heterogeneity 2 of 2 . . . . . . . . . . . . . . . . . . . 202
B.7 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for the
effects of age and the interaction between age and exposure - Very
high between-trial heterogeneity 1 of 2 . . . . . . . . . . . . . . . . 203
B.8 Means, empirical standard deviations and mean squared error over
the 1000 replications of each scenario’s meta-analysis results for the
effects of age and the interaction between age and exposure - Very
high between-trial heterogeneity 2 of 2 . . . . . . . . . . . . . . . . 204
B.9 Means and empirical standard deviations over the 1000 replications
of each scenario’s probability of the extrapolation assumption hold-
ing - Low between-trial heterogeneity . . . . . . . . . . . . . . . . . 205
xv
B.10 Means and empirical standard deviations over the 1000 replications
of each scenario’s probability of the extrapolation assumption hold-
ing - Moderate between-trial heterogeneity . . . . . . . . . . . . . . 206
B.11 Means and empirical standard deviations over the 1000 replications
of each scenario’s probability of the extrapolation assumption hold-
ing - High between-trial heterogeneity . . . . . . . . . . . . . . . . . 207
B.12 Means and empirical standard deviations over the 1000 replications
of each scenario’s probability of the extrapolation assumption hold-
ing - Very high between-trial heterogeneity . . . . . . . . . . . . . . 208
B.13 Means and empirical standard deviations of the average ESS over
the 1000 replications - Model 1 . . . . . . . . . . . . . . . . . . . . 209
C.1 True E-R model parameter values for age groupings in scenarios 1
to 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
C.2 True E-R model parameter values for age groupings in scenarios 6
to 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
C.3 Average absolute bias, empirical standard deviation (ESD) and em-
pirical mean squared error (EMSE) for the estimated B-spline in-
tercept/slope over age curve, integrated over age for each scenario
considered. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
C.4 Average absolute bias, empirical standard deviation (ESD) and em-
pirical mean squared error (EMSE) for the estimated bootstrapped
PALM intercept/slope over age curve, integrated over age for each
scenario considered. . . . . . . . . . . . . . . . . . . . . . . . . . . . 225
C.5 Average absolute bias, empirical standard deviation (ESD) and em-
pirical mean squared error (EMSE) for the estimated single PALM
tree intercept/slope over age step function curve, integrated over
age for each scenario considered. . . . . . . . . . . . . . . . . . . . . 225
xvi
C.6 Average absolute bias, empirical standard deviation (ESD) and em-
pirical mean squared error (EMSE) for the estimated intercept/slope
over age step function curve based on the categorical covariates
model approach, integrated over age for each scenario considered. . 226
xvii
List of Figures
3.1 Paediatric Study Decision Tree: Image reproduced from Food and
Drug Administration1 . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.2 Flow diagram of systematic review results . . . . . . . . . . . . . . 32
3.3 Plot showing distribution of methods across four main areas . . . . 33
6.1 Extrapolation strategies, assumptions made and required studies,
based on the FDA paediatric decision tree.1 . . . . . . . . . . . . . 76
6.2 (a) Simulated adult and adolescent IPD and lines of best fit. (b)
Elicited modal values of the dose-response relationship in younger
children, captured in expert prior E1, with corresponding 90% cred-
ibility interval. Also plotted are adult and adolescent lines of best
fit obtained from the simulated IPD. . . . . . . . . . . . . . . . . . 96
6.3 Average ESS under bias prior E1 when the true PK-PD relation-
ships in adults and adolescents follows Model 1, with bars of ± 1
standard deviations of the mean . . . . . . . . . . . . . . . . . . . . 103
6.4 Average ESS when the true PK-PD relationships in adults and ado-
lescents follows Model 1 and bias prior E1 has the covariance matrix
scaled by 0.1, 0.25, 0.5, 1, 2, or 10. . . . . . . . . . . . . . . . . . . 104
xviii
6.5 (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of± 1 standard deviations of the mean, when the
true PK-PD relationships in adults and adolescents follows model
S1 (when no differences between PK-PD curves in adults and ado-
lescents). (b) Median PK-PD curves for adults, adolescents
and younger children following model S1, along with lower bounds
of 90% empirical credibility intervals for the median response in
younger children resulting from the expert bias prior E1 when its
variance matrix is unscaled; or scaled by a factor of 0.5 or 2. Cred-
ibility intervals are calculated conditioning on the true values of
the adult and adolescent PK-PD parameters. Similarity bounds at
placebo and the EC90 given by criteria (6.11) and (6.12) are also
shown. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
6.6 (a) Average prior probability that PK-PD relationships in adults
and younger children satisfy criteria (6.11)-(6.12), with bars of ± 1
standard deviations from the mean. The true PK-PD relationships
in adults and adolescents follow model S3. (b) Median PK-PD
curves for adults, adolescents and younger children following model
S3, along with lower bounds of 90% empirical credibility intervals for
the median response in younger children resulting from the expert
bias prior E1 when its variance matrix is unscaled; or scaled by a
factor of 0.5 or 2. Credibility intervals are calculated conditioning
on the true values of the adult and adolescent PK-PD parameters.
Similarity bounds at placebo and the EC90 given by criteria (6.11)
and (6.12) are also shown. . . . . . . . . . . . . . . . . . . . . . . . 108
xix
6.7 (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of± 1 standard deviations of the mean, when the
true PK-PD relationships in adults and adolescents follows model
S4 (when clearly large differences between PK-PD curves in adults
and adolescents). (b) Median PK-PD curves for adults, ado-
lescents and younger children following model S4, along with lower
bounds of 90% empirical credibility intervals for the median re-
sponse in younger children resulting from the expert bias prior E1
when its variance matrix is unscaled; or scaled by a factor of 0.5
or 2. Credibility intervals are calculated conditioning on the true
values of the adult and adolescent PK-PD parameters. Similarity
bounds at placebo and the EC90 given by criteria (6.11) and (6.12)
are also shown. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
7.1 Plot showing how the intercept of the E-R model changes with age
in simulation scenarios 1-11. . . . . . . . . . . . . . . . . . . . . . . 128
7.2 Plot showing how the slope of E-R model changes with age in sim-
ulation scenarios 1-11. . . . . . . . . . . . . . . . . . . . . . . . . . 129
7.3 Integrated absolute bias (blue circles) and integrated empirical SD
(red triangles) for the E-R model intercept. On the horizontal axis,
‘BS’ refers to the Bayesian penalised B-splines approach, ‘Categor-
ical’ the linear model adjusted for a categorical age covariate, and
‘PALM’ and ‘singlePALM’ label the bootstrapped PALM tree ap-
proach and single PALM tree, respectively. . . . . . . . . . . . . . . 133
xx
7.4 Integrated absolute bias (blue circles) and integrated empirical SD
(red triangles) for the slope of the E-R model. On the horizontal
axis, ‘BS’ refers to the Bayesian penalised B-splines approach, ‘Cat-
egorical’ the linear model adjusting for a categorical age covariate,
and ‘PALM’ and ‘singlePALM’ label the bootstrapped PALM tree
approach and single PALM tree, respectively. . . . . . . . . . . . . . 134
7.5 Integrated absolute bias (blue circles) and integrated empirical SD
(red triangles) for the expected response. On the horizontal axis,
‘BS’ refers to the Bayesian penalised B-splines approach, ‘Categor-
ical’ the linear model adjusting for a categorical age covariate, and
‘PALM’ and ‘singlePALM’ label the bootstrapped PALM tree ap-
proach and single PALM tree, respectively. . . . . . . . . . . . . . . 135
7.6 Integrated absolute difference between the target response and true
expected response when children are dosed according to theK group
optimal dosing rule. Results are shown for dosing rules obtained
modelling the E-R relationship using Bayesian penalised B-splines
(solid blue line) and bootstrapped PALM trees (dashed red line). . 136
7.7 Percentage of 1000 simulations in which K∗, the optimal number
of age groups in the dosing rule, takes each value shown. K∗ is
selected according to the algorithm described in Section 7.6.2 for
Bayesian penalised B-spline (blue) and bootstrapped PALM tree
(pink) approaches. The values of K∗ chosen by applying the algo-
rithm in Section 7.6.2 to the true underlying E-R relationships in
each scenario are shown by the yellow bars. . . . . . . . . . . . . . . 137
xxi
7.8 Fitted curves of the relationship between log base-10 transformed
cyclosporine concentrations and PBM proliferation based on fre-
quentist two parameter Emax model fit for each of the four age
groups considered. Fitted curves are the solid lines and the points
are simulated data. . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
7.9 Plots of the Bayesian penalised B-spline and bootstrapped MOB
fits of (a) the Emax parameter and (b) the EC50 parameter. The
median of each parameter, with 2.5th and 97.5th quantiles, over the
1000 simulated bootstrap samples and true parameter values given
by the green dotted lines are also shown. . . . . . . . . . . . . . . . 141
7.10 Fitted relationships between log base-10 transformed cyclosporine
concentrations and PBM proliferation based on parameter estimates
for the four age groups obtained with (a) the Bayesian penalised B-
spline approach and (b) the bootstrapped MOB approach. . . . . . 142
7.11 Plot of the objective function values from the optimisation proce-
dure used to identify age groups for the Bayesian penalised B-splines
approach (blue line) and bootstrapped MOB (red line). . . . . . . . 143
B.1 App screen capture illustrating step 2 of the elicitation scheme. . . 185
B.2 App screen capture illustrating step 3 of the elicitation scheme. . . 186
B.3 App screen capture illustrating step 3 of the elicitation scheme. . . 187
B.4 App screen capture illustrating step 4 of the elicitation scheme. . . 188
B.5 App screen capture illustrating step 4 of the elicitation scheme. . . 189
B.6 App screen capture illustrating step 5 of the elicitation scheme. . . 190
B.7 App screen capture illustrating step 6 of the elicitation scheme. . . 191
B.8 App screen capture illustrating step 6 of the elicitation scheme. . . 192
xxii
B.9 (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of± 1 standard deviations of the mean, when the
true PK-PD relationships in adults and adolescents follows model
S2. (b) Median PK-PD curves for adults, adolescents and younger
children following model S2, along with lower bounds of 90% empir-
ical credibility intervals for the median response in younger children
resulting from the expert bias prior E1 when its variance matrix is
unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are
calculated conditioning on the true values of the adult and ado-
lescent PK-PD parameters. Similarity bounds at placebo and the
EC90 given by criteria (11) and (12) are also shown. . . . . . . . . . 193
B.10 (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of± 1 standard deviations of the mean, when the
true PK-PD relationships in adults and adolescents follows model
S5. (b) Median PK-PD curves for adults, adolescents and younger
children following model S5, along with lower bounds of 90% empir-
ical credibility intervals for the median response in younger children
resulting from the expert bias prior E1 when its variance matrix is
unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are
calculated conditioning on the true values of the adult and ado-
lescent PK-PD parameters. Similarity bounds at placebo and the
EC90 given by criteria (11) and (12) are also shown. . . . . . . . . . 194
xxiii
B.11 (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of± 1 standard deviations of the mean, when the
true PK-PD relationships in adults and adolescents follows model
S6. (b) Median PK-PD curves for adults, adolescents and younger
children following model S6, along with lower bounds of 90% empir-
ical credibility intervals for the median response in younger children
resulting from the expert bias prior E1 when its variance matrix is
unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are
calculated conditioning on the true values of the adult and ado-
lescent PK-PD parameters. Similarity bounds at placebo and the
EC90 given by criteria (11) and (12) are also shown. . . . . . . . . . 195
C.1 Example to demonstrate the structure of a single PALM tree fitted
to simulated data, produced from the ‘partykit’ package.2,3 . . . . . 213
C.2 (a) Plot of the the intercept parameter over age from the boot-
strapped PALM fit to the simulated example data, showing the
median intercept, with 2.5th and 97.5th quantiles, over the 1000
simulated bootstrap samples and true parameter values given by
the green dotted lines. (b) Plot of the the slope parameter over
age from the bootstrapped PALM fit to the simulated example data,
showing the median slope, with 2.5th and 97.5th quantiles, over the
1000 simulated bootstrap samples and true parameter values given
by the green dotted lines. . . . . . . . . . . . . . . . . . . . . . . . . 214
xxiv
C.3 (a) Plot of the the intercept parameter over age from the B-spline
fit to the simulated example data, showing the median intercept
with 2.5th and 97.5th quantiles and true parameter values given by
the green dotted lines. (b) Plot of the the slope parameter over
age from the B-spline fit to the simulated example data, showing the
median slope with 2.5th and 97.5th quantiles and true parameter
values given by the green dotted lines. . . . . . . . . . . . . . . . . 216
C.4 Plots for the supplementary scenario showing (1) the true underly-
ing E-R relationship; (2) how the intercept of the E-R model changes
with age; (3) how the slope of the E-R model changes with age. . . 219
C.5 Directed acyclic graph illustrating the causal relationships between
age, observed/unobserved covariates and response. . . . . . . . . . . 220
C.6 Integrated absolute bias (blue circles) and integrated empirical SD
(red triangles) for (1) E-R model intercept; (2) E-R model slope;
(3) expected response. On the horizontal axis, ‘BS’ refers to the
Bayesian penalised B-splines approach, ‘Categorical’ the linear model
adjusted for a categorical age covariate, and ‘PALM’ and ‘singlePALM’
label the bootstrapped PALM tree approach and single PALM tree,
respectively. Panels display the supplementary scenario with and
without the additional covariate in the analysis model. . . . . . . . 221
C.7 Integrated absolute difference between the target response and true
expected response when children are dosed according to theK group
optimal dosing rule, for the supplementary scenario. Results are
shown for dosing rules obtained modelling the E-R relationship us-
ing Bayesian penalised B-splines (solid blue line) and bootstrapped
PALM trees (dashed red line). . . . . . . . . . . . . . . . . . . . . . 222
xxv
C.8 Percentage of 1000 simulations in which K∗, the optimal number
of age groups in the dosing rule, takes each value shown. K∗ is
selected according to the algorithm described in Section 7.6.2 for
Bayesian penalised B-spline (blue) and bootstrapped PALM tree
(pink) approaches. The values of K∗ chosen by applying the algo-
rithm in Section 7.6.2 to the true underlying E-R relationships in
the supplementary scenario are shown by the yellow bars. . . . . . . 222
C.9 True underlying E-R relationships for scenarios 1 to 5, 7 and 8, as




1.1 Decision making in clinical research
In order for new medicines to be approved for use in humans, evidence must be
accrued demonstrating a medicine’s efficacy, safety and correct dosage before a
decision regarding licencing (and subsequent use in the general population) can be
made. The primary approach to accrue this evidence is to perform clinical trials.
Clinical trials are defined as planned investigations of a treatment in human sub-
jects with the aim of assessing one or more of the following: safety; efficacy; clinical
effects; pharmacokinetics (PK; what effect the body has on an administered drug
i.e. absorption, distribution, metabolism and excretion); pharmacodynamics (PD;
the effect an administered drug has on the body); and adverse reactions.4,5 Clin-
ical research is often separated into phases, with trials in each phase designed to
address specific questions, though for some trials the distinction between phases
may not be as clear and there are different opinions on the exact details of each
phase.6 The ICH E8 guidelines suggest that classifying trials by study objectives
could be preferred and that, ideally, information from small early studies in drug
development should be used to support and plan larger and more definitive stud-
ies.7
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Before clinical research can begin, there is a preclinical phase of testing the treat-
ment in vitro and in vivo on animal subjects which allows for a preliminary as-
sessment of the safety of a treatment for the proposed investigation in humans.7
Early phase clinical research begins with first-in-man Phase I studies which are
designed to address the initial safety, PK and PD of a treatment. These are usually
performed in healthy volunteers, unless the test treatment is likely to be unsafe
for healthy subjects, such as in oncology studies. Phase II studies seek to assess
whether the treatment may be potentially efficacious in a larger group of subjects
with the condition to be treated, providing a threshold to be crossed when moving
to Phase III, though not with enough certainty to provide definitive conclusions.
Additionally, Phase II studies may inform the design of future Phase III studies,
such as the identification of an appropriate dose range. Phase III studies are large
confirmatory studies which aim to confirm whether a treatment can be considered
efficacious and intend to provide adequate evidence in favour of the treatment
being licensed for use. Phase IV studies take place after the treatment has been
approved and marketed and explore the use of the treatment in practice. Safety
is an important aspect and is monitored throughout all phases of clinical research.
Seamless Phase II/III studies aim to combine Phase II and III studies into one
trial consisting of two stages: the first stage focuses on treatment, dose or sub-
group selection; the second stage then aims to definitively compare the selected
treatment/dose/subgroup with control.8,9
Clinical trials are specifically designed such that if a conclusion of a causal treat-
ment effect is claimed there is confidence in the results. One such design choice
is for the clinical trials to be controlled. This is where a separate group of par-
ticipants do not receive the test treatment but instead a placebo or active control
(such as the current standard of care) for comparison to the test treatment. Par-
ticipants may be randomised to test treatment or control in an attempt to remove
bias associated with treatment allocation and to enable causal inferences to be
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made. If participants are not made aware of what treatment they have been as-
signed, then the trial is said to be blinded; this is used in an attempt to reduce
the bias associated with the placebo effect. Researchers may also be blinded from
treatment allocation in order to eliminate the risk of bias from any preferential
care which may arise or blinded from the assessment of outcomes to reduce chance
of bias in estimating treatment effects.10 There are often situations where blind-
ing is not possible, for example where treatment involves physical therapy, surgery
or qualitatively different interventions. The gold standard for clinical trials are
randomised controlled trials (RCT) which allow for causal inferences to be made
regarding the effects of a treatment relative to control.11
Clinical trials are designed in such a way that inferences made regarding a param-
eter, say θ (e.g. a treatment effect), can be considered reliable whilst looking for a
clinically meaningful result. For frequentist studies, they are designed to control
type I and II error rates at chosen levels whilst testing a null hypothesis, H0 (for
example, no treatment effect, θ = 0) against an alternative hypothesis, H1 (e.g.
positive treatment effect exists, θ > 0, or some treatment effect exists, θ 6= 0). The
type I error rate, α, is the probability of rejecting H0 given that it is true. The
type II error rate, β, is the probability of failing to reject H0 when it is in fact false;
the power of a trial is 1− β. When a hypothesis test is performed, a p-value and
confidence interval for the parameter of interest can be calculated. The p-value
is the probability of obtaining a test statistic at least as extreme as the result
observed, under the null hypothesis; that is, how much probability is contained in
the tail(s) of the distribution of the test statistic under H0, beyond the test result
observed. If the alternative hypothesis is only in one direction from H0 (as with
the θ > 0 example above), a one-sided test is performed, otherwise a two-sided test
is performed and both tails of the test statistic distribution must be considered.
When this p-value is less than the significance level of the test, the result of the
hypothesis test is said to be statistically significant. A (1 − α)100% confidence
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interval is defined such that if one were to repeat an experiment according to some
protocol many times, (1−α)100% of the confidence intervals calculated according
to the same method would contain the true value of the parameter of interest.
In contrast to the frequentist approach, in a Bayesian study model parameters are
also considered to be random variables and suitable prior distributions for the pa-
rameters of interest (such as treatment effects) are updated with accumulated data
from the clinical trial using Bayes Theorem to produce posterior distributions for
parameters.12 These posterior distributions can then be used to make probability
statements about the parameters of interest, e.g. the true value of the treatment
effect has a 95% probability of lying between a and b. Such an interval is called a
credibility interval, and has a much more simple interpretation than the frequen-
tist confidence interval. Choice of prior distributions for parameters in a Bayesian
study is an important step. Options include specifying priors as: non-informative
(such as flat priors placing equal weight on all possibilities); vague/diffuse (to pro-
vide minimal information on specific parameters and have little influence on the
posterior); operational (chosen to ensure certain operating characteristics under
different scenarios); or informative (based on existing data or expert opinion). For
informative priors we discuss the use of expert opinion in Section 1.6 and the
paper presented in Chapter 3 provides details of some approaches where prior dis-
tributions are formed from existing data. Many Bayesian models can be complex
and analytically intractable, meaning that explicit evaluation of posterior distri-
butions is not possible and numeric approaches to sample from the posterior must
be taken, for example, using Markov chain Monte Carlo (MCMC) methods. Mod-
ern statistical computing software such as OpenBUGS13 and Stan14 (e.g. using
the ‘RStan’ package15 run through R16) have made analysing complex models in a
Bayesian framework much more simple. OpenBUGS performs Bayesian modelling
using Gibbs sampling,17 whilst RStan uses Hamiltonian Monte Carlo,17 both are
flexible and user-friendly approaches to implementing Bayesian inference.
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When small populations would mean recruiting to both treatment and control
arms would be difficult, existing data may be taken as evidence of the control to
compare to a single arm trial. Eichler et al.18 define a threshold crossing approach
for situations where RCTs are not feasible. Defining the factual as the average
outcome on an experimental treatment and the counterfactual as how patients
would have responded on average if not given the new treatment (i.e. given noth-
ing or another treatment known to be effective), Eichler et al. state that a RCT
is the standard way to assess the factual over the counterfactual. Eichler et al.
propose the following threshold crossing framework: use existing data to decide
on an efficacy threshold that a new single arm trial must successfully cross for the
new treatment to be deemed effective and a futility threshold that if not crossed
would mean the new treatment is deemed ineffective, otherwise if between these
thresholds the treatment would be deemed to be ‘promising’ with either a second
single-arm trial (where success is only possible by exceeding the efficacy threshold)
or a RCT (if feasible) being performed.18
In this thesis, emphasis will be on how to inform the development of medicines for
children.
1.2 Paediatric clinical trials
Paediatric clinical trials are important for the development of safe and effective
medicines for children. However, Bourgeois et al.19 looked at the proportion of
trials, which were performed in children, of drugs intended to treat diseases with
a large burden in the paediatric population between 2006 and 2011 listed on Clin-
icalTrials.gov. The authors found that within the diseases considered, only 12%
of trials were in paediatrics even though 59.9% of the disease burden was in the
paediatric population. An important issue in paediatric trials is the potential
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heterogeneity of the paediatric population.20 Batchelor and Marriott21 state that
anatomical and physiological differences between younger and older children and
adults can create differences for drug PK. Furthermore, there may be age-related
changes in the safety profile and pharmacodynamics of a drug, although Stephen-
son22 states that adults’ and children’s responses to many drugs have much in
common. To capture this heterogeneity, the ICH E11 guideline23 suggests one
possible set of age groupings to categorise paediatric patients: preterm newborn
infants, term newborn infants (0 to 27 days), infants and toddlers (28 days to 23
months), children (2 to 11 years), adolescents (12 to 16/18 years, dependent on
region); though it is emphasised that any classification of the paediatric population
into age categories is somewhat arbitrary and that there is considerable overlap
in terms of physical, cognitive, and psychosocial developmental issues across those
categories suggested.
Within paediatric trials there can be an issue of gaining consent, with parents and
guardians having to give consent on behalf of the child in most cases; in most EU
countries the legal age for independent consent in paediatric clinical trials is 18,
below this often only assent is sought for differing age ranges.24 Clearly, there are
no healthy volunteers in paediatric clinical trials, so trials are always in the pop-
ulation with the condition to be treated. There is also a common perception that
recruitment into paediatric trials will be challenging, with clinicians, parents and
guardians being reluctant to expose children to experimental treatments.25 How-
ever, recent research has shown that there is a willingness from both parents and
practitioners to enter children into trials, so barriers to recruitment are perhaps
not as great as perceived.26 Funding of paediatric trials has also had challenges,
with Bourgeois et al.19 identifying that between 2006 and 2011 the primary fund-
ing sources for trials in the paediatric population were government and nonprofit
organizations.
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In 2006 the EU Paediatric Regulation (EC 1901/2006) came into effect, with the
objective of motivating the development of new medicinal products in children
aged 0 to 17 years, and to ensure that new medicines are appropriately licensed
for use across the paediatric population.27,28 Following this regulation, for all new
medicines an agreed paediatric investigation plan (PIP) is required, with results
of studies as described in the PIP needed for marketing authorisation. PIPs are
defined as prospectively agreed documents stipulating how the development of a
new medicine should proceed in children and outline all of the studies that are
to be conducted, detailing the conditions, indications and age groups concerned.
Proposals for PIPs are submitted to the Paediatric Committee (PDCO) of the
European Medicines Agency (EMA) for consideration; the Paediatric Regulation
states submission should be no later than completion of adult PK studies.27 The
PDCO is responsible for agreeing or refusing the PIP, with positive PIP opinion
(adopted by the PDCO) summarising the binding elements of an agreed develop-
ment plan. In order to get the approval to market a medicine, all applications
must include the results of any studies described in the agreed PIP, unless the
medicine is exempt because of a deferral or waiver.29 Prior to the introduction of
the EU Paediatric Regulation, it has been estimated that at least 50% of drugs
prescribed for children have never been tested in the paediatric population.28,30,31
However, Weda et al.32 concluded that the introduction of the Paediatric Regula-
tion (1901/2006/EC) does not seem to have led to a lower prevalence of off-label
use, where they define off-label use as “intentional use of an authorised product not
covered by the terms of its marketing authorisation”. Based on data from 16 EU
Member States, 32 studies of hospital based paediatric off-label drug prescription
showed a range of 13-69% of investigated drugs being used off-label.32
Hampson et al.33 reviewed 73 PIP opinions to explore strategies that were adopted
to support dose recommendations in the paediatric population and suggested that
there are opportunities for using Bayesian methods to quantify uncertainty regard-
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ing extrapolation assumptions in paediatric medicine development.
1.3 Extrapolation
The European Medicines Agency (EMA) defines extrapolation as:
‘extending information and conclusions available from studies in one
or more subgroups of the patient population (source population(s)),
or in related conditions or with related medicinal products, in order to
make inferences for another subgroup of the population (target popula-
tion), or condition or product, thus reducing the amount of, or general
need for, additional information (types of studies, design modifications,
number of patients required) needed to reach conclusions’.34,35
Examples of extrapolation in practice include extrapolating from historical data to
predict drug effects in contemporary patients, extrapolating from one geographic
region to another to predict clinical benefits, or extrapolating from adults to sup-
port licensing decisions in the paediatric population. In order for extrapolations to
be appropriate, strong assumptions on similarity are required between the source
and target populations; a big challenge is deciding whether and to what extent
extrapolation is appropriate. The US FDA1 and International Council for Har-
monisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
E1123 guidelines outline an algorithmic, assumptions based approach to decid-
ing on the level of extrapolation appropriate in paediatric medicine development
and for determining which data are needed to support paediatric licensing of a
medicine. For a particular treatment and indication, the choice of the level of ex-
trapolation depends on whether it is reasonable to make the following assumptions
between adults and children: similar disease progression; similar response to the
intervention; similar PK-PD relationships; and whether there is a PD response
that can be used to predict efficacy. Depending on which of these assumptions
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are deemed reasonable, extrapolations can range from no extrapolation, through
partial extrapolation, to complete extrapolation. According to Dunne et al.,36 for
each level of extrapolation the evidence required in the paediatric population is as
follows: for no extrapolation a full development programme is required; for partial
extrapolation the evidence needed ranges from a single adequate, well-controlled
trial to confirm efficacy to a PK-PD study to confirm response; for complete ex-
trapolation only PK studies, to establish dosing, and safety studies are needed (in
certain cases only safety data may be needed). Hampson et al.33 describe this
type of extrapolation, where uncertainty regarding extrapolation assumptions is
not accommodated, as ‘deterministic extrapolation’.
An alternative framework for the use of extrapolation in the development of
medicines for paediatrics has more recently been proposed by the EMA.34,35 This
framework supports the use of quantitative methodology to help understand (in
terms of disease, drug pharmacology and clinical response) how relevant existing
source population (e.g. adults) information is to the target paediatric popula-
tion and identify any important assumptions and uncertainties about the relation
between dose, PK, PD and clinical efficacy which should be documented as an ‘ex-
trapolation concept’. Conditional on these assumptions, the question of whether
clinical efficacy can be predicted in the paediatric population, from the source
population, can be assessed and a specific extrapolation plan can be developed
to address any identified gaps in knowledge (and also identify where large confi-
dence exists, to avoid unnecessary duplication of information). This extrapolation
plan would detail any trials and study objectives needed to fill in knowledge gaps
and provide evidence which could validate the extrapolation concept. After any
planned studies, if the extrapolation concept is deemed to be valid, relevant evi-
dence from the source population and evidence generated in the paediatric popu-
lation could contribute to regulatory decision making for marketing authorisation.
In order to mitigate uncertainty and risk in any regulatory decisions made, addi-
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tional post-authorisation data may need to be gathered.35 Such an approach to
extrapolation, where knowledge regarding extrapolation assumptions can be up-
dated and verified, is referred to by Hampson et al.33 as ‘stochastic extrapolation’.
A benefit of extrapolation in the setting of paediatric trials is the potential to
reduce the number and size of studies required to demonstrate efficacy of a new
medicine in children. This is important as it may be difficult to recruit children
into clinical trials, there may not be many children meeting inclusion criteria for
recruitment (e.g. having already been exposed to the drug off-label) and there
may be constraints on the number and type of clinical measurements which can be
taken from children. Additionally, there is a tradeoff between risk and benefit for
testing medicines in children: if a highly effective treatment already exists there
may be a reluctance to expose children to a potentially harmful new treatment;
however, if there is currently an unmet medical need in children, it would be con-
sidered ethical to trial a drug without proven efficacy, even with the potential for
adverse events. Conversely, the consequences of extrapolating when the assump-
tions do not hold could include exposing children to an ineffective medicine or
exposing children to an unacceptably toxic dose.
Examples of extrapolation in practice can be seen in the cases of Zmax (azithromycin
extended-release) for treating Community-Acquired Pneumonia, where use in the
paediatric population (6 months and older) is based on extrapolation of adult
efficacy data with additional safety and PK data in paediatric patients;37 and
oxcarbazepine (an anti epileptic drug), where the efficacy data from trials of ad-
junctive therapy (the test treatment in conjunction with another treatment) were
used to inform the approval of oxcarbazepine as monotherapy.38 In patients with
focal epilepsies, adjunctive therapy data from adults and paediatrics were used to
support the extrapolation of efficacy data from adults on oxcarbazepine monother-
apy to paediatric patients in order to gain FDA approval. However, it should be
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noted that this extrapolation was made with the knowledge that oxcarbazepine
was already approved as monotherapy for paediatric patients in the EU.
1.4 Epilepsy
Much of the work in this thesis will be placed in the context of epilepsy clini-
cal trials as there is a consensus of expert groups that extrapolation of efficacy
from adults to younger children can be appropriate for focal epilepsies. Epilepsy
is defined as “a tendency to suffer recurrent epileptic seizures” and is one of the
most common groups of neurological disorders.39 Epilepsy may occur at any age,
but most commonly starts in childhood and old age.40 There are many types
of epilepsy (called epilepsy syndromes) and many types of seizures. Seizures can
be defined as “a disturbance of movement, feeling or consciousness occasioned by
sudden, inappropriate and excessive electrical discharges in the grey matter of the
brain”.41 Epileptic seizures are usually grouped into either generalised or focal
(also called partial) seizures. A seizure is called a focal seizure if the discharge
remains in one part of the brain; there are a range of possible focal seizures de-
pending on the location of the discharge. Generalised seizures involve all parts
of the brain. A primary generalised seizure involves all parts of the brain at the
seizure’s onset. The discharge of a focal seizure can also lead to a focal seizure
with secondary generalisation, where the focal discharge can spread through the
brain, initiating a generalised seizure discharge.
With regard to focal epilepsies, whilst there is evidence to suggest that differences
between treatment effects in adults and children would be quantitative rather than
qualitative42 there has been some disagreement between expert groups regarding
what age is acceptable to extrapolate from adults down to. French et al.,43 a
group of US experts, suggest 2 years of age could be appropriate, whilst an EMA
paediatric epilepsy experts group meeting44 suggested 4 years of age could be
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acceptable. The FDA recently concluded that extrapolation of efficacy from adult
to paediatric patients aged greater than 4 years of age with focal epilepsies is
acceptable.45
1.5 Meta-analysis
Meta-analytic methods involve quantitatively synthesising evidence across multi-
ple related but independent studies in order to make inference based on a body
of relevant research and potentially allow for an increase in power to detect a
treatment effect over all included studies.46,47 The term ‘meta-analysis’ was first
used by Glass48 to mean “The statistical analysis of a large collection of analysis
results from individual studies for the purpose of integrating the findings”; since
then, more modern meta-analyses do not necessarily rely on a “large collection”
of results, with Davey et al.49 reporting that from 2011 and earlier, 36% of the
22453 meta-analyses listed in the Cochrane Database of Systematic Reviews were
based on two studies, whilst 75% were based on five or fewer studies.
Meta-analyses may synthesise summary measures reported from completed studies
in an aggregate data meta-analysis or make use of the original individual partic-
ipant data (IPD) from each included study. An IPD meta-analysis may be per-
formed in either a one-step or two-step approach, described by Riley et al.50 as
follows. In a one-step approach, the IPD over all studies are fitted together in
one overall model, whilst ensuring that the clustering of each study is handled
appropriately (e.g. by inclusion of study as a factor in the model47). In a two-step
approach, first the IPD in each trial are analysed in an appropriate manner pro-
ducing summary measures for each included study, with the second step being an
aggregate data meta-analysis performed using these aggregate data. Of course, if
the original study results can be exactly reproduced from the IPD in this first step,
an aggregate data meta-analysis using reported summary results and the results
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of a two-step IPD meta-analysis are equivalent. There are many benefits to IPD
meta-analyses such as greater consistency in analysis across studies (inclusion /
exclusion criteria, analysis methodology, summary measures used, consistency in
handling missing data); potential verification of original study results and mod-
elling assumptions; possible long-term follow-up results may be available for in-
clusion; and publication bias can be reduced by inclusion of unpublished studies,
where available.50 The primary disadvantage of IPD meta-analyses is how heavily
resource intensive they can be; expert statistical input will likely be required for
the more advanced meta-analytic methods used, whilst obtaining, understanding
and cleaning each set of IPD can take a considerable amount of time and contact
with original study investigators, with no guarantee that the original data will
always be completely available.50 A disadvantage of any meta-analysis is that if
included studies are not of high quality then any biases contributing from indi-
vidual studies will result in inferior overall results. Though, there are approaches
available for measuring (and adjusting for) the risk of bias in studies to be included
in a meta-analysis.51,52
When performing a meta-analysis there are two ways to model between-study vari-
ability: fixed-effects, where study-specific treatment effects are considered to be
the same across all studies; and random-effects, where study-specific treatment
effects are allowed to be different between studies, allowing for the incorporation
of between-study heterogeneity.47 Focusing on the case of aggregate data for sim-
plicity of presentation, a fixed-effects meta-analysis can be described as follows.
Let the parameter of interest, θ, be the overall population treatment effect and
summary measures Yj, for j = 1, . . . , H trials, be estimates of this treatment effect.
The Yj can be modelled as:
Yj = θ + j,
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where the j’s are random error terms and follow a normal distribution with mean
0 and variance σ2j ; typically the variances σ
2
j are taken to be the estimated variance
of the Yj summary measure, s
2
j = v̂ar(Yj). As such, the Yj can be assumed to be
taken from a distribution:
Yj ∼ N(θ, s2j),
with mean θ;46,47 the Yj and s
2
j are summaries that could be calculated in a two-
step IPD meta-analysis.
For a random-effects meta-analysis, summary measures Yj are taken to be esti-
mates of study-specific treatment effects θj and can be modelled as realisations of
a study-specific distribution:
Yj ∼ N(θj, s2j).
That is, the random-effects model assumes that treatment effects in each study can
be different and that these θj effects are themselves realisations from a population
distribution:
θj ∼ N(θ, τ 2),
with mean θ, the overall treatment effect, and τ 2 which measures the between-
study variance. As such, summary measures Yj can be modelled as:
Yj = θ + ξj + j,
where the j terms are defined as in the fixed-effects approach and model the vari-
ability within study, and the ξj are random error terms which are normally dis-
tributed with mean 0 and variance τ 2 and model the variability between studies.
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The between-trial heterogeneity term τ 2 is often unknown and will be estimated
as part of the random-effects meta-analysis.46,47
Deciding between fixed and random effects meta-analyses can be based on a prior
understanding of the underlying population. For example, if studies included in
the meta-analysis were spaced apart in time, standard of care could have changed
slightly resulting in each study giving a different (though still relevant) estimate of
treatment effect. Alternatively, a test of whether there exists significant between-
study heterogeneity can also be performed. One such approach is to consider
Cochran’s Q statistic, which can be used to test for heterogeneity of study treat-
ment effects.46,53 The Q statistic is found as a weighted sum of squared deviations










is an estimate of the overall treatment effect and the weights,
wj = 1/s
2
j , are the reciprocal of the estimated variances of the Yj summary mea-
sures. Under the null hypothesis of no between-trial heterogeneity this Q statistic
is approximately Chi-square distributed with H − 1 degrees of freedom, so at a
specified significance level a standard hypothesis test can be performed to test
for heterogeneity between trials.46,54 However, Hardy and Thompson54 show that
using Cochran’s Q as a test for heterogeneity has low power, especially when one
study in the meta-analysis contributes a large proportion of the total information
of all studies and do not recommend basing the choice of a fixed or random effects
meta-analysis solely on such tests of heterogeneity, instead suggesting clinical in-
sight may be more relevant.
In cases where there may be several potentially correlated variables to be modelled,
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a multivariate meta-analysis is possible.55 In the bivariate random-effects case the
following illustrates this idea. Summary measures Y1,j and Y2,j are taken to be
estimates of study-specific treatment effects θ1,j and θ2,j, respectively, and can be














where s21,j and s
2
2,j are estimated variances of the Y1,j and Y2,j summary measures
and ρj is the within-study correlation.
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This multivariate meta-analysis allows borrowing of information between the θ1,j
and θ2,j parameters and is used in this thesis in Chapter 6 in a Bayesian framework.
Compared to the frequentist approaches already discussed in this section, Bayesian
methods differ in that the model parameters, such as the between-study variance,
are also considered to be random variables and must be assigned prior distribu-
tions. One benefit of the Bayesian approach is the potential to approximate the
information contained in the existing studies of a meta-analysis as a prior distri-
bution, which could be used for the design or analysis of a future related study,
see for example the meta-analytic predictive priors of Schmidli et al.57 Sutton and
Abrams58 describe several advantages and disadvantages of the Bayesian approach
being used in a meta-analysis. Disadvantages suggested include sensitivity to the
choice of prior distributions, subjectivity involved when using informative priors
and computational complexity, all of which are issues in most Bayesian analyses.
Advantages suggested by Sutton and Abrams58 include the fact that parameter
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uncertainty can be accounted for in the analysis, the potential for easier extension
to more complex models and the ability to incorporate external evidence (including
expert opinion) in informative prior distributions.
1.6 Elicitation of expert opinion
The elicitation of expert prior opinion is the process of constructing a probability
distribution that represents the knowledge and uncertainty extracted from an ex-
pert regarding one or more unknown quantities, such as a probability or treatment
effect. Elicitation of expert opinion can be a useful way to quantify the state of
knowledge about an unknown quantity prior to data collection. For rare diseases
or small populations, where a conventional, well powered frequentist trial may not
be feasible, elicited expert prior distributions can be used in the design and anal-
ysis of a future Bayesian clinical trial to improve the understanding of a treatment.
Based on a thorough review of literature, O’Hagan et al.59 suggest the following
steps to a model for the whole elicitation process: (a) background and preparation,
including identifying quantities of interest and planning the elicitation session; (b)
identifying and recruiting experts; (c) motivating and training experts, includ-
ing explaining probability, probability distributions, common rules and instinctive
processes people use when forming judgments (heuristics, such as anchor-and-
adjustment), possible biases and trialling practice elicitation questions; (d) struc-
turing and decomposition, including considering any dependencies and reviewing
the available evidence base with experts; and (e) the elicitation itself, eliciting spe-
cific summaries from experts, constructing the probability distribution to represent
these summaries, assessing adequacy and having the expert iteratively update if
needed. Of course, many alternate approaches are possible.59 As mentioned in
(c), when people need to provide judgments where uncertainty is involved there
are several simple strategies that are often employed called heuristics.59,60 For
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example, the anchor-and-adjustment heuristic is where a judgment is based on the
adjustment from an initial starting value, called an anchor. This can be an issue
as when making such quantitative judgments, experts often stay too close to the
anchor value and fail to adjust far enough in either direction. It is important to
keep such heuristics in mind when developing elicitation schemes to try to at least
reduce the risk of associated biases.
The aim of prior elicitation is to quantify expert opinion as a useful probabil-
ity distribution, X. When eliciting opinion, the choice of probability distribution
used to quantify expert knowledge will depend on the unknown quantity of inter-
est. For example, opinion on a probability may be appropriately modelled by a
beta distribution, whilst opinion on a continuous variable which can take any real
number could be modelled by a normal distribution. Clearly, if the expert opin-
ion is to be quantified by a continuous distribution, it is impossible to elicit their
opinion for the infinite number of probabilities contained within that distribution.
Instead, several probabilities or specific summary measures of the distribution can
be elicited and the probability distribution can be inferred from these elicited val-
ues.59 Specific summaries of the distribution may include location measures (e.g.
mean, median or mode) and measures of variability (e.g. standard deviation).
However, measures of variability are difficult to elicit directly,59 instead the spread
of the distribution is often inferred by quantiles or credibility intervals, which can
be used to give a value for the desired parameter by taking into consideration the
mathematical properties of the distribution in question.
The bisection method begins by the statistical facilitator eliciting from the expert
the median of X, that is, the value x0.5 such that P (X < x0.5) = 0.5; an expert
may be asked to give a value such that X is equally likely to be less than or greater
than the value given.59 Following this, the expert is then asked to bisect the dis-
tribution above and below the median, i.e. provide quantiles x0.25 and x0.75 such
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that P (X < x0.25) = 0.25 and P (X < x0.75) = 0.75. For a normal distribution
this provides more points along the distribution than the number of parameters,
meaning that unless x0.25 and x0.75 are symmetrical around x0.5, a perfect fit to the
expert’s values will not be possible. The minimum number of questions needing
answers to be elicited is equal to the number of parameters in the chosen probabil-
ity distribution. Eliciting more quantities than the number of parameters means
that it is unlikely a set of parameter values will be found that gives a distribution
matching the elicited opinion exactly, instead the parameters of the distribution
could be chosen in an optimal way; for the normal case, if eliciting more than one
quantile for the measure of variability, the variance parameter could be chosen to
minimise the sum of the absolute or squared differences between elicited and fitted
quantiles of the distribution. Compared to absolute differences, squared differences
give larger weight to large differences when optimising. For particularly complex
elicitation problems, eliciting the answers to more questions will help with stabil-
ity when fitting the elicited distribution. Additionally, the redundant information
can be useful for assessing modelling assumptions; if the quantiles are dramati-
cally asymmetric, and one is confident that the expert has indeed understood the
questions, a symmetric distribution may not appropriately capture expert belief.
An alternative method could be to elicit X as a histogram.61,62 In this approach,
X is split into bins and the expert is asked to place a certain number of ‘chips’
(representing probability) amongst the bins to represent their belief regarding the
probability distribution X. Placing all chips in one bin suggests that the expert
is completely certain that X lies within that bin and placing an equal number
of chips in every bin would suggest complete uncertainty regarding X.62 With a
small number of chips it may be difficult to adequately reflect X, for example, an
expert may want to spread at least some probability across all bins to properly
reflect their uncertainty, yet still focus more chips in bins where they wish to place
most probability; a small number of chips may make this challenging. However, if
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an expert finds it difficult to adequately assign their probability to bins, a small
number of chips may make the task more manageable to reflect their opinion. The
elicited histogram could then be used to approximate a parametric distribution for
X, for example, by considering quantiles of the histogram.
When eliciting opinion from a group of experts there are several approaches to
combining opinion in to one overall prior distribution.59 One approach is to elicit
individual prior distributions from each expert and mathematically combine them,
for example, as a weighted sum. Such a weighted sum could either assign equal
weight to all experts or could weight individual experts differently, say by clinical
experience, though such weightings would be highly subjective. Alternatively, a
consensus opinion over all experts could be quantified by having experts give their
individual opinions, then join together to agree on one final prior distribution
through constructive and open discussion; care must be made by the statistical
facilitator to ensure that experts equally share opinion, come to one agreed prior
and no one expert dominates the discussion.63 Advantages of this type of be-
havioural aggregation include the automatic averaging over all experts opinion;
drawing on every experts opinion at once to form one prior without the need for
a complex mathematical aggregation model; and all experts must agree on a final
prior distribution (compared to mathematical aggregation, where a weighted com-
bination of priors could result in a distribution no expert agrees with). However,
the statistical facilitators job is more challenging, strong personalities could heav-
ily influence the final results, more reserved personalities may not contribute their
valuable experience and it may not be clear how to proceed if experts are unable
to agree on a final prior.
An example of a user-friendly software for eliciting probability distributions is
contained in the Sheffield Elicitation Framework (SHELF).64 SHELF is a formal
procedure comprising of advice and tools for a facilitator with expertise in prior
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elicitation to elicit expert opinion on an uncertain quantity and to quantify this
opinion as a probability distribution. SHELF offers templates to structure and
record elicitation sessions (called SHELF workshops) and an R16 package which
allows interactive elicitation, fitting and visualisation of expert opinion as proba-
bility distributions; the approaches to prior elicitation can either be performed in
an interactive Shiny65 application or by the facilitator manually inputting elicited
quantities. SHELF allows the use of several methods to elicit opinion: quar-
tile method (bisection approach described earlier); tertile approach (similar to
bisection, though rather than splitting the distribution into four parts with equal
probability, the distribution is split into three parts); and the roulette method (the
histogram approach described earlier). SHELF proposes first eliciting opinion from
individuals, then having experts regroup to share their expertise and opinions, be-
fore eliciting a group consensus distribution. To answer the issue of experts not all
coming to a perfect agreement regarding the consensus prior distribution, SHELF
asks the experts to consider the opinion of a rational impartial observer (RIO);
after the RIO has seen all individual expert opinion and heard all discussions,
experts must agree on a prior distribution that the RIO might reasonably believe
to be true about the uncertain quantity of interest.
There are numerous examples of prior elicitation in practice across many fields,
such as engineering, physics, psychology, agriculture, economics and medicine.59,61,66
One example of elicitation being used in a clinical trials context is that of the
MYPAN study (mycophenolate mofetil for childhood polyarteritis nodosa) where
expert prior opinion was elicited for a future Bayesian RCT testing mycopheno-
late mofetil (MMF) against cyclophosphamide (CYC) for the treatment of children
aged 4–18 years old with polyarteritis nodosa (PAN).67,68 A Bayesian trial design
was chosen to improve understanding about treatments for PAN, as recruitment
for a definitive frequentist trial would not have been feasible; a frequentist non-
inferiority trial with 90% power, 2.5% one-sided significance level and remission
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rates on both treatments assumed to be 70% would have required 513 patients on
each treatment arm, with previous studies of PAN suggesting recruitment would
have taken over 30 years.68 The Bayesian approach taken in the MYPAN trial
began by first eliciting expert opinion on the 6-month remission rate on CYC (pC)
and the log-odd ratio, θ, between the 6-month remission rate on PAN (pE) and pC .
Expert opinion on pC and θ was elicited by asking six questions about different
probabilities and proportions, marking answers on a visual analogue scale ranging
from 0 to 1, with answers rounded to the nearest 0.05 probability. The prior for pC
was modelled as a beta distribution and experts were asked questions to establish
the mode and lower quartile to infer the distribution. The prior for θ was taken
to be a normal distribution, asking experts questions to establish the prior proba-
bility that pE > pC and pE − pC < −0.1; answers to these questions were used to
infer values for the mean and variance of the prior distribution for θ. Redundant
questions regarding pE were also asked in order to assess goodness of fit of the
model and the consistency of expert opinion. Individual experts had plots of the
probability density functions for pC and pE, fitted based on their elicited opinion,
presented to them and were allowed to make changes to previously answered ques-
tions until they felt the plots represented their prior belief. All experts were then
brought together to discuss their individual opinions and had a further opportu-
nity to revise their answers. By taking the means and medians of the expert’s final
answers to the elicitation questions, a set of consensus prior distributions were de-
termined that all experts agreed upon. Further to this, Hampson et al.67 elicited
expert opinion regarding the relevance of a related trial of MMF and CYC treating
a different (but related) condition to PAN. The 6-month remission rates for both
treatments between both study populations were related by log-odds ratios λC
(for CYC) and λE (for MMF). These λC and λE parameters were used to measure
the difference in treatment effect of CYC and MMF, respectively, between the
trials. Expert opinion regarding probability distributions for these log-odds ratios
was elicited in a similar way to the previous log-odds prior. Again, experts gave
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individual opinions to begin with and then came together to reach a consensus
opinion and agree on a single set of answers to the elicitation questions, giving
consensus prior distributions. Existing data from the relevant trial were then re-
vealed, updating the prior probability densities for pC , pE and θ to be shared with
the experts. Ultimately, the experts agreed on these updated prior distributions
(incorporating the relevant trial data) as the consensus prior distribution to be
used for the Bayesian trial.67 This example highlights the complexity of expert





This thesis aims to explore extrapolation in paediatric medicine development and
consists of four substantive pieces of work: a systematic review of methods for
extrapolating between populations; conclusions of a focus group of epilepsy ex-
perts eliciting their opinions regarding extrapolation in paediatrics; a quantitative
framework to inform extrapolation decisions in younger children using existing data
from trials of adults and adolescents; and approaches to quantify how parameters
of an E-R model vary over age to derive dosing rules.
Chapter 3 contains the systematic review paper entitled “Extrapolation of efficacy
and other data to support the development of new medicines for children: A
systematic review of methods”.69
Chapter 4 gives some background to the focus group of epilepsy experts. This
leads to the second published paper included in this thesis which is contained in
Chapter 5, entitled “Clinical drug development in epilepsy revisited: A proposal
for a new paradigm streamlined using extrapolation”.70
Chapter 6 contains the third piece of work entitled “A quantitative framework
to inform extrapolation decisions in children”. This chapter details a framework
using existing data from trials of adults and adolescents, along with expert opinion
on external biases, to quantify prior uncertainty regarding the similarity of PK-PD
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relationships between adults and younger children.
The final piece of work contained in this thesis is given in Chapter 7 and is entitled
“Exposure-response modelling approaches for determining optimal dosing rules in
children”. This chapter considers approaches to quantify how parameters of a
PK-PD model vary over a continuous age range and, given this, an approach
for deriving optimal dosing rules which account for pharmacological differences
between paediatric age groups.
Finally, Chapter 8 ends with a discussion overview of the thesis, considering some
limitations and potential future work.
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Chapter 3
Extrapolation of efficacy and
other data to support the
development of new medicines for
children: A systematic review of
methods
3.1 Introduction
Extrapolation has been defined as extending data and conclusions available from
studies conducted in a ‘source population’ to make or support inferences for a ‘tar-
get population’.34 Extrapolating from existing data, also commonly referred to as
bridging or borrowing strength, is common in drug development.36,71 Examples
include incorporating historical data into the analysis of contemporary clinical tri-
als72–74 and, more controversially, using information on a drug’s short-term effect
to draw conclusions about its long-term effect.75 Alternatively, one may seek to
test the efficacy of a medicine in a new geographic region when data are available
26
confirming it is beneficial for patients from another locality. In such cases, it may
suffice to conduct a smaller ‘bridging’ study in the new region that will collect
efficacy and safety data to support the extrapolation of data from other localities
to this site.76
For extrapolations to be appropriate, source and target populations should be
similar in terms of the key parameter(s) of interest. Extrapolations are ‘com-
plete’, in the sense that existing data obviate the need to collect data from the
target population, when there is strong prior opinion that differences between
populations are small. Such opinion may be informed by pre-clinical work or ex-
periences of developing related drugs or treating related patient groups. When
there is greater uncertainty about the biological plausibility of similarities, ‘par-
tial’ extrapolations may be more acceptable. A partial strategy would stipulate
that existing data in the source population be complemented by supportive data
in the target population generated by a reduced drug development programme.
This reduced programme would be targeted to fill in gaps in existing knowledge
or to verify similarities about which there is most uncertainty. To illustrate how
an extrapolation strategy might be selected, suppose that data from the standard
of care arm of several historical trials are available to inform the design and anal-
ysis of a new study. If investigators are confident that the standard of care has
changed little over time and response rates have been stable, the historical data
may be used as the control arm of the new (single-arm) trial. Otherwise, the his-
torical data may be used to augment data from the new study, which would be
designed as a randomised controlled trial (RCT) but would allocate fewer patients
to control. Making full use of existing data can have important implications for
the efficiency and feasibility of drug development in difficult to study populations
such as rare diseases or groups where there are ethical and practical barriers to
trial recruitment.
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The use of extrapolation to facilitate the development of safe and effective medicines
for children has received much attention.1,23,36,77 Adult data are often available
at the time development of a new medicine begins in children. Moreover, trials
in children can be more challenging to conduct due to practical constraints on
available sample sizes and pharmacokinetic sampling.25 There is also a common
perception that recruitment into paediatric trials will be challenging, although
this has been contradicted by recent research finding that parents and practition-
ers are willing to enter children into trials.26 Dunne et al.36 discuss the paediatric
study decision tree1,23 shown in Figure 3.1, which is an algorithmic approach to
determining which additional data are needed in children to support paediatric
licensing decisions. The level of extrapolation is determined by whether adults
and children can be assumed to be similar in terms of key characteristics, such
as disease progression and the pharmacokinetic-pharmacodynamic (PK-PD) rela-
tionship of the drug. While this framework clearly identifies scenarios in which
different extrapolation strategies are appropriate, it neither accommodates un-
certainty about extrapolation assumptions nor allows for differences between age
groups of children. To capture the heterogeneity of growth, development and phar-
macokinetics in the population, the ICH E11 guideline23 suggests one possible age
grouping: preterm newborn infants, term newborn infants (0 to 27 days), infants
and toddlers (28 days to 23 months), children (2 to 11 years) and adolescents (12
to 16/18 years, dependent on region). Batchelor and Marriott21 state that there
may be age related changes in drug pharmacokinetics caused by anatomical and
physiological differences between younger and older children and adults. However,
Stephenson22 notes that adults’ and children’s responses to many drugs have much
in common. The European Medicines Agency (EMA)34 has proposed a general
framework for extrapolation allowing for the incorporation of uncertainty about
assumptions. This framework stipulates that an extrapolation concept, containing
explicit hypotheses on expected differences between populations, should inform
the development of an extrapolation plan. This plan will detail which additional
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Figure 3.1: Paediatric Study Decision Tree: Image reproduced from Food and
Drug Administration1
data will be generated in the target population, and these data should, in turn, be
used to verify the extrapolation concept.
This chapter describes the findings of a systematic review conducted to identify
statistical methods that can be used to optimise extrapolations in paediatric drug
development. We sought methods relevant for using data from a source popu-
lation to support inferences for a target population. To provide focus for the
literature search, we restricted our attention to publications developing methods
in the context of four applications in which extrapolations are common, namely,
paediatric clinical trials; trials extrapolating efficacy across ethnic groups or ge-
ographic regions; the use of historical data in contemporary clinical trials; the
use of short-term endpoints to support inferences about long-term outcomes. The
rest of the chapter proceeds as follows. Section 3.2 outlines the strategy used to
identify relevant papers and methods which are briefly summarised in Section 3.3.
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In Section 3.4, we give a detailed account of the methods found, grouped accord-
ing to four common approaches. We conclude in Section 3.5 with a discussion
of the suitability of these methods for making extrapolations in paediatric drug
development.
3.2 Methods
Articles were identified by searching the Science Citation Index Expanded (SCI-
EXPANDED) database of the Web of Science. Searches were restricted to English
language papers listed on Web of Science prior to 31st January 2014 in the follow-
ing categories: biology; mathematical and computational biology; mathematics
(applied, interdisciplinary applications); medical informatics; research and exper-
imental medicine; pediatrics; and statistics and probability. Preliminary searches
were also made of other databases (JSTOR, PubMed) but no additional relevant
articles were found. Separate searches of the SCI-EXPANDED database were
made to identify potentially relevant papers proposing statistical methods for: (a)
incorporating historical data into contemporary clinical trials; (b) using data on
short-term endpoints to support inferences on long-term outcomes; (c) paediatric
clinical trials; and (d) bridging clinical trials. Since there was considerable overlap
between the search terms needed to identify papers on the last two topics, these
were combined so that a total of three separate searches were made. Search terms
can be found in the web based materials accompanying this manuscript (Appendix
A.1). We searched for papers containing these search terms either in the title, ab-
stract or keywords.
Articles identified using this search strategy were then screened, first by title and
then by abstract. At each stage the following types of manuscripts were ex-
cluded: (a) conference proceedings; (b) reports of clinical trials; (c) reports of
meta-analyses or evidence synthesis analyses; and (d) papers unrelated to medical
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statistics (returned because one search term, ‘bridge’, occurs in many contexts).
A full text review of the remaining articles was then performed. At this stage
manuscripts were excluded if they did not consider statistical methods; if they
used source population data only to inform the design of a future trial; or if they
considered trials using a historical control arm without consideration of possible
differences between populations. From each paper we extracted details of all statis-
tical methods relevant for extrapolating data from a source population to support
inferences for a target population. Methods for establishing whether data from
source and target populations are consistent were regarded as relevant, assuming
that if commensurability is established it would be appropriate to analyse data
pooled across populations. A data extraction form (Appendix A.2) was completed
for each statistical method and the number of methods extracted from each paper
was recorded. When identical methods were found in more than one paper, we
recorded the method as it appeared in the earliest publication. Papers presenting
only duplicate methods were excluded from the review. Data were extracted by
one author (IW) seeking guidance from others (LVH, TJ) where necessary.
3.3 Results
Searches identified 52 papers satisfying the stated inclusion/exclusion criteria as
summarised in Figure 3.2, from which we extracted 102 methods. A single method
was extracted from each of 34 papers. Of the remaining papers, eight presented
two methods each, while 10 presented three or more methods each.
Methods can be categorised into four main areas: (i) paediatric drug development
(5 of 102 methods); (ii) use of historical data in contemporary clinical trials (48
of 102); (iii) bridging trials extrapolating efficacy data between ethnic groups or
geographic regions (43 of 102); and (iv) the use of short-term data to support
inferences on long-term outcomes (6 of 102). This is displayed in Figure 3.3. All
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Figure 3.2: Flow diagram of systematic review results
five methods in category (i) considered extrapolating information from an adult
source population to support inferences about children. Of the 48 methods in
category (ii), 25 sought to extrapolate from a historical control group to support
conclusions about control response rates in a contemporary patient group. Of the
43 methods in category (iii), 14 took as the target population an unstudied patient
group in a new geographic region and sought to borrow strength from existing data
on patients in another geographic region for whom the treatment had already been
shown to be efficacious. One further method in this category evaluated the con-
sistency of data in two ethnic groups of patients. The remaining 28 methods in
category (iii) were proposed to assess the consistency of treatment effects across
regions of a multi-regional clinical trial (MRCT).
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Figure 3.3: Plot showing distribution of methods across four main areas
Of the 102 methods, 100 expected data from the source and target populations to
make inferences about key parameters in the latter group, and as such are appro-
priate for making partial extrapolations. An example of a method that did not
expect data from the target population, Nedelman et al.38 suggest that a necessary
condition for using adult efficacy data to support conclusions about the efficacy
of oxcarbazepine as a monotherapy for children with epilepsy, is that PK-PD re-
lationships should be similar in adults and children receiving oxcarbazepine as an
add-on therapy.
None of the methods found considered extrapolating safety data across popula-
tions. Instead all methods expected either efficacy or PD data (100 of 102) or PK
data (2 of 102). In the context of paediatric drug development, this may be due to
the fact that the paediatric study decision tree stipulates that safety data must be
collected in children regardless of one’s confidence in extrapolation assumptions.
Most methods (100 of 102) sought to make comparisons between treatments while
two methods were proposed in the context of dose-finding trials.
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3.4 Thematic analysis of methods for extrapola-
tion
Methods were first classified according to the type of statistics used, that is,
Bayesian or frequentist statistics. Categories were then refined to form three broad
groups of approaches, namely, Bayesian methods using existing data to create an
informative prior distribution for a parameter of a target population; Bayesian
and frequentist methods assessing the commensurability of parameters of source
and target populations; frequentist methods synthesizing data across populations
using a joint model or weighted test statistic. Further details of the extrapolation
methods are given below.
In all descriptions of methods, we will index parameters and data from the source
(target) population by a subscript S (T). Therefore, xS (xT ) will denote data
from a source (target) population which depends on an unknown parameter θS
(θT ). When θS and θT are assumed equal, we will refer to their common value as
θ. When several datasets are available from a source population, we will let H
denote the total number of datasets available and nhS denote the size of dataset h,
h = 1, . . . , H. Throughout, pi(·) will be used to denote a general prior or posterior
probability density function (pdf).
3.4.1 Bayesian methods
Searches identified 58 Bayesian methods from 25 papers.72–74,78–99 Of these, 54
methods72–74,78–95 sought to create an informative prior for θT while four
96–99 as-
sessed the consistency of treatment effects or PK responses between the source
and target populations.
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3.4.1.1 Using existing data in a source population to create a prior for
θT
All methods in this category sought to augment data from a future trial in the
target population (xT ) with existing data from one or more studies in the source
population (xS). For example, θT and θS could be response rates on the standard
of care available to patients in a new and historical trial, respectively. In this
setting, differences between θT and θS may arise due to differences between trial
protocols, advances in medical care or demographic shifts in the patient population
over time. More generally, the source data will be useful for learning about θT only
if the clinical effects of treatments in the source and target populations patients
are similar. Of the 54 methods which used xS to create an informative prior for θT ,
most proposed discounting these data to account for potential differences. Thirty-
one methods72–74,78–85 considered differences between θT and θS, and formulated
priors for θT which when updated with emerging data from the new trial adaptively
weight xS according to the commensurability of xS and xT . Fifteen methods
adopted a fixed non-adaptive approach to down-weight xS. Eight methods did
not down-weight xS at all, so that the final posterior distribution for θT would
attribute equal weight to the source and target population data.
Adaptive down-weighting of data from the source population
Most approaches in this category were proposed for incorporating data from a
historical trial into a contemporary study. One approach which has received
much attention is the power prior and 10 variations on this were found.72,73,78,79
Power priors are formed by raising the likelihood of the historical data to a power
a0 ∈ [0, 1]. More formally, assuming parameters are consistent across populations,
let L(θ | xS) denote the likelihood of the source data and let pi0(θ) represent the
prior for θ held before these data became available. Then the hierarchical power
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prior for θ after observing xS is:
72
piPP (θ, a0|xS) ∝ L(θ|xS)a0pi0(θ)pi(a0). (3.1)
The prior for a0 captures prior uncertainty about the commensurability of param-
eters of the historical and contemporary data. Ibrahim and Chen72 suggest placing
a beta, truncated gamma or normal prior on a0. Once data from the new trial
become available, they are used to update equation (3.1) using Bayes theorem to
derive a posterior distribution for θ and a0 given xS and xT . Both datasets are used
to learn about a0 and thus determine the contribution of the historical data to the
marginal posterior distribution for θ. If xS and xT are commensurate, in the sense
that they are consistent with the hypothesis that θT = θS, greater posterior weight
will be placed on powers close to 1, in which case observations from both datasets
are regarded as equally informative for θT and pooled. Conflicting datasets will
result in information from xS being discarded as greater posterior weight is placed
on powers close to 0. Ibrahim and Chen72 extend piPP in equation (3.1) to incorpo-
rate data from multiple historical studies. Versions accommodating data following
generalized linear fixed and mixed effect models, proportional hazards models and
cure rate models are also derived.
It has been noted that the hierarchical power prior in equation (3.1) violates the
likelihood principle since it omits the normalising constant for a0.
78,100 Modifying






piMPP (θ, a0|xS) = C(a0)L(θ|xS)a0pi0(θ)pi(a0), (3.2)
which Hobbs et al.73 refer to as the modified power prior (MPP). Chen et al.79
extend the MPP to accommodate several historical datasets, as well as binary
and normally distributed data. Hobbs et al.73 modify the MPP in equation (3.2)
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by extending the Bayesian model for xS and xT to incorporate a parameter τ
measuring the correlation between parameters of the historical and contemporary
data, and stipulating that θT | θS, τ ∼ N(θS, 1/τ) and a0 | τ ∼ Beta(g(τ), 1).
Here g is a positive function specified by the analyst which is small for τ close to
0 and large when τ is large. Thus given the historical and contemporary data are
commensurate (inconsistent), the prior distribution for a0 is concentrated about
powers close to 1 (0). From this model one can derive the location commensurate
power prior (LCPP) as












where φ is the pdf of a standard normal variable and pi(τ) is a vague prior on τ .
Once the new study has been completed, conflicting historical and contemporary
data consistent with small τ will lead to an adaptive down-weighting of xS in the
marginal posterior for θT .
A similar Bayesian model for xS and xT is assumed to derive the commensurate
prior (CP) for θT .
73 Again modelling conditional prior opinion on θT as θT | θS, τ ∼
N(θS, 1/τ), the CP for θT given xS and θS is




τ) pi0(θT ) pi(τ). (3.3)
Once data from the new trial become available, the posterior density for (θT , τ)
given xT and xS is proportional to equation (3.3) multiplied by L(θT | xT ). If
the historical and contemporary data are consistent with τ ≈ 0, the historical
data are discarded and the marginal posterior distribution for θT tends towards
the distribution that would result from updating the initial prior for θT with xT .
On the other hand, if data are consistent with τ ≈ ∞, the marginal posterior
for θT converges to the posterior that would result from pooling xT and xS to
update pi0(θT ) assuming θT = θS. Hobbs et al.
80,81 suggest defining pi(τ) in (3.3)
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as a conditionally conjugate prior distribution or using a ‘spike and slab’ prior.
Alternatively, an empirical Bayesian approach can be adopted, replacing τ by its
marginal maximum likelihood estimate (MLE).80 Hobbs et al.81 use the CP73 to
incorporate historical control data into a new adaptive RCT. The randomisation
ratio between the novel treatment and control is updated group sequentially on the
basis of the current effective sample size of the historical data: more patients are
randomised to the novel treatment when there is weak evidence of heterogeneity
between the historical and contemporary control data. The CP approach has been
extended to accommodate a variety of data types, including responses following
general linear mixed effect models, and generalised linear models with fixed or
mixed effects. Hobbs et al.80 illustrate this approach with applications to binary,
survival and count data.
Hobbs et al.73 adapt the CP in equation (3.3) for the case of normally distributed
data to propose a location commensurate prior (LCP), assuming historical patient
responses have mean µS and variance σ
2
S, and data from the new trial have mean
µT and variance σ
2
T . If no information is available for µS before the historical trial,
so that pi0(µS) ∝ 1, the posterior distribution for µS after observing a historical




S ), replacing σ
2
S by
its MLE. Before the new trial data become available, we model µT | µS, τ ∼
N(µS, 1/τ). Placing a non-informative prior on σ
2
T and a vague prior on τ , we
obtain the LCP:
piLCP (µT , σ
2










Updating the LCP with xT , the weight attributed to the historical data by the
posterior distribution for (µT , σ
2
T ) will depend on the consistency of xS and xT with
the claim that µS = µT . Hobbs et al.
73 extend the LCP to derive the location
scale commensurate prior (LSCP): the weighting of the historical data depends
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Meta-analytic predictive (MAP) priors are an approach to combining data across
several heterogeneous source populations to formulate an informative prior for θT .
The use of historical control data potentially allows for the randomisation of fewer
contemporary patients to control in a future RCT. Two methods developed this
approach,74,82 synthesising data from the control arms of several historical trials
in a Bayesian random-effects meta-analytical model to derive the posterior pre-
dictive distribution for the parameter of interest in the control group of a new
study. The MAP prior is then updated using Bayes theorem when data from the
new trial become available. We classify methods74,82 as adaptive approaches to
down-weighting data from the source population since the MAP prior can be ap-
proximated as a mixture of conjugate distributions57 and have heavier tails than
a simple conjugate prior. Thus, in the event of a prior-data conflict, the historical
data will eventually be discarded from the posterior analysis of the new trial.
When deriving the MAP prior, meta-analytic models are formulated assuming
parameters of the historical and contemporary datasets are exchangeable. Suppose
there are H historical trials generating estimates xS1, . . . , xSH of θS1, . . . , θSH . If
patient responses are normally distributed, θSh is the expected response on control
in historical trial h, or it may be the log-odds of response on control if outcomes
are binary. Neuenschwander et al.74 assume parameter estimates are normally
distributed with known standard errors sS1, . . . , sSH . A Bayesian random-effects
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meta-analytic model is:
XSh | θSh ∼ N(θSh, s2Sh), for h = 1, . . . , H,
θS1, . . . , θSH , θT |θ?, ν2 ∼ N(θ?, ν2),
θ? ∼ pi(θ?),
ν2 ∼ pi(ν2). (3.4)
In the special case that ν is known, the posterior distribution of θ? given the
historical data is









where wh = (s
2
Sh + ν)
−1. Before the new trial begins, the prior distribution of θT
is its posterior predictive distribution given the historical data. If ν is known, this
distribution is










Neuenschwander et al.74 recommend using priors for ν to check the sensitivity
of conclusions in a fully Bayesian meta-analysis. Gsteiger et al.82 extend this
method to derive the MAP prior for the log mean count on control in a new trial
when count data are overdispersed and follow a negative binomial model. Chen
et al.79 propose a similar method for normally distributed and binary data which
synthesises historical and contemporary data within a Bayesian random-effects
meta-analytic model. Hobbs et al.80 state that when H = 1, there is a one-to-one
relationship between the commensurability parameter τ in equation (3.3) and the
between-study variance ν in model (3.4).
Cuffe83 considers a new RCT extrapolating from a single historical study to support
inferences for the expected response on control. Responses from nS (historical) and
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nT (contemporary) control patients are summarised by the sample means xS and
xT , respectively. These statistics are assumed to follow a Bayesian random-effects
model
XS | θS ∼ N(θS, σ2/nS) and XT | θT ∼ N(θT , σ2/nT ),
θS, θT | θ? ∼ N(θ?, σ2/nb),
θ? ∼ N(0, σ21), (3.5)
where σ2 is assumed known and σ21 is chosen to be large. It follows that the
posterior marginal expectation of θT is
lim
σ1→∞
E(θT |xT , xS) = nbnS
2nSnT + nbnT + nbnS
xS +
2nSnT + nbnT
2nSnT + nbnT + nbnS
xT . (3.6)
Model (3.5) indexes the between-trial variance, and thus the degree of information
borrowed from xS to estimate θT , by the parameter nb. Since this will often be
unknown, Cuffe adopts an empirical Bayesian approach, evaluating the posterior
expectation of θT at
nˆb = (nm/dm) max{dm − |xT − xS|, 0+}, (3.7)
so that the historical data contribute to our estimation of θT only if the discrepancy
between these and the new data is less than a pre-specified maximum tolerable
difference (dm). The maximum influence of the historical data, attained when
xS = xT , is pre-specified as nm. The condition 0+ in equation (3.7) ensures nb is
strictly positive. On conclusion of the contemporary RCT, data on the experimen-
tal treatment are summarised by the statistic xa. A classical frequentist analysis
is then conducted to test for a treatment effect, comparing xa with an estimate
of E(θT | xT , xS) derived substituting nˆb into equation (3.6). Cuffe finds that in-
corporating historical control data into the analysis of a contemporary RCT may
actually reduce the power to detect a clinically relevant effect if the critical value
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of the frequentist test must be adjusted to ensure adequate type I error rate con-
trol under all possible values of (θT − xS). Viele et al.101 describe the results of a
simulation study comparing methods for incorporating control data from a single
historical trial into the analysis of a contemporary RCT. The authors find that,
in general, incorporating historical control data does have benefits for increasing
power and reducing the type I error rate when |θT − xS| is close to 0, although
how far this ‘sweet spot’ extends before losses in power or increases in type I error
rate are incurred depends on the method used for extrapolation.
Mixture priors are another approach for using existing data to create an informa-
tive prior distribution for θT . Two methods
84,85 use mixture priors to augment
data from a future clinical trial in a new geographic region with data, xS, from
an area that has previously been studied. These methods set the prior for the
treatment effect in the new region as
pi(θT | xS) = ω pi1(θT ) + (1− ω) pi2(θT ),
where pi1(·) is an informative prior derived from xS, and pi2(·) is a non-informative
distribution used to dilute the information for θT obtained from xS so that pi(θT |
xS) has heavy tails. Hsiao et al.
84 recommend that the mixing proportion ω be
fixed by the regulatory authority of the new region. This weight may be specified
in view of differences between the new and previously studied regions in terms of
intrinsic and extrinsic ethnic factors. The corresponding posterior distribution for
θT will also be a mixture distribution, with components that are the posterior dis-
tributions if pi1(θT ) or pi2(θT ) were the priors, and weights that are a function of the
data, such that more weight is given to the posterior that would result from updat-
ing the prior component most commensurate with xT . Hobbs et al.
73 also consider
mixture priors, proposing a prior for the mean and variance of patient responses
in a new trial which is a mixture of m LSCPs with fixed pairs of commensurability
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parameters (τ1, γ1), . . . , (τm, γm) and fixed weighting proportions ω1, . . . , ωm. This
method allows for the consideration of different plausible relationships between
the location and scale parameters of the historical and contemporary data.
Non-adaptive down-weighting of data from the source population
Fifteen methods72,73,85–93 used existing data from a source population to formu-
late an informative prior for θT , down-weighting these data in a non-adaptive,
pre-specified manner. The power prior can be considered in this category if a0 in
equation (3.1) is taken to be a fixed constant and Hobbs et al.73 refer to this ap-
proach as the conditional power prior (CPP). Six methods72,73,85–87 propose power
priors with fixed a0. Ibrahim and Chen
72 propose a variation on this approach for
the case that historical data are from a single trial and patient responses follow
an arbitrary regression model. Neither paper discusses how to choose a0.
72,73 De
Santis86 defines a geometric prior, raising the likelihood of data from a single his-
torical trial to a power a0 = r/nS, where r is a constant specified by the analyst.
The author also modifies this approach to weight different historical datasets by
different fractions when they differ in their relevance to the new trial. De Santis86
illustrates how the geometric prior can be used to inform early stopping decisions
in a new Bayesian clinical trial. Rietbergen et al.87 consider the CPP incorporat-
ing data from several historical studies, assigning data from each study a weight
elicited from expert opinion. Gandhi et al.85 consider the CPP for the purposes
of incorporating existing binary data from a geographic region in which a drug
has been shown to be effective into the analysis of a bridging trial conducted in
a new region. The authors recommend performing sensitivity analyses to explore
the impact on inferences of different choices of weights. Hobbs et al.73 also provide
a variation on the commensurate prior described in the previous subsection which
treats τ as fixed.
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Schoenfeld et al.88 augment data from a clinical trial in children with data from
a completed adult trial, assuming parameters of adult and paediatric data are
samples from a normal population distribution with mean θ? and known variance
ν2. The choice of ν2 reflects opinion on between population differences. This
method is equivalent to the CPP when data are available from one adult study:
if data from more than one adult trial are available, these should be summarised
by a single estimate derived from a meta-analysis of adult studies. Schoenfeld et
al.88 also consider an approach for determining the sample size needed to ensure
the Bayesian paediatric trial incorporating adult data has high Bayesian power.
Augmenting paediatric data with adult data means that fewer children may be
required.
Chen et al.89 derive a Bayesian empirical prior distribution for a treatment effect
θT in a specific local region of a MRCT which borrows strength from data from
other trial sites. The prior θT ∼ N(µˆ, σ2) is specified by defining µˆ as the global
treatment effect estimate found by averaging across effect estimates obtained from
each trial region. Meanwhile, σ2 is taken to be a linear function of the variance of
the region-specific effect estimates, where smaller values of the coefficient of the
interregional variance allow for more borrowing of strength across regions. Chen
et al.89 recommend that this coefficient be specified ahead of time and chosen to
reflect the consensus opinion of the local regulatory authority and the trial sponsor.
Six other methods in this category of approach shift the location and/or inflate
the standard error of an estimate of θS to create an informative prior for θT while
discounting the source population data.90–93 For example, French et al.92 formulate
a normal prior distribution for θT with mean equal to the MLE of θS obtained from
xS, and standard deviation equal to four times the standard error of the MLE;
the authors propose using this prior for the Bayesian interim monitoring of a trial
which will terminate with a conventional frequentist analysis. Whitehead et al.93
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consider Bayesian sample size calculations, using historical placebo data to create
an informative prior distribution for the expected response on placebo in the new
trial. This prior is normally distributed, with the mean taken to be the mean
response from the historical placebo group and precision chosen to reflect how
many patients the prior should represent.
No down-weighting of data from the source population
Eight methods85,91,92,94,95 used data from a source population to create an in-
formative prior distribution for θT without any down-weighting. Thus, once avail-
able, data from the target and source populations are pooled to derive a posterior
distribution for θT .
3.4.1.2 Assessing consistency between source and target populations
Four Bayesian methods were proposed to assess the consistency of parameters
in source and target populations.96–99 Pei and Hughes96 seek to assess whether
candidate doses for adults and children result in similar percentages of patients
experiencing low levels of a drug; inferences are made testing whether the propor-
tion of children recording PK levels below a quantile estimated from adult data is
non-inferior or equivalent to a design value. Tsou et al.97 use Bayesian most plau-
sible prediction102 to assess the consistency of treatment effect estimates generated
by a new clinical trial comparing an experimental treatment (E) with control (C)
in a new geographic region, and reference studies which have demonstrated the
advantage of E versus C in an original geographic region, under the assumption of
normally distributed treatment effect estimates. The difference between treatment
group sample means for the bridging trial, θˆT , is said to be consistent with the
results of the H reference studies, denoted by θˆS = (θˆS1, . . . , θˆSH), if and only if
p(θˆT | θˆS) ≥ ρB min{p(θˆSh | θˆS\h);h = 1, . . . , H},
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where p(θˆT | θˆS) is the posterior predictive probability of θˆT given the results
of all reference studies, θˆS\h is the vector of reference effect estimates excluding
θˆSh, and ρB > 0 is a pre-specified constant which reflects the prior confidence
of the regulatory authority in the commensurability of data from the new and
original geographic regions. Posterior predictive probabilities are derived assuming
a non-informative prior distribution for the common treatment effect θ before
any data are observed. The posterior predictive probability p(θˆT | θˆS) therefore
provides a measure of the plausibility of θˆT given the previous trial results. Chow
et al.98 also use posterior predictive probabilities to assess the consistency of data
from a bridging trial and reference studies. Gould et al.99 propose an approach
whereby the results of a bridging study are judged to be consistent with those of the
reference studies if they fall within contours or regions of the posterior predictive
distribution derived from the reference confirmatory trials. The sample size of the
bridging trial may be chosen to find an acceptable balance between the producer
risk, that is, the probability of incorrectly rejecting a conclusion of consistency, and
the consumer risk, which is the probability of incorrectly concluding consistency.
3.4.2 Frequentist methods
Forty-four frequentist methods were identified9,38,96–98,103–127 of which 11 meth-
ods9,103–112 synthesised data from source and target populations in a joint model,
three methods113–115 combined data across populations through a weighted test
statistic, and 30 methods38,96–98,109–112,116–127 proposed criteria to assess the con-
sistency of estimates of key parameters in different populations.
3.4.2.1 Joint model incorporating data from source and target popu-
lations
Five methods9,103–106 proposed using short-term data to support inferences about
a long-term endpoint assuming simple models to relate observations on differ-
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ent outcomes. In this setting, θT and θS could represent long- and short-term
treatment effects, or characterise the distribution of the two endpoints. Several
authors extrapolate from short-term data to inform early stopping decisions for
sequential trials. Hampson and Jennison103 seek to increase the efficiency of group
sequential tests (GSTs) monitoring a long-term outcome by incorporating data on
a correlated short-term endpoint so as to increase the Fisher information avail-
able for θT at each interim analysis. MLEs of θT are found maximising the joint
likelihood of xS and xT assuming pairs of responses on the same patient follow
a bivariate normal distribution. No assumption is made about the form of the
relationship between the short- and long-term responses other than that they are
correlated. The authors derive optimal designs and show that incorporating data
on a highly correlated short-term endpoint can reduce the expected sample size
of a trial by around 5% of the fixed sample size when the time to availability of
the short-term endpoint is at least half that of the long-term endpoint. A similar
problem is considered by Galbraith & Marschner,104 who incorporate into GSTs
repeated measurements of a continuous endpoint taken at an arbitrary number
of follow-up times. The vector of repeated measurements for each individual is
assumed to follow a multivariate normal distribution, with correlations between
the measurements being exploited to improve estimation and inference associated
with the long-term measurement. Marschner and Becker105 increase the interim
information available for a long-term response probability by incorporating data
on a short-term binary endpoint, deriving the MLE of the long-term response rate
from the joint likelihood of the combined dataset. The values of the short- and
long-term endpoints may be associated, however, a patient’s short-term response
does not necessarily determine their long-term response.
Stallard9 uses observations on short- and long-term endpoints to support early
stopping and treatment selection decisions in a seamless Phase II/III clinical trial.
Responses on the same patient are assumed to follow a bivariate normal distribu-
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tion, fitted using the double regression method of Engel and Walstra.128 Wu¨st and
Kieser106 also consider bivariate normal outcomes and derive a more precise esti-
mator of the variance of the long-term outcome incorporating short- and long-term
data. Using this improved estimator to inform blinded sample size adjustments
at an interim analysis reduces the variability of the final trial sample size when
compared to using long-term data alone.
Six methods107–112 synthesize data from source and target populations using a
frequentist random-effects model. Thall and Simon107 combine historical and con-
temporary control data via a univariate random-effects meta-analysis while Arends
et al.108 model short-term and long-term outcomes from trials using a multivariate
random effects model. Chen et al.109 and Ko110 use a random effects model to ac-
commodate heterogeneity between regions and test for an overall treatment effect.
Liu et al.111 use a random effects model to test for similarity or non-inferiority
between treatment effects in different regions. Ko112 models survival data from dif-
ferent regions using a proportional hazards model with frailties to allow patients
in different regions to have varying underlying hazards of experiencing an event.
3.4.2.2 Combining data across populations in a weighted test-statistic
Three methods113–115 propose making final inferences about the efficacy of a new
treatment in a new geographic region on the basis of a test statistic combining
information from the source and target populations. Suppose ZT and ZS are
standardised test statistics comparing mean responses on a new treatment and
placebo in a new and original region, respectively. For reasonable sample sizes,
ZT and ZS follow at least approximately standard normal distributions. Lan et






1− ω ZT ,
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with 0 ≤ ω ≤ 1. Chow et al.98 suggest that |Zw| > z1−α/2, where z1−α/2 is
the (1−α/2) quantile of a standard normal distribution, implies the results of the
bridging study are consistent with those of the reference study which demonstrated
efficacy of the new treatment relative to placebo in the original geographic region.
The weight ω should be pre-specified by the regulatory agency, although Lan et
al.113 suggest that this weight may be based on evidence of efficacy established in
the original region.
3.4.2.3 Assessing the consistency of data from source and target pop-
ulations
Thirty methods were proposed to assess the consistency of data from different pop-
ulations. Chen et al.116 survey nine methods in their systematic review for testing
the commensurability of a treatment effect across regions of a MRCT, of which
we extracted eight. These methods comprised ‘Global methods’ assessing consis-
tency based on a test-statistic combining data across all trial regions; ‘Multivariate
quantitative’ methods assessing consistency by considering all pairwise differences
between region-specific effect estimates; and ‘Multivariate qualitative methods’ as-
sessing whether patients from all trial regions can benefit from a new treatment.
All eight methods assumed patient responses to be normally distributed. Let ∆j
be the difference in mean response on treatments E and C in trial region j, for
j = 1, . . . , s. Then, ∆ =
∑s
j=1 nj∆j/n is the overall treatment effect for the trial,
where nj is the number of patients per treatment in the jth region and n is the
total number of patients per treatment.
One Global method is Cochran’s Q statistic53 for testing the null hypothesis H0 :
∆1 = ∆2 = . . . = ∆s = ∆, against the alternative that at least one ∆j is different.
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where χ2s−1;1−α is the (1−α) quantile of a central chi-square distribution with (s−1)
degrees of freedom. The test of H0 based on the Q statistic is well known to have
low power54 in certain situations; for example, in the current context, when the
total information available for estimating ∆ is low or there are large imbalances
between the contributions of different centres to this total information. Higgins’
I2 statistic,129 defined as I2 = 100(1 − (s − 1)/Q), measures the degree of incon-
sistency between ∆1, . . . ,∆s. However, interpretation of I
2 can be problematic
since it increases as a non-linear function of the between-centre heterogeneity.130
This statistic also depends on the within-centre precision131 and the number of
centres, s, such that under H0, E(I2) = −200/(s − 3) if s > 3.130 An alternative
measure of consistency not found by this review but pointed out by a reviewer
is H2 = Q/(s − 1), which Higgins and Thompson132 state does not intrinsically
depend on the number of studies.
Global test statistics can also be used to test for a qualitative interaction between
the treatment effect and trial regions. The Gail-Simon test133 of H0 : {∆j ≥
0, for all j = 1, . . . , s} ∪ {∆j < 0, for all j = 1, . . . , s} rejects the null hypothesis













Chen et al.116 also review multivariate quantitative methods which test H0 : ∆1 =
. . . = ∆s = ∆ and declare treatment effects as consistent if there are no significant
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pairwise differences between effect estimates, that is, if
|∆ˆi − ∆ˆj| < zα/2
√
2(nj + ni)/(ninj) for i, j = 1, . . . , s, i 6= j.
A variation on this approach has been proposed for testing H0 : |∆1 − ∆| > m
or . . . or |∆s −∆| > m,134 where rejecting H0 implies that all regional effects lie
within an equivalence margin m of ∆.
Multivariate qualitative methods reviewed by Chen et al.116 include testing H0 :
∆1 ≤ δ∆ or . . . or ∆s ≤ δ∆, to determine whether all regional effects are non-
inferior to the global treatment effect, proposed by Liu et al.111 One further
method is based on confidence interval coverage which declares the treatment ef-
fect to be consistent across regions if ∆ˆj > pi∆ˆ− zα/2
√
2/nj for j = 1, . . . , s. The
Pharmaceuticals and Medical Devices Agency (PMDA) suggest declaring consis-
tency if a positive trend is observed, that is, if ∆ˆj > 0 for all j = 1, . . . , s, or if
∆ˆj > δ∆ˆ for all j = 1, . . . , s.
135 The PMDA recommend setting δ ≥ 0.5 although
Chen et al. comment that this may be too conservative when several trial regions
are included. This literature review found 15 further methods97,109,110,112,117–124
proposing consistency criteria similar to the PMDA method. For example, let ∆ˆ,
∆ˆS\j? and ∆ˆj? denote the treatment effect estimates derived from pooling data
across all trial regions, all regions excluding region j?, and region j? alone, respec-
tively. Ko et al.120 consider several alternative criteria for determining whether a
new treatment should be deemed efficacious in region j? when there is strong sta-
tistical evidence to reject H0 : ∆ = 0. For example, investigators may pre-specify
one of the following criteria for their study: 1) ∆ˆj? ≥ ρ∆ˆS\j? ; 2) ∆ˆj? ≥ ρ∆ˆ;
3) ρ ≤ ∆ˆj?/∆ˆS\j? ≤ 1/ρ; or 4) ρ ≤ ∆ˆj?/∆ˆ ≤ 1/ρ. Here ρ ∈ (0, 1) may be
pre-specified by the regulatory agency of region j?. Alternatively, Chen et al.125
derive standardised weighted least squares residuals from ∆ˆ1, . . . , ∆ˆs and use these
to create Q-Q plots for assessing consistency between regional treatment effects.
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Pei and Hughes96 propose a frequentist version of their method described in Sec-
tion 2.4.1.2 which seeks to assess whether candidate doses for adults and children
result in similar percentages of patients experiencing low levels of a drug.
Hsiao et al.126 propose two-stage designs for bridging trials. The trial begins re-
cruiting patients from the original region. If efficacy in this region is confirmed at
the interim analysis, the trial proceeds to recruit patients from the new region in
Stage 2. Otherwise the trial terminates early for lack of benefit. On conclusion of
the trial, data accumulated from both regions are pooled and analysed to test a
one-sided null hypothesis of no treatment effect. If the result of Stage 1 is similar
to the pooled result of Stage 2, the result from the new region is declared consis-
tent with that from the original region and we conclude that the new treatment is
effective in both localities.
Cai et al.127 propose evaluating the similarity of data from clinical trials performed
in different ethnic populations using a ‘distribution adjusted mean’. This method
assumes that there is a covariate Y prognostic for the primary endpoint which
differs in distribution between the two ethnic groups. If Y is continuous, its do-
main can be partitioned into intervals and the relative frequency of each interval
in the target population is recorded. These frequencies are then used to calculate
the weighted average response in the source population, averaging across the mean
responses for each interval of Y . This adjusted mean response is then compared
with the unadjusted mean for the target population to assess the consistency of
response between the populations.
Nedelman et al.38 develop a method comparing children and adults receiving a new
drug as an add-on therapy, with the aim of using these data to support inferences
about children receiving the drug as monotherapy. If the PK-Efficacy relationship
is similar for adults and children receiving add-on therapy, this is taken to support
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an assumption of similar relationships for adults and children receiving monother-
apy. Separate linear models are fitted to the PK-Efficacy data from adults and
children, and model parameters are compared to establish whether there are dif-
ferences between age-groups.
Chow et al.98 apply the ‘reproducibility probability’ method136 to bridging studies,
calculating the reproducibility probability as the power of the bridging study to
detect a treatment effect equal to the estimated effect from the reference study
which itself produced a significant result. If the reproducibility probability exceeds
a critical value (determined by a regulatory agency) then the bridging study may
be considered unnecessary, that is, clinical data from the original region can be
completely extrapolated to the new region to support claims of efficacy.
3.5 Discussion
This systematic review summarises statistical methods relevant for extrapolating
data from a source population to a target population, and has captured a wide
range of methodology. Several of the approaches identified are potentially appli-
cable for making extrapolations to support paediatric drug development. In this
context, adult data, pre-clinical data and data on children receiving treatment
for related conditions may all be available at the time development of a medicine
begins in children. Thus, methods which can harness existing data to derive infor-
mative prior distributions for key parameters in children are particularly appealing.
However, we speculate that down-weighting existing data would be more accept-
able in this setting to account for potential differences between adults and children.
Therefore, the applicability of those eight methods which give comparable weight
to historical and contemporary data is likely to be limited unless there is a strong
prior rationale for similarities. Alternatively, the methods identified by this review
for assessing the consistency of parameters of source and target populations may
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be used as objective criteria for determining when it is appropriate to pool data
from adults and children, or indeed pool data across different age groups of chil-
dren.
When there is some prior understanding of the factors that may explain differences
between populations, a weight for the existing data may be pre-specified. Other-
wise Bayesian approaches such as the power prior, commensurate prior, mixture
prior or MAP prior, which adaptively down-weight existing data, may be pre-
ferred. One criticism that has been made of MAP priors is that the posterior
predictive distribution for θT given historical data must be typically derived using
Markov Chain Monte Carlo. Therefore, since the prior is not available analytically,
it cannot be easily reproduced by others unless they have access to the historical
data combined in the meta-analysis. To overcome this challenge, Schmidli et al.57
propose representing the MAP prior as a mixture of a small number of conjugate
prior distributions which can be easily recorded and shared.
In Section 3.1 it was noted that there may be differences between age groups of
children. Twenty-five methods38,72,80,116,122,127 identified by this review can ac-
commodate a heterogeneous target population because key parameters are taken
to be parameters of (semi-)parametric models capable of adjusting for baseline
demographics. Several methods proposing a joint model for data from the source
and target populations assume only that data from different populations are cor-
related. However, this is unlikely to be the case for paediatric drug development
when source and target data will typically be observations on different patients.
In this case multivariate meta-analytic models, as used by Arends et al.,108 are
potentially more relevant since they can capture correlations between parameters
of different populations. Future research will consider tailoring these models to
support extrapolations in paediatric trials.
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Several papers were identified by our literature search which, although they did
not contain statistical methods, are relevant for discussion. Manolis et al.77 dis-
cuss the role of modelling and simulation in paediatric investigation plans (PIPs),
which are documents pre-specifying what studies will be conducted to support
development of a medicine for children. The authors review positive PIP opin-
ions (summarising key elements of PIPs supported by the EMA) and find that
population PK models are the most frequently referenced modelling approach,
while exposure-response and dose-response models are rarely cited: modelling and
simulation, when proposed, is typically used to support dose predictions, study
optimization and data analysis. Khalil and La¨er137 review physiologically based
pharmacokinetic (PBPK) models as applied to paediatric drug development, where
parameters of PBPK models for children may be extrapolated from another species
or age group.
Other methods not included in the systematic review were found proposing other
ways for using data from a source population to support inferences for a target
population. Reif et al.138 fit a population PK model to data from an adult Phase
I trial and use this model to design clinical trial simulations needed to devise a
sparse PK sampling schedule for children. De Santis139 consider using a design
prior borrowing information from historical data to plan a clinical trial, for in-
stance to inform sample size selections. Additionally, 12 methods included in the
review79,82,88,93,97,99,107,111,113,115,124 use source data to inform the design (through
sample size calculations) and analysis of a prospective trial in the target popu-
lation. In addition, four methods81,86,92,126 use source and target data to inform
mid-study adaptations to the study in the target population.
Software was available for few of the 102 methods identified by this review. Com-
puter syntax was included in a main paper or accompanying supplementary mate-
rial for 9 methods;82,87,92,93,95,96,99 code was stated as available upon request from
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the corresponding author of one method;121 syntax for another method78 was in-
cluded in a related commentary article.140 The strategy used to identify available
software is described in Appendix A.3, while the results are listed in online Supple-
mentary Appendix D which can be found at (http://www.research.lancs.ac.
uk/portal/en/publications/-(8911844e-2638-4dec-a844-8b842f034168).html)
and is described in more detail in Appendix A of this thesis.
This systematic review has aimed to be a comprehensive overview of methods
for extrapolation. However, one limitation is that we chose to focus our literature
searches on the four application areas listed in Section 3.2 and by doing so may have
missed other relevant methods. Another limitation is that one author extracted
the data so independent reviews of all papers were not performed.
56
Chapter 4
Background to ‘Clinical drug
development in epilepsy revisited’
paper
4.1 Introduction
After the systematic review presented in Chapter 3, we then sought to elicit the
opinion of UK based epilepsy experts regarding the role and acceptability of ex-
trapolation in paediatric epilepsy treatment research. This meeting placed our
extrapolation research into a clear context and resulted in a publication in the
journal CNS Drugs given in Chapter 5. In Chapter 5, we discuss the opinions
of experts regarding extrapolation and propose a new paradigm for the develop-
ment of epilepsy medicines streamlined using the partial extrapolation assumption
which the experts felt appropriate for focal epilepsies. Section 4.2 below discusses
the organisation of the epilepsy experts meeting.
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4.2 One-day meeting outline
An initial plan for the meeting was laid out in the proposal for the NIHR grant
(NIHR-RMOFS-2013-03-05): expert opinion regarding the role of extrapolation in
paediatric epilepsy drug development would be elicited during a 1-day meeting.
The plan was for the meeting to elicit opinion regarding perceived sources of het-
erogeneity in the paediatric population, such as between different age groups; the
appropriateness of source populations (e.g. adults) from which efficacy data can
be extrapolated to younger children; and the evidence base needed in such source
populations to support extrapolations.
Experts were defined as neurologists with experience in adult and/or paediatric
epilepsy and the aim was to recruit 6 to 8 experts who would be identified through
the International League Against Epilepsy, Association of British Neurologists and
the British Paediatric Neurology Association; our collaborator Dr. Graeme Sills,
a Senior Lecturer in the Department of Molecular and Clinical Pharmacology at
the University of Liverpool, was instrumental in identifying the experts to be in-
vited and informally contacted each expert to gauge their interest. Initially, 12
experts were invited, with seven experts attending the meeting: two adult neurol-
ogists (Anthony G. Marson; Philip E. M. Smith) and five paediatric neurologists
(Richard Appleton; J. Helen Cross; Tim Martland; Ailsa McLellan; Chris Rittey).
Before the meeting could take place, Dr. Lisa Hampson, as principal investigator
for the project, had to gain ethical approval. This involved filling in an ethics self
assessment form, confirming that any recordings taken would be deleted as soon as
possible after transcription and ensuring that all experts read through and signed
a consent form. Experts were sent this consent form prior to the meeting, along
with a participant information sheet which provided details about the purpose of
the meeting, what would be expected of experts, what data would be collected
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and what they could do if they changed their mind about participating.
As the experts were based across the UK, the Manchester Meeting Place (part of
the University of Manchester) was chosen as a central location and the one-day
meeting was held on the 6th November 2014. The meeting was split into morn-
ing and afternoon sessions, and on arrival the experts were given an information
booklet which contained the participant information sheet, a list of attendees, an
agenda, and the morning and afternoon session slides.
During the morning session, a brief talk was given outlining the project work,
project team, the aims of the meeting, and an explanation of extrapolation (defi-
nition; use; issues specific to paediatric epilepsy medicine development; examples
of extrapolation). A discussion session was held in the afternoon where several
questions were asked:
• Are paediatric patients just small adults?
• Are all paediatric patients the same?
• If a drug is safe in adults, is it safe in paediatrics?
• Can we extrapolate efficacy data from adjunctive therapy to monotherapy?
• When is it reasonable to use therapies in paediatrics that are licensed only
for adults?
This discussion session was recorded and the company UK Transcription were
hired to transcribe the recordings. Based on these discussions, an opinion paper
was written which discussed the experts thoughts on the place of extrapolation in
paediatric epilepsy medicine development and a new paradigm for having phase
II and III trials recruit both adults and children aged 2 years and above, justified
by the experts belief about an assumption of partial extrapolation between adults
and children being appropriate.
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Chapter 5
Clinical drug development in
epilepsy revisited: A proposal for
a new paradigm streamlined
using extrapolation
5.1 Introduction
The European Medicines Agency (EMA) defines extrapolation as ‘...extending in-
formation and conclusions available from studies in one or more subgroups of the
patient population (source population). . . to make inferences for another subgroup
of the population (target population). . . ’34,141 There are several examples of how
this definition can be applied. Using the terminology of Dunne et al.,36 extrapo-
lation can range from complete (no additional data needed in the target popula-
tion) to partial (supporting data needed) to none. Extrapolation can be used to
streamline drug development. Avoiding unnecessary studies in populations whose
response to therapy is well understood enables sponsors to focus research on patient
groups about which least is known. This chapter considers how the extrapolation
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of adult efficacy and safety data can be used to streamline the development of
drugs for use in paediatric epilepsies.
Off-label prescribing in paediatrics is prevalent in the US142 and EU.143 In routine
clinical practice, informal extrapolation from adult data increases the confidence
of doctors and families about off-label prescribing in children. When develop-
ing new medicines, it is reasonable practice to extrapolate from adult data to
predict the clinical benefits of a new medicine in paediatrics such that smaller
trials may suffice to demonstrate efficacy in this age group. However, extrap-
olations only have value if robust assumptions on similarity hold when applied
to the adult and paediatric populations. The US Food & Drug Administration
(FDA)1 and ICH E1123 guidelines outline an algorithmic approach for determin-
ing which data are needed to support paediatric licensing of a medicine depending
upon whether it is reasonable to assume that disease progression, drug pharmacol-
ogy, and pharmacokinetic-pharmacodynamic (PK-PD) relationships are consistent
across adults and paediatric patients. An alternative framework has recently been
proposed which stipulates that emerging and cumulative data in the target popu-
lation should be used to confirm extrapolation assumptions.34,141
In the context of epilepsy research, it is not always possible to predict clinical
benefits in paediatric patients using adult data due to disparities in the different
types (syndromes) of epilepsy and in their specific natural histories. The accept-
ability of extrapolation will depend on several factors, including age, seizure type
and epilepsy syndrome, treatment regimen, and the individual antiepileptic drug
(AED). Whilst there is broad agreement that efficacy in adults with focal epilepsies
can be extrapolated to paediatric patients with focal epilepsies, there is disagree-
ment about the boundary of certainty, with different expert groups supporting
extrapolation down to the ages of either 243 or 4 years.44 The FDA has recently
suggested that complete extrapolation of efficacy from adult to paediatric patients
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aged 4 years and older with partial onset seizures is acceptable.45 This is a major
development, and one that is consistent with our view, but the potential of ex-
trapolation goes much further.
This chapter explores these issues and provides recommendations on the role of
extrapolation in drug development for epilepsy and identifies opportunities to im-
prove current practice. It reflects work conducted within a project funded by
the National Institute for Health Research (UK) on extrapolation approaches in
paediatric trials.
5.2 Considerations
5.2.1 Are paediatric patients just small adults?
In the case of common focal epilepsies, the answer may well be yes. The aetiology
of extra-temporal focal epilepsy in both adults and children is predominated by
vascular lesions, trauma, and, most frequently, cortical dysplasias. Dysplasias are
present from birth and while the time to seizure onset may vary widely, the un-
derlying pathology is the same which suggests that this is likely to reflect a single
pathophysiological process independent of age.
All patients aged 2 years and above with focal epilepsy would be expected to re-
spond similarly to drug treatment in terms of seizure frequency reduction, provided
that dosing led to an equivalent serum concentration-time profile. Although there
are some subtle differences in semiology of focal seizures in the youngest age groups
(i.e. paucity of automatisms, predominance of bilateral motor signs, etc.), these
rapidly disappear with age and there is no evidence that these seizure types are
differentially responsive to first-line therapies for focal epilepsy.144 Consequently,
it should be possible to extrapolate efficacy data obtained in adults with focal
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epilepsy to patients aged 2 years and above. It would be inappropriate, however,
to extrapolate efficacy to patients below 2 years of age primarily because of greater
variability in aetiology and difficulties in diagnosis.
While the natural history of epilepsies may differ between adults and paediatrics,
any differences in treatment effect between adult and paediatric patients with focal
epilepsies are likely to be quantitative rather than qualitative.42,43,145,146 However,
this does not obviate the continued need for trials of new AEDs in paediatrics,
particularly in the case of the rarer epilepsy syndromes.
5.2.2 Are all paediatric patients the same?
For focal epilepsies, the older age groups proposed in the ICH E11 guidance (Table
1)23 could in theory be merged to create a single group that encompasses children
and adolescents aged 2 to 16/18 years. However, there would be less confidence
regarding the younger age groups and discussions with neonatologists would be
required.
There is no doubt that preterm and term infants are relatively under-investigated
with minimal Phase I or randomised controlled trial (RCT) data. Extrapolation
of efficacy data from adults or older paediatric patients to these groups is not pos-
sible because of differences in the pathophysiology of the epilepsy as well as brain
biochemistry, brain development, and drug-metabolism. Drug-clearance is low in
preterm and term newborn infants, subsequently increases rapidly until around 2
years, and then declines steadily until around 12 years at which point it is con-
sidered to have reached adult levels, such that adult dosing can be considered
for adolescents aged > 12 years;147 this is well-illustrated by carbamazepine.148
However, sufficient variability exists that PK studies are likely to be required to
support dose choices for paediatric patients aged 2 to 12 years even when efficacy
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is extrapolated.
In general, the behaviour of AEDs in patients aged 2 years and above is usually
predictable. There is a need for more robust studies in patients under 2 years with
both focal and generalised epilepsies. This is acknowledged to be challenging,
especially for patients less than 1 month old in whom the study design would be
critical.
5.2.3 If a drug is safe in adults, is it safe in paediatrics?
There are a variety of adverse outcomes associated with AED use, including those
that are acute and dose-related, those that are chronic and exposure-related, and
those that are idiosyncratic and likely to be immune-mediated. For the purposes
of this article we group them all under the term “safety”. Most safety issues are
considered to be essentially similar in adults and paediatrics at equivalent doses.
There is anecdotal evidence suggesting that some idiosyncratic reactions occur
at differing frequencies in adults and children (i.e. lamotrigine-induced Stevens-
Johnson syndrome) but this may simply reflect differences in drug disposition and
in systemic exposure to the drugs or their reactive metabolites. Those aside, it is
possible, with appropriate caution, to extrapolate most adult safety data to pae-
diatric patients aged 2 years and above.
Important safety issues that are specific to paediatrics include effects on growth
and on pubertal, motor, speech and language, and cognitive development. These
paediatric safety signals cannot be reliably identified from an adult population.
Effects on learning and on social and educational development are also important
and in paediatric patients with severe epilepsies it may be difficult to distinguish
the influence of the epilepsy and its underlying aetiology from the effects of the
medications used to treat it. Nevertheless, improvements in attention, memory,
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cognition, and behaviour can be observed during AED withdrawal in paediatric
patients with challenging epilepsy, suggesting a strong influence of drug treatment.
Seizure aggravation is another important safety issue, particularly in rare idio-
pathic focal epilepsies that are typically diagnosed in childhood only. Standard
treatments can occasionally exacerbate seizures in these children but their low
prevalence in the focal epilepsy population means that they might evade detection
in controlled trials of short duration. Inclusion of EEG follow-up in the Phase
II/III trial protocol for paediatric participants would improve detection of these
paradoxical effects.
5.2.4 When is it reasonable to use therapies in paediatrics
that are licensed only for adults?
For drugs licensed for use in adults but not in paediatrics, this would depend on
the clinical situation with a risk-benefit trade-off determining the acceptability of
off-label prescribing. When prescribing off-label in paediatrics, a drug will often
be tried initially in adolescents before then being used in younger patients.
There would likely be greater confidence to enter patients in clinical trials rather
than prescribe an AED off-label, particularly because of the detailed monitoring
performed within a trial. There is a clear need for paediatric RCTs to be conducted
earlier than at present and in parallel or in conjunction with adult trials. This
would incentivise the recruitment of children into trials since accrual can be chal-
lenging when a trial treatment licensed in adults is available off-label in children.
Improving enrolment will improve the quality of paediatric RCTs since inadequate
accrual currently obliges many trialists to recruit from small, inexperienced centres,
increasing patient heterogeneity and the risk of internal biases. Earlier paediatric
RCTs would also widen participation in trials to include children with refractory
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epilepsy who are often excluded from new drug studies on the basis that they have
already been prescribed the drug off-label after failing all other licensed medicines.
It is important to acknowledge that there may be paediatric-specific issues for
any RCTs undertaken in the idiopathic focal epilepsies of childhood and partic-
ularly benign partial epilepsy with centro-temporal spikes (BECTS) and benign
epilepsy of childhood with occipital paroxysms (BECOP; Panayiotopoulos syn-
drome). The natural history of BECTS (and probably BECOP), is such that a
spontaneous remission may occur any time, including soon after its onset or di-
agnosis. Consequently, any apparent efficacy of a drug in RCT participants with
BECTS or BECOP may be due to the drug itself or to the natural history of the
syndrome. This might risk assay sensitivity in a non-inferiority trial but would be
of less concern if the trial was designed to detect differences and found them.
5.2.5 Can we extrapolate efficacy data from adjunctive
therapy to monotherapy?
Extensive trial data and clinical experience with existing AEDs has failed to find
any instance where a drug behaves differently in terms of its spectrum of efficacy
and adverse effects when administered alone or as adjunctive therapy, except in
circumstances where drug interactions might be expected. Consequently, it would
be reasonable to extrapolate efficacy data from adjunctive trials to inform the use
of an AED as monotherapy.
Mintzer et al (2015) state that the need for separate monotherapy and adjunctive
therapy licenses in epilepsy is “unnecessarily restrictive” and that AEDs should
be approved for specific seizure types or epilepsy syndromes only.149
66
5.3 An alternative paradigm for developing medicines
for focal epilepsies
This section outlines our proposal for future clinical development of drugs for
focal epilepsies. This proposal uses a partial extrapolation of adult efficacy data,
generating only supportive efficacy data in children aged 2 years and above, and a
limited extrapolation of adult safety data to justify joint Phase II and III studies
recruiting adult and paediatric patients aged 2 years and above.
5.3.1 Phase I trials
The primary purpose of these trials remains the identification of a safe range
of doses of a new compound to be used in the subsequent clinical development
programme. Such studies should continue to be undertaken in healthy male adults
only in an effort to reduce variability, limit confounding influences and minimize
the likelihood of unexpected adverse events.
5.3.2 Phase IIa and IIb trials
The primary purpose remains determination of the effective dose range and a pre-
liminary assessment of safety and efficacy. Trials should be randomised, placebo-
controlled, adjunctive therapy studies following current guidelines for adjunctive
trials but now recruiting patients with focal epilepsy aged 2 years and above,
obviating the current requirement for a separate development programme in pae-
diatrics. Using partial extrapolation of adult efficacy data, power calculations
should be based on the entire study population but the final analysis should be
stratified by age. Long-term extension will allow provisional assessment of safety
in adults, paediatrics or both. There would not be a requirement to complete the
long-term extension before progressing to Phase III. PK investigations will reveal
the dose-concentration relationship in adults, paediatrics or both. Wherever pos-
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sible, PK data should be analysed using population-PK models to accommodate
sparse sampling schedules. Inclusion of mandatory EEG follow-up for paediatric
participants would allow detection of seizure aggravation.
5.3.3 Phase III trials
The primary purpose remains the identification of efficacy in comparison to placebo.
Traditional approaches are appropriate; i.e. randomised and placebo-controlled tri-
als of adjunctive therapy. Efficient adaptive150 and/or Bayesian151 strategies to the
design and analysis of trials should be considered if appropriate. Studies should
again recruit patients with focal epilepsy aged 2 years and above and should be
powered to detect treatment effects based on the total sample size accumulated
across adults and paediatrics but should also include potential for stratified anal-
ysis. Minimum sample sizes in each age group might be pre-specified to ensure
that reliable (but not necessarily definitive) conclusions can be drawn from the
paediatric data. If a significant treatment effect was demonstrated in adults but
not in paediatric patients and the differences could be attributed to sample size
alone, then the treatment would still be acceptable for paediatric use provided
there were no qualitative differences in the effects between adults and paediatric
patients.
Long-term extension will allow additional open-label assessment of safety and effi-
cacy in adults, paediatrics or both. Further PK investigations and EEG follow-up
may be required, particularly in paediatric patients.
5.3.4 Licensing of treatments
Under this new paradigm, since all pivotal trials would be conducted in both pae-
diatrics and adults, licensing should also apply to all age groups from 2 years
upwards. Licenses should be granted for a general indication of focal epilepsy,
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allowing the discretionary use as either adjunctive therapy or monotherapy unless
there is reason to impose a restriction. Approval for paediatric use (2 to 16/18
years) should be conditional on a prospective, time-limited commitment to collect
safety data from paediatric patients on growth and on neurological and cognitive
development. Ideally, these neuro-developmental safety data would be collected
within a randomised, placebo-controlled design, but this is likely to pose signif-
icant logistical issues. Consequently, it would be appropriate and sufficient to
collate multiple audit and observational data. This is a pragmatic solution since
the challenges of deducing unbiased estimates of causal effects from observational
data in the presence of unmeasured confounders are well documented.152 Caution
should also be exercised to prevent or at least monitor the use of drugs licensed for
focal epilepsy in more complex epilepsies that express multiple seizure types; the
focal component may be improved but other seizure types may be simultaneously
exacerbated.
The approach proposed above has been used to develop rufinamide for Lennox-
Gastaut syndrome.153,154 However, this was a syndrome-specific development pro-
gramme for a relatively rare epilepsy. The paradigm suggested here is a more
general framework for common epilepsies which considers other factors such as
adjunctive therapy and monotherapy. It dispenses with the need for a separate
paediatric development programme and a separate monotherapy trial programme,
neither of which have clear additional benefits in focal epilepsies.
5.3.5 Shift in research culture
The adoption of this proposed framework for drug development in epilepsy may
require a shift in culture. A network of specialist paediatric epilepsy centres is
needed to coordinate recruitment of patients into regulatory trials of AEDs, in
a manner similar to the common practice in paediatric oncology. Rather than
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specialists making third or fourth line treatment decisions for paediatric patients,
they should randomise those patients into trials; this would advance knowledge
much more rapidly. Those anxious about undertaking combined trials in adults
and paediatrics should consider the SANAD studies, which remain the largest ever
randomised trials in epilepsy and which successfully recruited across the age spec-
trum from 5 years upwards.155,156 Fears over inclusion of paediatric patients in
randomised trials should be tempered with examples of paediatric epilepsy stud-
ies that have successfully hit their recruitment targets in a timely manner157–160
and with evidence regarding parents opinions on enrolment of their children into
RCTs.26 Finally, improved interaction with neonatologists would help to ensure
that treatments for epileptic seizures in the very youngest age groups do not lag
behind those for others.
5.4 Conclusions
This proposed paradigm for drug development in epilepsy has many potential ben-
efits for epilepsy and epilepsy research; paediatric patients gain from immediate
access to new treatments, trialists have access to a broader patient population,
fewer trials and less restrictive licensing will incentivise sponsors, broaden their
market and re-invigorate drug development for epilepsy, and R&D savings can
be expected to have knock-on effects for medication costs and the allocation of
healthcare resources.
It is acknowledged that there are potential dangers in a condensed AED trial pro-
gramme because of the volume of data and number of patient exposures. There
may also be additional complexities to conducting trials in adults and children if,
for example, drug formulations or dosing rules vary across age groups, although
several successful trials show these barriers are not insurmountable.160 The next
step in this process is to seek the opinion of patients, parents and guardians,
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regulatory authorities, and sponsors on the risks, benefits and feasibility of the
proposed paradigm.
This commentary is written within the context of growing international interest in
the place of extrapolation in the development of medicines for paediatric epilepsies.
Following the publication of robust evidence demonstrating that efficacy in RCTs
recruiting adults with focal epilepsies can similarly predict efficacy in children,42
a US consortium from academia, industry, the FDA and the Epilepsy Foundation
was formed to further explore and develop this concept. The Pediatric Epilepsy
Academic Consortium for Extrapolation (PEACE) has since drafted a white paper
establishing disease similarity in adults and children. Additional pharmacometric
analyses are also currently underway at the FDA to further evaluate pharmacoki-
netic and pharmacodynamic properties of AEDs. The PEACE group has shown
that ever since a 1994 National Institute of Neurological Disorders and Stroke
(NINDS) workshop agreed that most children with focal epilepsies would respond
to a drug that was also efficacious in adults with focal epilepsies,161 further clinical
and basic science data have served to strengthen this viewpoint. After excluding
children below four years and those with focal seizures associated with epileptic
encephalopathy, such as Lennox-Gastaut syndrome, the pathophysiology of focal
epilepsies is similar in children and adults. The PEACE white paper will therefore
recommend that AEDs shown to be effective in adults with focal epilepsies should
be considered as effective in children aged four years and above. This proposal
will be limited to efficacy, noting that safety and PK may not necessarily be ex-
trapolated.
There are subtle differences in the proposals being developed by the PEACE group
in the US and those presented here. Nonetheless, it is encouraging to note that
these discussions are taking place, simultaneously and independently, on both sides
of the Atlantic. Extrapolation is clearly high on the agenda of those interested in
71
expediting the development of new medications for epilepsy.
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Chapter 6
A quantitative framework to
inform extrapolation decisions in
children
6.1 Chapter background
Our systematic review in Chapter 3 highlighted many approaches taken in the
literature to extrapolating between source and target populations, across both fre-
quentist and Bayesian methodology. In this chapter, we aim to develop a quantita-
tive framework to inform extrapolation decisions in children, after data has been
collected in adults and adolescents, but before data in younger children. With
wanting to utilise existing data to inform extrapolation decisions in an unstudied
population, a Bayesian framework seems appropriate. Within a Bayesian frame-
work, we can model exposure-response relationships in existing studies, borrowing
strength across multiple studies in a Bayesian meta-analytic model, quantifying
this as a prior distribution. The focus group meeting of epilepsy experts high-
lighted how useful the elicitation of expert opinion can be. We quantify subjective
expert opinion to learn about the similarity of studied and unstudied populations.
We consider adjusting the results of our Bayesian meta-analytic model for elicited
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expert opinion on whether differences between E-R relationships in adults and
adolescents are representative of differences between adults and younger children.
Ultimately, in this chapter we propose that this bias adjusted meta-analysis can
be used to inform extrapolation decisions in younger children.
6.2 Introduction
An experimental medicine must pass through several phases of experimentation,
and only once its safety and efficacy have been confirmed can it be approved for
general use. At the time of planning a drug development programme, relevant
information may already be available from routine clinical practice; clinical trials
of the drug performed in related diseases or different age groups; or studies of sim-
ilar medicines. The design of the development programme can then be optimised
in light of this so that any new studies fill in the gaps in our existing knowledge
base without replicating information. Leveraging existing data in this way is par-
ticularly desirable when our aim is to develop medicines for small or vulnerable
populations such as children. The European Medicines Agency (EMA) defines ex-
trapolation as “. . . extending information and conclusions available from studies in
one or more subgroups of the patient population (source population) . . . to make
inferences for another subgroup of the population (target population). . . ”34,35 In
many cases, we may seek to extrapolate adult efficacy data to children. Wadsworth
et al.69 report the findings of a systematic review of statistical methods relevant
for extrapolating efficacy and other data from adults to children. The authors
identify methods originally proposed in a variety of contexts, ranging from incor-
porating historical controls in new studies to evaluating the consistency of results
across sites in a multi-centre trial, reflecting the wide ranging applications of ex-
trapolation.
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To justify the extrapolation of adult efficacy data to children, we must often make
strong assumptions about the similarity of age groups in terms of disease progres-
sion, response to intervention and pharmacokinetic-pharmacodynamic (PK-PD)
relationships. These assumptions are made explicit in the paediatric decision tree
(see FDA1 and Figure 6.1) where, in the terminology of Dunne et al.,36 judgements
about the plausibility of each aspect of similarity determine whether a ‘complete’,
‘partial’ or ‘no’ extrapolation strategy is adopted. Dunne et al.36 reviewed 370
paediatric studies submitted to the FDA between 1998 and 2008 to identify cases in
which efficacy data were extrapolated: of the 166 drug products considered, 14.5%
followed a complete extrapolation strategy, 68% a partial extrapolation strategy
and 17.5% did not extrapolate. Sun et al.,71 in an update on the review by Dunne
et al.,36 reviewed 388 paediatric studies between 2009 and 2014. The proportion of
products using partial extrapolation fell to 29%, whilst the use of no and complete
extrapolation both rose to 37% and 34%, respectively. There is likely to be prior
uncertainty about the plausibility of different assumptions. Hlavin et al.162 use
a scepticism factor to represent uncertainty about the plausibility of a complete
extrapolation approach, whereby the full weight of evidence supporting drug ef-
ficacy in adults is taken to support a claim of efficacy in children. This factor
could be established from historical data or expert opinion. The EMA extrapola-
tion framework stipulates that data which are subsequently collected in the target
population should be used to confirm extrapolation assumptions.34,35
Since 2006, the EU paediatric regulation27 has mandated that the programme of
studies intended to support licensing of a medicine for children in the EU must
follow a Paediatric Investigation Plan (PIP), which itself must be agreed ahead
of time with the EMA’s Paediatric Committee (PDCO). When selecting (approv-
ing) an extrapolation strategy, sponsors (regulators) must first ask themselves
how plausible needed assumptions are given the data currently to hand, where
extrapolation strategies relying on more plausible assumptions are to be preferred.
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Figure 6.1: Extrapolation strategies, assumptions made and required studies,
based on the FDA paediatric decision tree.1
This chapter presents a framework for using existing data to inform a decision on
whether to perform a complete extrapolation of efficacy data from adults to chil-
dren or a partial extrapolation instead. This decision will determine whether the
sponsor will collect only PK data in children to support dose-finding, or both PK
and PD data. The proposed framework requires pre-specification of a numerical
criterion which PK-PD curves in adults and children must satisfy in order to be
considered ‘similar’. The sponsor can then use historical data or expert opinion to
quantify the prior plausibility of the stated degree of similarity. This process en-
ables sponsors and regulators to define transparent success criteria which emerging
data in the target population must satisfy in order to be judged as verifying the
assumption.
We propose that the process of choosing between complete and partial extrapola-
tion strategies should begin by performing a Bayesian random-effects meta-analysis
of existing PK-PD data to derive priors for parameters representing differences
between PK-PD relationships in adults and children. When studying small pop-
ulations it is likely that few historical studies will be available for synthesis. The
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methodological challenges associated with performing meta-analyses of few trials
have been noted in Friede et al. and Turner et al.163,164 In this setting, using a
frequentist approach, we lack power to detect between-trial heterogeneity,163 while
the results of a Bayesian random-effects meta-analysis are sensitive to the choice of
prior for the between-trial heterogeneity parameter.163,165 Furthermore, ‘external
biases’51 may be inherent in the existing data if there are differences between the
source and target populations, for example, if existing data are measurements on
adults and adolescents but our question is whether PK-PD relationships in adults
and children aged 2-11 years are similar. This data scenario often arises in practice
because drug development in adults and children is typically staggered, starting in
adults first. Furthermore, older adolescents are also often recruited into adult tri-
als in therapeutic areas such as epilepsy155,156,166,167 and asthma.168,169 To derive
prior distributions for key parameters accounting for external biases, existing data
may be down-weighted according to either a pre-specified weight (see, for example,
Ibrahim and Chen;72 Tan et al.;170 Rietbergen et al.87) or a dynamic weight reflect-
ing their commensurability with new data collected in the target population.72–74
The challenges of dynamic downweighting are noted in Galwey.171 Alternatively,
we can model the external biases and either define empirical priors51,172 or priors
elicited from expert opinion51 on the bias parameters. We adopt the latter ap-
proach here.
To make things consistent, throughout this chapter we illustrate the proposed ex-
trapolation framework with applications to anti-epileptic drug (AED) development
in mind. In this setting, there is broad agreement about the acceptability of extrap-
olating efficacy data in adults with partial-onset seizures (POS) to older children
with POS, although there is some uncertainty about what age we can extrapolate
down to.43–45,70 This chapter proceeds as follows. In Section 6.3 we introduce
our framework, define a Bayesian bias-adjusted multivariate meta-analytic model
for existing PK-PD data and propose a quantitative criterion to justify complete
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extrapolation of the efficacy data. Section 6.4 describes a scheme for eliciting
expert opinion on external biases that may be inherent in the existing data. In
Sections 6.5 and 6.6, we describe the simulation study used to evaluate properties
of our framework in a range of scenarios before concluding in Section 6.7 with a
discussion.
6.3 Using existing data to inform an extrapola-
tion decision
6.3.1 Motivation
Our aim is to use existing adult and adolescent data to inform our decision of
whether to adopt a complete or partial extrapolation approach for younger chil-
dren. Suppose PK-PD data are available from H historical trials which recruited
both adults and adolescents. Let Yij represent the response of the i
th subject in
historical study j, for i = 1, . . . , Nj, and j = 1, . . . , H. Then, writing Aij as a
binary indicator of age which takes the value 1 if the ith subject in study j is an




γkxkij + γCCij + γAAij + γICijAij
 , (6.1)
where Cij is a measure of drug exposure; x1ij, . . . , xKij are baseline covariates (such
as weight) influencing response; and g is the link function of the generalised linear
model.
For present purposes, we assume that regression parameters remain constant across
studies. In this case, the relationship between exposure and the expected PD re-
sponse, hereafter referred to as the PK-PD ‘relationship’ or ‘curve’, is said to be
identical in adults and adolescents in each study if γA = γI = 0. The assumption
of between-trial homogeneity is relaxed in Section 6.3.3, in which case γA and γI
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can be interpreted as population means.
To simplify the presentation of our methods, we will assume throughout that the
PD response of interest is normally distributed and that a linear model is an ad-
equate description of the underlying relationship between exposure and response,
so that
Yij = γ0 +
K∑
k=1
γkxkij + γCCij + γAAij + γICijAij + ij, (6.2)
where ij ∼ N(0, σ2) is a random error term. Linear models have been used
to analyse PK-PD data for the AEDs oxcarbazepine38 and topiramate166 setting
Y = log{Z+110}, where Z is the percent change from baseline in seizure frequency
and C represents the steady state trough concentration under repeated dosing.
Consider now the data that we would accumulate if we performed a PK-PD study,
indexed by T , in adults and younger children, that is, the target population. If we
made a complete extrapolation of efficacy data from adults to younger children,
we would not need to perform this study but it is useful to consider the data
that it would generate. Suppose we measure PD responses YiT , for i = 1, . . . , NT ,
following the linear model
YiT = β0 +
K∑
k=1
βkzkiT + βCCiT + βAAiT + βICiTAiT + iT , (6.3)
where iT ∼ N(0, σ2); z1iT , . . . , zKiT are baseline prognostic covariates defined
analogously to x1ij, . . . , xKij; CiT is a measure of exposure for subject i defined
similar to Cij; and AiT is a binary age covariate taking the value 1 if subject i
is a younger child and 0 otherwise. PK-PD relationships in adults and younger
children would be said to be identical if βA = βI = 0. The age boundary separating
adolescents from younger children can be chosen based on the ICH E11 guidance23
which stipulates that children are aged 2 to 11 years and adolescents 12 to 16-
18 years (dependent on region). We relate parameters in the source and target
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populations described by models (6.2) and (6.3) via the relations:
βA = γA + δA and βI = γI + δI . (6.4)
This makes the assumption that the PK-PD relationship in younger children only
differs from adolescents by additive bias terms δA and δI . Here δA and δI rep-
resent external biases arising because PK-PD curves in adolescents and younger
children may differ due to the effects of maturation and physical development on
drug absorption, distribution, metabolism and elimination, and on the action of
and response to a drug.173 Stephenson22 also notes that the responses of adults
and children to many drugs have much in common, although there are examples,
such as warfarin174 and cyclosporine,175 where there are true pharmacodynamic
differences between age groups. An alternative to the additive bias model (6.4)
is a proportional model stipulating βA = δAγA and βI = δIγI .
51 However, we
prefer an additive model in this setting since there may be differences between
adults and younger children even if there are no differences between adults and
adolescents. Furthermore, we can think of differences between adults and younger
children as the sum of differences between adults and adolescents and differences
between adolescents and younger children.
The existing data, DE, are said to be relevant for learning about likely differences
between PK-PD relationships in adults and younger children if δA and δI are both
close to 0. In the following sections, we outline how priors for (βA, βI) can be
derived by first performing a Bayesian meta-analysis of DE to obtain posterior
distributions for (γA, γI), and then adjusting for our prior opinion on (δA, δI) ac-
cording to model (6.4). Based on the priors for (βA, βI) thus obtained, we can
calculate the prior probability that PK-PD curves in adults and younger children
are similar enough to satisfy the criterion for complete extrapolation that will be
proposed in the following section. If this probability is high, it may be used to
80
support a decision not to perform a PK-PD study in younger children and instead
leverage the adult data to support a claim of efficacy in this age group.
6.3.2 Extrapolation criterion
We define how similar PK-PD curves in adults and younger children must be in
order to justify a complete extrapolation of efficacy data. Let C? denote a level of
exposure known to be effective in adults, for example, the adult EC90, the exposure
at which the expected adult response is 90% of the maximum. We propose a
similarity criterion evaluating whether a summary measure of the distribution of
responses in adults and younger children on placebo and at an effective level of
exposure are equivalent. Then, PK-PD curves are said to be similar if
M[h{Y (CT = 0;AT = 1)}]−M[h{Y (CT = 0;AT = 0)}] ∈ (−η1, η1) (6.5)
and
M[h{Y (CT = C?;AT = 1)}]−M[h{Y (CT = C?;AT = 0)}] ∈ (−η2, η2), (6.6)
where h(Y (CT , AT )) is a function of the PD response of a subject randomised
to exposure CT in age group AT ; and M is a measure of location such as the
mean or median. It may be more straightforward to specify equivalence margins
with differences between a transformed outcome in mind. For example, in the
context of AEDs, criteria (6.5)-(6.6) would be written setting h(Y (CT ;AT )) =
exp(Y (CT ;AT ))− 110. In this case, it would be more appropriate to use the me-
dian as a summary measure since the log-normal distribution is asymmetric. In
practice, bounds η1 and η2 would be set by regulators based on clinical judgement.
Larger bounds imply that larger differences between the average PD responses of
adults and younger children will be tolerated if we incorrectly perform a complete
extrapolation and dose younger children targeting the adult effective concentra-
tion. Whilst different equivalence bounds can be applied at exposures CT = 0 and
CT = C?, to simplify, we set η1 = η2.
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Working in a Bayesian framework, the prior probability of criteria (6.5)-(6.6) can
be taken as a measure of the prior plausibility of an assumption that PK-PD curves
are similar enough in adults and children to justify a complete extrapolation of
efficacy data across these subgroups. We speculate that a prior probability in
excess of 0.8 or 0.9 would be sufficient to support the immediate adoption of a
complete extrapolation strategy. Lower probabilities would prompt a sponsor to
collect additional PK-PD data in younger children, where the exact sample size
may be determined according to an expected value of information calculation.176,177
However, a very low prior probability could be consistent either with extreme
uncertainty about the relevance of the existing data or a strong degree of scepticism
about the similarity of PK-PD curves in adults and younger children. In both cases
the most appropriate testing strategy would be to plan a PK-PD study in younger
children sized to support independent dose-finding in this age group.
6.3.3 Bayesian bias adjusted meta-analytic model for ex-
isting data
We begin the process of quantifying what is known about differences between
adults and younger children by using a Bayesian meta-analysis to learn about γA
and γI . We assume individual patient data are available but summary measures
could be used if maximum likelihood estimates and corresponding standard errors
are available for all parameters in the linear predictor of model (6.2). At the
first level of the meta-analytic model, existing data from study j, j = 1, . . . , H,
enrolling adults and adolescents, are modelled as
Yij = γ0j + γCjCij + γAjAij + γIjCijAij + ij, (6.7)
where ij ∼ N(0, σ2) and for ease of presentation, we assume that the only baseline
covariate prognostic of outcome is age. To limit model complexity we regard the
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study-specific intercepts and effects of exposure as fixed effects, with population





To accommodate between-trial heterogeneity in the remaining study-specific pa-
rameters in model (6.7), we model (γAj, γIj) as samples from a bivariate Normal
(BVN) population distribution with mean µ = (γA, γI) and covariance matrix
Σ. Considering the prior distributions for Σ, one approach would be to place an
inverse-Wishart prior on the covariance matrix. However, our investigations found
the result of the meta-analysis to be very sensitive to the choice of the inverse-
Wishart scale matrix; decreasing the diagonal elements of this matrix reduces the
variances of the marginal posterior distributions of γA and γI . Gelman
178 shows
that inverse-Gamma(ε, ε) priors with ε ≈ 0 are informative for variance param-
eters in hierarchical models and suggests that inverse-Wishart prior distributions
for covariance matrices incur similar issues. To avoid this sensitivity, we adopt an
alternative parameterisation179 for the BVN population distribution which gives
the analyst more flexibility in how they specify priors for variance parameters. For
j = 1, . . . , H, define
γAj ∼ N(γA, ξ21),
γIj | γAj ∼ N(λ0 + λ1(γAj − γ¯A), ξ22),
where γ¯A = (1/H)
∑




















where, under this representation, γI = λ0 + λ1(γA − γ¯A). It is clear therefore that
the proposed parameterisation allows for a correlation between γAj and γIj, for
each j = 1, . . . , H.
83
The definition of the meta-analytic model is completed by defining priors for all
unknown parameters. For each j, j = 1, . . . , H, the study-specific intercept and
effect of exposure, γ0j and γCj, are assigned independent Normal(0, ζ
2) prior dis-
tributions. For the residual precision we stipulate σ−2 ∼ Gamma(a, b), with a and
b chosen to define a diffuse prior. For parameters of population distribution (6.8),
we place a Normal(0, 100) prior on γA and specify priors ξ1 ∼ Gamma(a1, b1),
ξ2 ∼ Gamma(a2, b2), λ0 ∼ t(µt, σt, νt), and λ1 ∼ Normal(µ1, σ21). In the examples
we have considered, we have chosen parameters of these prior distributions to en-
sure the prior for the correlation between each pair (γAj, γIj) has a bucket shape
placing probability mass at −1 and 1 and furthermore that prior probability mass
is placed on a range of plausible values for the between-trial standard deviations.74
The Bayesian meta-analytic model can be fitted using Markov Chain Monte Carlo
(MCMC). The joint posterior distribution of (γ0, γC , γA, γI) will not be of a stan-
dard form. Similar to Schmidli et al.,57 to facilitate communication and repro-
ducibility of the joint posterior we approximate it as a mixture of K 4-dimensional
multivariate Normal (MVN) distributions using the ‘flexmix’ package180–182 in R:16
f(γ0, γC , γA, γI | Y1, . . . ,YH) ≈ ΣKi=1ωi φ4(µi,Σi), (6.9)
where φ4(µ,Σ) is a four-dimensional MVN probability density function (pdf) with
mean µ and variance Σ; and Y1, . . . ,YH are vectors representing the adult and
adolescent data from existing studies 1, . . . , H. Increasing K in (6.9) increases the
accuracy of the finite mixture approximation as measured by the Kullback-Leibler
(KL) divergence;57,183 however, these increases diminish as K increases and must
be balanced against increases in model complexity. In our investigations, we have
found setting K = 2 in (6.9) to be adequate and in the simulations described in
Section 6.5, we occasionally found that some two-component model fits actually
returned a one-component solution, that is, the posterior could be accurately ap-
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proximated by a single 4-dimensional MVN distribution.
If we consider (γA, γI) to be systematically biased for the parameters (βA, βI) in
model (6.3), then we can elicit expert opinion on the size of these external biases.
We assume that prior opinion on the vector of bias parameters can be modelled
as a bivariate normal distribution, written as δ ∼ N2(ν, Π), where ν = (νA, νI)
are the prior modal values of the biases. Our protocol for eliciting ν and Π
is described in Section 6.4. Then, by sampling pairs (γA, γI) and (δA, δI) from
f(γ0, γC , γA, γI |Y1, . . . ,YH) and φ2(ν,Π), respectively, we generate samples from
the prior distribution of (βA, βI) given the existing data. Fitting these Monte Carlo
samples using maximum likelihood estimation, we obtain the approximate prior
g(βA, βI | Y1, . . . ,YH) = Σ2i=1ωiφ2(µi,Σi). (6.10)
6.3.4 Effective sample size
It is useful to quantify how much we have learnt about differences between adults
and younger children from the existing data in adults and adolescents. From this,
we can infer to what degree the existing data are down-weighted due to our uncer-
tainty about their relevance. We measure our uncertainty by the effective sample
size (ESS)184 of the (βA, βI) prior shown in (6.10). The ESS is defined as the
total number of subjects (adults and younger children) that would be required to
participate in a future PK-PD study to provide the same amount of information
about βA and βI as is represented by prior (6.10).
To calculate the ESS we follow the approach of Morita et al.184 For each sample
size m = 1, . . . ,M , we compare the trace of the Fishers information matrix of
g(βA, βI | Y1, . . . ,YH) with that of the posterior gm (βA, βI |D) formed by updating
an -information prior, g(βA, βI), with hypothetical new data D, a vector listing
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the PD responses, ages and exposures of m subjects recruited into a new PK-PD
study of adults and younger children. The -information prior is of the same form
as g(βA, βI | Y1, . . . ,YH), with the same number of mixture components, mixture
weights and component-wise means and correlations, but with the component-wise
variances inflated such that the -information prior contains minimal information.
The ESS is obtained by interpolating between values of m to find the sample size
corresponding to the smallest distance between the traces of the information ma-
trices of g(βA, βI | Y1, . . . ,YH) and gm (βA, βI |D).
Assuming data from a new PK-PD study in adults and younger children would
follow model (6.3), the trace of the information matrix of gm (βA, βI |D) is a func-
tion of unknown model parameters and the unobserved PD responses, ages and
exposures contained in D, and therefore must be estimated using Monte Carlo
simulation. In practice we recommend simulating PD responses from model (6.3)
assuming β0 = γ0 and βC = γC , where γ0 and γC are as defined in Section 6.3.3;
the remaining model parameters βA and βI should be set equal to their expec-
tations defined according to g(βA, βI |Y1, ...,YH).184 This means that if there is a
prior-data conflict, the ESS may not be an accurate indicator of the contribution
of the prior (based on existing data and prior opinion) to the posterior (combining
existing data and opinion with data from the new PK-PD trial). Age and exposure
covariates (A1T , C1T ), . . . can be sampled from models fitted to the existing data; in
particular, this would assume that adults and younger children would be recruited
into a new PK-PD study in the same proportion as adults and adolescents were
enrolled into the existing studies. Following these steps, for each m = 1, ...,M , one
can simulate 10,000 datasets from a new PK-PD study in adults and younger chil-
dren with sample size m, and calculate the average difference between the traces
of g(βA, βI |Y1, ...,YH) and gm (βA, βI |D). When evaluating the properties of our
procedure in Section 6.5, to increase the accuracy of calculations we computed
the ESS of g(βA, βI | Y1, . . . ,YH) simulating D setting β0 and βC equal to the
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values of γ0 and γC used to simulate the adult and adolescent data. Simulated
values of A1T , A2,T , . . . and C1T , C2T , . . . were sampled from the same models that
were used to generate the existing adult and adolescent data. We simulate 10000
new data sets for the Monte Carlo simulations and evaluate the difference between
the traces of g(βA, βI | Y1, . . . ,YH) and gm (βA, βI |D) by calculating the trace of
gm (βA, βI |D) for sample sizes m = 1, . . . ,M and averaging over the simulations,
so we have M trace averages.
6.4 Eliciting prior opinion on external biases
6.4.1 Overview
In this section we describe our proposal for eliciting an individual expert’s opinion
on the additive biases δA and δI . Experts should be subject matter specialists,
such as consultant-level clinicians with a relevant specialism. Our full elicitation
scheme can be broken down into four main components:
Part 1 Present to each expert fitted dose-response curves for adults and adolescents
derived from existing data;
Part 2 Elicit each expert’s prior modal guess at the dose-response curve in younger
children;
Part 3 Elicit from the expert their uncertainty about their answer to Part 2 as a
90% credibility interval;
Part 4 Use the expert’s answers from Parts 2 and 3 to derive a fitted prior for δA and
δI . Feedback to the expert the consequences of their opinions by presenting
summaries of their fitted priors for the dose-response relationship in younger
children. Give the expert the opportunity to revise their earlier answers until
they are happy that their fitted prior reflects their beliefs.
87
Note that we frame elicitation questions in terms of the dose-response, rather than
PK-PD, relationship since clinicians are likely to be more familiar expressing be-
liefs about the former; in our experience, serum concentrations of AEDs (and other
drugs) are not typically measured in routine clinical practice, so clinicians tend to
be more familiar with dose than with concentration. Answers to elicitation ques-
tions can then be translated to opinions on PK-PD parameters assuming a certain
relationship between dose and exposure which might be derived using existing
PK-PD data or through a further elicitation exercise with pharmacometricians or
clinical pharmacologists. In the examples we have considered, we have assumed
dose-proportionality holds over the dose range of interest, with a known constant
of proportionality. Below we give more detail on each aspect of the elicitation
scheme.
6.4.2 Rationale for the elicitation scheme
It is challenging to elicit opinion directly on the biases δA and δI . Instead, we
propose an indirect approach, whereby an expert is first presented with fitted
adult and adolescent dose-response curves derived from a meta-analysis of histor-
ical trials and then conditional on this information, is asked for their opinion on
the dose-response curve in younger children. We show below that under certain
assumptions, we can deduce from the expert’s answers their joint prior distribu-
tion for (δA, δI). In some cases, it may be necessary to present plots and frame
elicitation questions in terms of a transformed PD response which is easier for the
expert to express opinion on. For example, in clinical trials for adjunctive ther-
apies in epilepsy, the primary endpoint is often log-transformed percent change
in seizure frequency from baseline,38,166 which would be challenging to express
opinions on; instead, the percent change scale would be more interpretable for
experts. We will discuss this issue in more detail in the following subsection and
start by assuming that Y is on a scale that experts can express opinions on directly.
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Let d denote dose. Assuming dose-proportionality, we can write exposure as
C = κd. It seems reasonable to suppose that, when presented with the fit-
ted adult and adolescent dose-response curves, the expert will take these to be
the true response curves for these age groups, disregarding any estimation er-
ror. Ignoring for the moment between-study heterogeneity in PK-PD parame-
ters, model (6.2) stipulates that at dose level d?, the fitted average PD response
in adults is F1d? = γ0 + γCκd? and the fitted average response in adolescents is
F1d? + F2d? = γ0 + γCκd? + γA + γIκd?. Therefore, from the presentation of the
existing data, at dose level d? an expert can deduce: a) the average response in
adults, F1d? ; and b) the difference between the adult and adolescent expected re-
sponses F2d? = γA + γIκd?.
Assuming bias model (6.4) and assuming no drift in the parameters of the adult
PK-PD relationship so that in a future PK-PD study enrolling adults and younger
children we would have β0 = γ0 and βC = γC , model (6.3) stipulates that the
expected response of a younger child in such a study given dose d? would be
E[YT | AT = 1, C = κd?] = γ0 + γCκd? + (γA + δA) + (γI + δI)κd?.
Conditioning on what has been learnt from the historical data, we have
E[YT | AT = 1, C = κd?] | F1d? , F2d? = F1d? + F2d? + δA + δIκd?.
Assuming that prior opinion on (δA, δI) is independent of opinion on other PK-PD








then at dose level d? we obtain
E[YT | AT = 1, C = κd?] | F1d? , F2d?
∼ N(F1d? + F2d? + νA + νIκd?, pi2A + 2piAIκd? + pi2I (κd?)2).
The parameters of an expert’s (unconditional) bias prior can therefore be identified
by asking for their conditional beliefs, given the existing data about the average
response of younger children on placebo, a ‘medium’ or a ‘high’ dose, where these
doses are denoted by d0, dM and dH , respectively. The proposed wording of the
elicitation questions is given in the following section. In practice, dM and dH could
be chosen on the basis of adult dose-finding studies or, if the drug is already li-
censed in adults, using WHO lists of defined daily doses.185 The assumption that
opinion on (δA, δI) is independent of opinion on other PK-PD model parameters
is a pragmatic one which ensures that elicitation questions have a direct inter-
pretation and can be answered by non-statisticians. If an expert expresses the
consistent opinion that the average response in younger children is similar to the
fitted average in adolescents, this suggests they believe that δA and δI are small,
that is, that the existing data are highly relevant for informing our understanding
of likely differences between adults and younger children. Note that the proposed
scheme asks for opinions on the relevance of the existing data after seeing how
supportive they are of a complete extrapolation of efficacy data from adults to
adolescents. To increase the credibility of beliefs elicited in this way, one could
interview independent experts not directly involved with the drug development
programme.
By asking an expert for their best guesses at the average PD responses in children
on placebo and a ‘high’ dose, we deduce fitted values of νA and νI . To find νA,
one can subtract (γ0 +γA) from the expert’s best guess at the average response on
placebo; νI is obtained by subtracting (γC +γI) from the slope calculated by divid-
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ing the difference between the expert’s best guesses at the expected PD responses
on a high dose and placebo by κdH . An expert’s uncertainty about the average
PD response in younger children on a dose d? is established by asking questions
to establish the 5th, 25th, 75th and 95th percentiles of their prior distribution for
this quantity. Given values of νA and νI , we can then adapt the approach of
186
to search over configurations of pi2A, pi
2
I and piAI to find the triplet which defines
a positive definite variance matrix and minimises the absolute difference between
percentiles of the fitted prior and the expert’s stated percentiles. To ensure posi-
tive definiteness, Π is represented in the optimisation routine using the Cholesky
decomposition.
6.4.3 Elicitation protocol
In order to capture expert opinion we developed an interactive web application
written in R16 using the ‘Shiny’ package.65 Screen shots from the app can be
found in Appendix B.1. The app expects the statistical facilitator to summarise
the protocols of the historical trials (eligibility criteria, outcomes, treatments, etc.)
and then directs them through the following elicitation protocol:
Step 1 Display the fitted dose-response curves for adults and adolescents derived
from the historical data. If individual patient data (IPD) are available,
overlay these as a scatter plot to provide a more complete description of
the existing data, as illustrated in Supplementary Figure B.1. Conditional
on these existing data, elicit opinion on how the average PD response in
younger children varies with dose according to Steps 2-5. When interacting
with clinicians, the dose-response curve should be referred to throughout as
the line of best fit that would be plotted if we were able to randomise a large
number of younger children to each of a range of dose levels.
Step 2 To elicit the expert’s prior modal guess at the dose-response curve in younger
children given existing data, first show them a range of different shapes for
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the dose-response curve in this age group and ask them to select the one
which most closely reflects their current best guess, as shown in Supple-
mentary Figure B.2. The range of shapes should include curves which: a)
lie above the fitted adult curve; b) between the fitted adult and adolescent
curves; c) lie below the fitted adolescent curve; d) are identical to either the
fitted adult or adolescent curves. Guide the expert to iteratively refine their
selected ‘shape’ until they find a line which more closely reflects their current
best guess at the dose-response curve in younger children, as illustrated in
Supplementary Figure B.3. Refinements are driven by the expert’s answer
to the following question, which is repeated for placebo and dose dH : “Given
the existing data, give your best guess at the average response amongst chil-
dren aged 2-11 years on dose d of the test treatment”. From this step of the
elicitation process, the prior modal values of the bias parameters νA and νI
can be deduced.
Step 3 To establish the expert’s uncertainty about the dose-response relationship
in younger children, given the existing data in adults and adolescents, ex-
plain the concept of a credibility interval. Then show the expert a range of
shapes which might be formed by interpolating between the limits of their
90% credibility intervals for the average PD response in younger children on
placebo and doses dM and dH . Four options are shown in Supplementary
Figure B.4, which have been informed by discussions with clinical experts.
The statistical facilitator should interpret each shape and ask the expert to
select the one most closely describing their prior uncertainty. For each dose
in turn, the expert is then asked: “Given the existing data, state a value
which you are 95% sure the average response amongst younger children on
dose d of the test treatment will lie below”. The expert’s answer is the 95th
percentile of their prior distribution for the expected PD response at the
dose in question. Only the upper limits of credibility intervals need to be
elicited to deduce fitted values for elements of the variance-covariance matrix
92
of δ (due to symmetry). Despite this, the fitted upper and lower limits of
credibility intervals for expected PD responses are shown to the expert. This
stage of the elicitation procedure is illustrated in Supplementary Figure B.5.
Step 4 To further refine and validate the expert’s priors, elicit three histograms rep-
resenting their prior distributions for the average PD response of younger
children on placebo, dose dM and dose dH . This information is collected to
check the consistency of the expert’s opinion, to increase the stability of the
prior fitting routine (by also using the 25th and 75th percentiles) and to pro-
vide a more accurate quantification of the expert’s opinion. Each histogram
is elicited by asking the expert to allocate a prior weight to different re-
sponse intervals, where their weights must sum to 1. For reference, coloured
lines marking the mode and 95th percentiles elicited from Steps 2 and 3 are
shown, along with the 5th percentile implied by symmetry. Supplementary
Figure B.6 is a screen shot of this process. The elicited histograms provide
the 5th, 25th, 75th and 95th percentiles of the expert’s prior distributions for
the average PD response of younger children on placebo, dose dM and dose
dH , which can be used to allow parameters of the prior variance matrix of δ
to be established.
Step 5 Once all three histograms have been elicited, feed back to the expert sum-
maries of the prior distribution for the dose-response relationship in younger
children that would be implied by their expressed opinions. In particular, al-
low the expert to compare the credibility bound established from Step 3 with
that from Step 4, to ensure that they are confident the histograms reflect
their belief. The average response line will be that given in Step 2, whilst
the uncertainty around that line will be taken from the opinions elicited in
Step 4. If the fitted prior lacks face validity, the expert should be allowed
to re-evaluate their answers to Step 4 until they feel confident that their
beliefs have been adequately captured. Supplementary Figures B.7 and B.8
illustrate this step of the scheme.
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6.4.3.1 Example: Application to AED development
The prior elicitation protocol and software described above has been tested and re-
fined through several rounds of applications asking clinicians about dose-response
curves for an AED. In that context, we defined an expert as a paediatric or adult
neurologist with practical experience of treating adult and/or paediatric epilepsy.
Testing included face-to-face pilot runs with eight neurologists (adult and paedi-
atric) attending the International League Against Epilepsy British and Irish Chap-
ters Meeting (Dublin, October 2016), which suggested that adult neurologists may
feel unable to provide confident answers regarding the paediatric population. How-
ever, the population of experts may be biased if adult neurologists are neglected
completely. The final version of the protocol was also piloted on three neurologists
via web conference. The figures in Supplementary Appendix B.1 are of the app
tailored to the AED development application.
A few comments on the application of our elicitation scheme to the AED ex-
ample are needed. In this context, the PD response, Y = log{Z + 110} is the
log-transformed percent change in seizure frequency from baseline. Since a log-
transformed percent change is difficult to give opinions on, it makes sense to elicit
beliefs on the percent change in seizure frequency, Z, instead. It seems natural to
think that if we took an expert’s best guess at the relationship between dose and
E(Z) and then transformed it, we would obtain their best guess at the relationship
between dose and E(Y ). Therefore, the prior mode for E(Y ) at a particular dose is
obtained by transforming the prior mode of E(Z). The expert’s quantiles of their
prior distribution for E(Z) can similarly be transformed to give corresponding
quantiles for E(Y ), as quantiles are invariant under a monotonic transformation.
Using the proposed elicitation procedure and Shiny app, bias priors (E1) and (E2)
below were elicited from two epileptologists who were presented with simulated
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IPD on a licensed AED shown in Figure 6.2 which were generated from the fitted
models presented in Girgis et al.166 We assumed the dose-proportionality constant,
κ, was equal to 1; the PK-PD relationship is then equivalent to the relationship

























Prior (E1) is consistent with the opinion that it is most likely that the average
PD responses of adolescents and younger children are the same. Prior (E2) is
consistent with the best prior guess that younger children have an average PD
response slightly worse than that for adolescents, so that differences between PK-
PD curves in adults and younger children are larger than those between adults
and adolescents. However, as can be seen from Figure 6.2(b), both experts were
uncertain about the dose-response curve in younger children given the existing
data which indicates that extrapolation decisions are likely to be made in the
presence of significant uncertainty. The implications of this are explored further
in the subsequent section.
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Figure 6.2: (a) Simulated adult and adolescent IPD and lines of best fit. (b)
Elicited modal values of the dose-response relationship in younger children, cap-
tured in expert prior E1, with corresponding 90% credibility interval. Also plotted
are adult and adolescent lines of best fit obtained from the simulated IPD.
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6.5 Simulation study
To assess the operating characteristics of our proposed extrapolation framework,
we performed a simulation study considering a wide range of realistic scenarios.
Scenarios were informed by applications to AED development for partial onset
seizures. Motivated by the PK-PD studies described in Girgis et al.166 and Nedel-
man et al.,38 in what follows we took the PD response to be Y = log(Z + 110),
where Z represents the percent change from baseline seizure frequency, and expo-
sure to be Cmin, the steady state trough concentration under repeated dosing.
6.5.1 Epilepsy application extrapolation criterion
In all simulation scenarios, PK-PD curves were said to be similar in two age groups
if the difference between median percent changes from baseline in seizure frequency
was less than 10%:
M[exp{Y (CT = 0;AT = 1)} − 110]−M[ exp{Y (CT = 0;AT = 0)} − 110]
∈ (−10, 10) and (6.11)
M[exp{Y (CT = C?;AT = 1)} − 110]−M[ exp{Y (CT = C?;AT = 0)} − 110]
∈ (−10, 10), (6.12)
where M represents the median and C? is the adult EC90, the exposure at which
the expected adult response is 90% of the maximum. Our choices for η1 and η2
were based on clinical feedback on acceptable differences in average responses. We
wrote the similarity criteria in terms of the transformed PD endpoint to make it
easier to elicit similarity bounds. We chose the median as our summary measure of
response since if Y follows a log-normal distribution with median mY , the median
of Z = exp{Y } − 110 is given by mZ = exp{mY } − 110, thus simplifying the
mapping of properties from Z to Y .
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6.5.2 Simulating historical PK-PD data in adults and ado-
lescents
We simulated the PD responses of adults and adolescents as normally distributed
with residual variance σ2 according to model (6.7). Setting σ2 = 0.0243 ensured
that for each i = 1, . . . , Nj, j = 1, . . . , H, each transformed response Zij lay within
±10% of its median given the patient’s age group and level of exposure with prob-
ability 0.95. We simulated age group indicators Aij ∼ Bern(0.15) so that on
average 15% of historical trial participants were adolescents. This proportion ap-
pears reasonable based on the studies cited in Girgis et al.166 Furthermore, we set
10% of patients in each study to be assigned to placebo. For patients allocated
to the drug, we generate log(Cmin) values as samples from a normal distribution
with mean log(2.94) and variance 0.921, truncating samples above by log(17.27)
to avoid excessively high concentrations. In this way, we generated Cmin values
with quartiles and 1st and 99th percentiles similar to those reported by studies
cited in Girgis et al.166 where Cmin values ranged between 0.19− 17.27 µg/ml.
For each simulated historical study, study-specific parameters of PK-PD model (6.7)












setting γ0 = 4.4469 and γC = −0.0627 which are maximum likelihood estimates of
these model parameters taken from Girgis et al.166 Let P and C represent the dif-
ference betweenM(Z | A = 1, C) andM(Z | A = 0, C) when C = 0 and C = C?, re-
spectively. We chose values for γA and γI such that values of P and C , when eval-
uated under the population mean parameters, spanned a realistic range of differ-
ences. We considered pairs (P , C) ∈ {(0, 0), (5, 5), (10, 10), (20, 20), (5, 10), (5, 20)}
corresponding to the six pairs of (γA, γI) labelled in Table 6.1 as PK-PD Models
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Table 6.1: Population means of the effects of age (γA) and the interaction between
age and exposure (γI) for adults and adolescents in the six PK-PD simulation
models, with the interpretation of each model. The population median PD re-
sponse refers to exp{mY } − 110, where mY =M(Y ) is calculated setting PK-PD
model parameters equal to their population means.
γA γI Model interpretation
Model S1 0 0 Population median PD response identical
in adults and adolescents
Model S2 0.057 0.006 Small differences between population
median PD responses satisfy (6.11)
and (6.12)
Model S3 0.111 0.010 Moderate differences between popula-
tion median PD responses satisfy (6.11)
and (6.12)
Model S4 0.211 0.018 Large differences between population me-
dian PD responses do not satisfy (6.11)
and (6.12)
Model S5 0.057 0.014 Small differences between population me-
dian PD responses on placebo; mod-
erate differences at EC90 satisfy (6.11)
and (6.12)
Model S6 0.057 0.027 Small differences between population me-
dian PD responses on placebo; large dif-
ferences at EC90 do not satisfy (6.12)
1-6.
The variances of study-specific PK-PD parameters were chosen to characterise low,
moderate, high and very high levels of between-trial heterogeneity. Parameters σ20
and σ2C stipulate the level of between-trial heterogeneity in the adult PK-PD re-
lationship: σ20 was therefore chosen so that for each historical study, the median
percent change from baseline in seizure frequency for adults on placebo lay within
±10% of the median of Z calculated setting the PK-PD model parameters equal to
their population means with probability 0.6 (very high heterogeneity), 0.7 (high),
0.8 (moderate) or 0.95 (low). Fixing σ20, σ
2
C was then set to ensure the study-
specific median percent change in seizure frequency on the EC90 lay within ±10%
of the median of Z calculated setting the PK-PD model parameters equal to their
population means with the same probability. We chose σ2A and σ
2
I to fix the prob-
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Table 6.2: Standard deviations for the intercept (σ0) and effects of exposure (σC),
age (σA) and the interaction between age and exposure (σI) chosen to reflect low,
moderate, high and very high levels of between-trial heterogeneity.
Level of heterogeneity σ0 σC σA σI
Low 0.057 0.008 0.059 0.009
Moderate 0.086 0.012 0.091 0.014
High 0.107 0.015 0.113 0.018
Very high 0.132 0.019 0.140 0.023
ability that an individual historical trial will be consistent with an assumption of
similar PK-PD curves in adults and adolescents according to criteria (6.11)-(6.12).
Specifically, we chose σ2A such that with probability 0.6, 0.7, 0.8 or 0.95, the true
difference between M{Z | A = 0, C = 0} and M{Z | A = 1, C = 0} lay within
±10%. For a particular choice of σ2A, we then fixed σ2I such that with probability
0.6, 0.7, 0.8 or 0.95, the true difference between M{Z | A = 0, C = EC90} and
M{Z | A = 1, C = EC90} lay within ±10%. Different configurations of the het-
erogeneity parameters are listed in Table 6.2.
Simulation scenarios considered different numbers of historical trials (H = 2, 3, 4, 5, 10, 20)
and numbers of subjects per trial (N = 30, 170). Numbers of historical trials were
chosen to explore a plausible range: Davey et al.49 report that 36% of the 22453
meta-analyses listed in the Cochrane Database of Systematic Reviews as of 2011
were based on two studies, 75% were based on five or fewer studies, and 1% were
based on 28 or more studies. Numbers of subjects per trial were selected to explore
the impact of smaller and larger trials; we had access to data from four industry-
sponsored trials of an anti-epileptic drug, the average sample size of which was 168
patients. Overall, this gave 288 different simulation scenarios to consider.
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6.5.3 Meta-analysis of simulated historical PK-PD studies
For each of the 288 simulation scenarios, we simulated 1000 trials and fitted
the Bayesian multivariate meta-analytic model described in Section 6.3.3 to each
dataset. All simulations were performed in R16 fitting the meta-analytic model by
calling OpenBUGS version 3.2.313 using the ‘R2OpenBUGS’ package.187 We fitted
the Bayesian model by running three chains using a thinning rate of 5, running
the chain for 30000 iterations including a burn-in of 10000 iterations. The ‘coda’
package188 was then used to extract posterior samples from the OpenBUGS output.
The meta-analytic model was fitted placing prior distributions on the unknown
parameters of the form described in Section 6.3.3, with parameters given in Table
6.3. Parameters defining the bivariate normal population distribution variability,
ξ1 and ξ2, were chosen so that the prior means of ξ1 and ξ2 were equal to our
choices for the moderate between-trial standard deviation for γA and γI ; 95% of
the probability mass for the ξ1 prior was between (0.0119, 0.2495); and 95% of
the probability mass for the ξ2 prior was between (0.0005, 0.0503). Therefore, low
weight was given to very low and high between-trial variances. We chose this range
based on the heterogeneity scenarios we explored; in practice one may have some
historical information about the range the between-trial variability is likely to lie
in. If not, a more diffuse prior, spreading probability mass over a wider interval
could be used. We tested the use of a more vague Gamma(1.5, 3) prior on both
ξ1 and ξ2, which resulted in a slight reduction in the probability of extrapolation;
perhaps as a more conservative approach, this could be appropriate. Our choice
of priors for λ0 and λ1 implies a reasonable spread of probability mass between −1
and 1 for the prior correlation coefficient.
101
Table 6.3: Prior distributions placed on unknown model parameters defined in
Section 6.3.3.
Parameter Prior Distribution
γ01, . . . , γ0H Normal(0, 100)
γC1, . . . , γCH Normal(0, 100)
ξ1 Gamma(2.097, 23.003)
ξ2 Gamma(1.118, 78.149)
λ0 t(0, 0.03, df = 3)
λ1 Normal(0, 1)
6.6 Results
In this section we summarise the results of the simulation study. Some tables and
figures are listed in the Supplementary Materials.
6.6.1 Meta-analysis of historical data
As can be seen from supplementary tables B.1 - B.8 in Appendix B.3, the Bayesian
multivariate meta-analysis of the existing adult and adolescent data accurately
estimates the effects of age and the interaction between age and exposure, with
low bias, empirical standard deviations and mean squared error in most scenarios.
In all cases, accuracy increases with the sample size per study. Empirical standard
deviations are highest under the highest level of between-trial heterogeneity, but
the bias remains small. The intercept and effect of exposure are also estimated
with small bias and high precision (results not presented). This suggests that the
meta analysis is capturing the true values underlying our simulated data well.
6.6.2 ESS of the approximate joint posterior for βA and βI
Figure 6.3 plots average ESSs of the BVN mixture approximation to the joint pos-
terior for (βA, βI), which are the target parameters describing differences between
adults and younger children. As only the parameter population means are chang-
ing between simulation models S1-S6, ESSs are almost identical across the different
underlying models. We therefore only present results for model S1; the means and
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Figure 6.3: Average ESS under bias prior E1 when the true PK-PD relationships
in adults and adolescents follows Model 1, with bars of ± 1 standard deviations of
the mean
empirical standard deviations are listed in Supplementary Table ST13. We note
that the between-trial heterogeneity appears to have little impact on ESSs. Addi-
tionally, if we consider the case where we have existing data from 20 studies, with
each study containing 170 subjects, it is interesting to note that for low between-
trial heterogeneity the ESS is 23.83; this demonstrates the downweighting of the
existing data due to the bias-adjusted meta-analysis. In particular, the expert’s
uncertainty captured by the variability in the elicited prior for the bias parame-
ters results in a large downweighting of the existing data. Were the expert more
confident in their answers to the elicitation questions, less downweighting would
be observed and a larger ESS would be obtained.
For moderate between-trial heterogeneity and 30 subjects per trial, Figure 6.4
shows how the ESS changes as the variance-covariance matrix of the bias prior
(E1) is scaled; the means and correlations of the bias prior remain the same but
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Figure 6.4: Average ESS when the true PK-PD relationships in adults and adoles-
cents follows Model 1 and bias prior E1 has the covariance matrix scaled by 0.1,
0.25, 0.5, 1, 2, or 10.
the variance is scaled by a factor c. Comparing the black line (c = 0.1) and the
pink line (c = 10), we see that the ESS of the existing data increases as prior
uncertainty about the external biases decreases.
6.6.3 Prior probability that PK-PD curves are similar in
adults and younger children
First we look at how the prior probability of similar PK-PD curves in adults and
younger children (hereafter referred to as the extrapolation probability) varies with
the true PK-PD relationship in adults and adolescents. Supplementary tables B.9
- B.12 in Appendix B.3 present the means and empirical standard deviations of
extrapolation probabilities for a range of scenarios. Figures 6.5(b), 6.6(b), and
6.7(b) illustrate PK-PD relationships in adults, adolescents and younger children
under simulation models S1, S3 and S4 and bias prior E1. Figures 6.5(a), 6.6(a)
and 6.7(a) illustrate how our confidence in the extrapolation assumption changes
as differences between adult and adolescent PK-PD relationships increase from
none (model S1), to moderate (S3) to large (S4). A general trend seen in our
results is that larger prior probabilities of extrapolation criteria (6.11)-(6.12) are
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recorded in scenarios where the true PK-PD curves in adults and adolescents are
more closely aligned. This makes intuitive sense when working with bias prior E1,
since this prior is consistent with the best guess that PK-PD relationships in ado-
lescents and younger children are identical. For example, comparing Figure 6.5(a)
with Figure 6.6(a), we see that when there are moderate differences between the
true adult and adolescent PK-PD curves (model S3), prior extrapolation probabil-
ities are lower than under model S1. This is because observed differences between
adults and adolescents increase our scepticism that PK-PD curves will be similar
in adults and younger children.
Scaling the variance matrix of the bias prior influences the extrapolation probabil-
ity. Under model S1 and bias prior E1, the probability of extrapolation reaches a
maximum value of 0.572 when the between-trial heterogeneity is low and data are
available from H = 20 historical studies, each having recruited 170 subjects. This
maximum probability is far from 1. Lines representing cases when the bias prior
variance matrix is scaled by a factor of 0.5, 0.01 or 0 show that if uncertainty about
external biases were to be significantly reduced, the prior extrapolation probability
would increase. For example, when the bias prior variance matrix is multiplied
by 0.01, the extrapolation probability does tend towards 1 as H increases. For
bias prior E1, a scale factor of 0 would reflect the opinion that we are certain that
differences between adult and adolescent PK-PD curves reflect differences between
curves for adults and younger children.
There is a question of whether it is plausible that an expert would be confident
enough in their beliefs for us to attain a high prior extrapolation probability. Sup-
pose a probability of 0.8 would be sufficient to support a complete extrapolation
strategy. Looking at Figure 6.5(a), we see that under model S1 with low between-
trial heterogeneity and 170 subjects per trial, if we scale the bias prior variance
matrix by 0.5, the probability of extrapolation reaches 0.8 when the number of ex-
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Figure 6.5: (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of ± 1 standard deviations of the mean, when the true PK-
PD relationships in adults and adolescents follows model S1 (when no differences
between PK-PD curves in adults and adolescents). (b) Median PK-PD curves
for adults, adolescents and younger children following model S1, along with lower
bounds of 90% empirical credibility intervals for the median response in younger
children resulting from the expert bias prior E1 when its variance matrix is un-
scaled; or scaled by a factor of 0.5 or 2. Credibility intervals are calculated condi-
tioning on the true values of the adult and adolescent PK-PD parameters. Simi-
larity bounds at placebo and the EC90 given by criteria (6.11) and (6.12) are also
shown.
isting studies exceeds five. Looking at Figure 6.5(b), we can see what this scaling
factor would correspond to in terms of the level of confidence an expert must have
in the location of the PK-PD curve in younger children. We speculate that experts
could possess this level of confidence in practice. Furthermore, from Figure 6.5(a)
we see that with at least 10 existing studies, low between-trial heterogeneity and
170 subjects per study, if an expert’s confidence in the relevance of the existing
data was consistent with bias prior E1 with variance matrix scaled by a factor
between 0.5 and 1, then the prior probability of extrapolation would still exceed
0.8; with enough existing data and strong, but still feasible, expert opinion, a high
probability of extrapolation is plausible.
Focusing on model S3, when there is low between-trial heterogeneity we notice that
smaller variances for the bias parameters lead to smaller extrapolation probabilities
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due to our increased confidence in the relevance of differences observed between
adults and adolescents. In contrast, under very high levels of between-trial het-
erogeneity, smaller bias prior variances lead to larger extrapolation probabilities.
We see from Figure 6.7(a) (model S4) that when there are large differences be-
tween the PK-PD relationships for adults and adolescents, the prior extrapolation
probability approaches 0 as H increases since we have greater precision to identify
differences in the source population. However, in this setting, the extrapolation
probability increases with the variances of the bias parameters. This is because
as our uncertainty about the relevance of the existing data increases, at each dose
our 90% prior credibility interval for M(Z) in younger children widens and we
place more probability mass on values consistent with criteria (6.11)-(6.12), as can
be seen in Figure 6.7(b) when the variance matrix of the bias prior is scaled by a
factor of two.
Clearly the prior extrapolation probability is heavily influenced by the variability
of the elicited bias prior. It seems natural that the prior extrapolation probabil-
ity should be a combination of quantitative evidence and subjective opinion. For
example, if existing data suggest that adult and adolescent curves are similar and
experts are confident that the relationship between these curves reflects that be-
tween adults and younger children, then complete extrapolation of efficacy data
from adults to younger children should be recommended. However, as can be seen
from Figure 6.5(a), if there is uncertainty about the relevance of the existing data,
the prior probability of extrapolation should be lowered to reflect this, perhaps
to the extent where we would caution against adopting a complete extrapolation
strategy in favour of collecting a reduced amount of PK-PD data in the youngest
age group. In a similar manner, if we observe differences between adult and adoles-
cent PK-PD curves, it seems appropriate that the extrapolation probability should
increase slightly as the variance of the bias parameters increases since the existing
data are discounted from our decision making, as shown in Figure 6.7(a).
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Figure 6.6: (a) Average prior probability that PK-PD relationships in adults and
younger children satisfy criteria (6.11)-(6.12), with bars of ± 1 standard deviations
from the mean. The true PK-PD relationships in adults and adolescents follow
model S3. (b) Median PK-PD curves for adults, adolescents and younger
children following model S3, along with lower bounds of 90% empirical credibility
intervals for the median response in younger children resulting from the expert
bias prior E1 when its variance matrix is unscaled; or scaled by a factor of 0.5 or
2. Credibility intervals are calculated conditioning on the true values of the adult
and adolescent PK-PD parameters. Similarity bounds at placebo and the EC90
given by criteria (6.11) and (6.12) are also shown.
Comparing results derived under bias prior E1 setting N1 = . . . = NH = N , we see
that the extrapolation probability increases asN increases from 30 to 170, although
differences diminish with larger values of H. This trend occurs under models S1
and S3 when differences between adults and adolescents are small enough to satisfy
criteria (6.11)-(6.12) and our best prior guess is that external biases are equal to
0. It arises because as the study-specific sample size and H increase, we are able
to estimate the population mean effects of age and age by exposure interaction on
the PD response more accurately. For a similar reason, from Figure 6.7(a) based
on model S4, for configurations of the bias prior with small variances the prior
extrapolation probability decreases with H as we are able to deduce with more
certainty that there are important differences between the adult and adolescent
PK-PD curves and because we are confident these differences reflect those between
108
adults and younger children. However, Figure 6.7(a) shows that in scenarios where
we have 30 subjects per study, or 170 subjects but the bias prior variance matrix
is scaled by a factor of 2, the extrapolation probability increases slightly with H.
Prior probabilities of extrapolation under models S3, S5 and S6 are provided in
Appendix B.2 as Figures B.9–B.11. Similar patterns are seen in the results gen-
erated under models S2 and S5 as under model S1, although prior probabilities
tend to be lower overall reflecting increased differences between adult and adoles-
cent PK-PD curves. A similar comment applies to results generated under models
S4 and S6, and the extrapolation probability is even lower under model S6 when
scaling the bias prior variance matrix by 2.
Figure 6.7: (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of ± 1 standard deviations of the mean, when the true PK-
PD relationships in adults and adolescents follows model S4 (when clearly large
differences between PK-PD curves in adults and adolescents). (b) Median PK-
PD curves for adults, adolescents and younger children following model S4, along
with lower bounds of 90% empirical credibility intervals for the median response in
younger children resulting from the expert bias prior E1 when its variance matrix
is unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are calculated
conditioning on the true values of the adult and adolescent PK-PD parameters.
Similarity bounds at placebo and the EC90 given by criteria (6.11) and (6.12) are
also shown.
We have repeated our investigations using bias prior E2 in place of prior E1.
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Prior E2 is consistent with the belief that the PK-PD curve in younger children
lies above that for adolescents (indicating a worse average response). Comparing
results generated under the two priors, we see that the probability of extrapolation
under E2 is lower in all scenarios, demonstrating that it is not only an expert’s
uncertainty about external biases which influences the probability of extrapolation
but also the expert’s opinion on the direction of differences between PK-PD curves
in adolescents and younger children. Bias prior E2 has the same covariance matrix
as prior E1 meaning that ESSs do not vary substantially since the ESS is driven
by the variability in the meta-analysis results and the prior variance of the bias
parameters but not the location of the bias prior.
6.7 Discussion
This chapter proposes a quantitative framework for using existing pharmacological
data to inform our understanding of likely differences between PK-PD relation-
ships in adults and younger children. The prior probability of acceptably small
differences between these relationships is used to inform a decision of whether to
perform a complete or partial extrapolation of adult efficacy data to younger chil-
dren. The elicitation of expert opinion is an essential yet challenging aspect of our
approach. Elicitation questions must be precisely tailored to the disease area and
comparison of interest, meaning that close collaborations with clinical colleagues
are necessary to ensure we construct an appropriate elicitation scheme. This is
especially important given the influence that the elicited bias prior has on the prior
extrapolation probability. Currently, we propose that extrapolation probabilities
in excess of 0.8 or 0.9 would support a decision to adopt a complete extrapolation
strategy, although further work will explore whether the choice of this cut-off can
be refined and formalised through use of a decision-theoretic argument. A decision
theoretic approach would consider various risks and costs including: the risk to
children of incorrectly adopting a complete extrapolation strategy when in fact
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PK-PD curves are different in adults and younger children, in which case dosing
younger children to match exposures seen in adults would lead to the former age
group being treated at toxic or ineffective doses; the costs to patients and the
sponsor of failing to perform a complete extrapolation when this is appropriate, in
which case younger children are recruited into an unnecessary PK-PD study and
the wider population outside this study is delayed access to the new medicine.
A low prior probability of similar PK-PD curves in adults and younger children
could be interpreted in different ways. For instance, the low probability could be
due to marked uncertainty about the magnitude of external biases or high levels
of between-study heterogeneity in the existing data. Another possibility is that
the extrapolation probability is low because there is a clear signal that there exist
large differences between PK-PD curves in different age groups. When it is unclear
whether a complete extrapolation strategy should be adopted or not, one could
use an expected value of information analysis189,190 to quantify the value, in terms
of improved decision making, of collecting varying numbers of additional PK-PD
data in younger children given the risks outlined above of incorrectly making a
complete extrapolation of efficacy data from adults to younger children or missing
an opportunity to do so when this is appropriate. Further work will explore using
a decision theoretic approach to set the extrapolation decision rule.
When performing the bias-adjusted meta-analysis upon which the prior proba-
bility of extrapolation is based, it is essential that included studies should have
been identified through a process of systematic review according to a pre-specified
protocol.191,192 The eligibility criteria for the systematic review should support
inclusion of studies that were not performed in the target population but are con-
sidered relevant on the basis of our current understanding of the disease of interest,
the drug’s mechanism of action and our understanding of the effects of baseline
covariates.
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Our current approach assumes exposure-response relationships can be captured by
models which represent age as a categorical variable, that is, assuming there are no
important differences within an age group. While this assumption will never hold
exactly, we do expect it to hold approximately for suitably defined age groups: if
important differences were expected to occur within an age group (for example,
in the setting of our motivating example, if children aged from 2 to 4 years were
expected to respond differently to those aged from 5 to 11 years), then a more
suitable approach would be to consider each homogeneous age group in turn and
select an extrapolation strategy for each by application of the methods described
in Sections 6.3 and 6.4. While the motivating example for this work has been
extrapolating across age groups, a similar framework could be used to inform the
extrapolation of efficacy data across ethnic groups or geographic regions, where
subgroups in this setting are naturally discrete.
In this chapter, we have considered the relatively simple case of linear PK-PD
models. It would be interesting to extend our approach to more complex cases
such as non-linear PK-PD models. With careful thought this could be possible,
although one would need to consider: a) how to parameterise the more complex
PK-PD models for adults, adolescents and younger children; b) how to represent
differences between the various PK-PD relationships and define decision criteria
governing extrapolation decisions; c) how one would devise a scheme to elicit opin-
ion on biases affecting parameters governing the similarity of PK-PD relationships.
Furthermore, depending on the choice of models for PK-PD relationships and bias
parameters, the resulting posterior distributions for key parameters in the extrap-
olation decision criteria may be more complex, so that larger mixtures of (Normal)
distributions may be required to obtain accurate approximations.
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6.8 Appendix: OpenBUGS code
model {
for(j in 1:H) {
for(i in 1:N) {
mu[i,j] <- gamma_0j[j] + gamma_Ej[j]*X1[i,j] +
gamma_Aj[j]*X2[i,j] + gamma_Ij[j]*X1[i,j]*X2[i,j]





gamma_Ij[j] ~ dnorm(gamma_I[j], tau2)


















optimal dosing rules in children
7.1 Chapter background
Our quantitative approach to informing extrapolation decisions in the previous
chapter made the assumption of homogenous age groups across adults, adolescents
and younger children. Homogeneity of age groups in terms of exposure-response
(E-R) relationships may not necessarily be entirely appropriate. As such, ap-
proaches to quantify how E-R model parameters change over age and a way to
utilise this information to identify distinct age groups for practical dosing rules
would be of great use.
7.2 Introduction
Children of different ages given a new medicine may be characterised by different
dose-exposure and E-R relationships due to age related differences in growth, de-
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velopment and physiological differences.23 Several regulatory guidance documents
have suggested general age groupings, such as the International Conference on Har-
monisation E11 document,23 which suggests one possible categorisation: preterm
newborn infants; term newborn infants (0 to 27 days); infants and toddlers (28
days to 23 months); children (2 to 11 years); and adolescents (12 to 16-18 years,
depending on region). The National Institute of Child Health and Human Devel-
opment (NICHD) guideline, suggests similar age groups, but with extra splits at 1
and 6 years. This chapter aims to estimate the E-R relationship in children over a
chosen age range and to identify age groupings which define practical and effective
dosing rules.
An understanding of how the E-R relationship of a drug varies with age will in-
form whether and how we leverage adult data to support drug development in
children. Hampson et al.33 reviewed paediatric investigation plans (PIPs) and
found that it was common to plan to identify paediatric doses by matching expo-
sures in children with target adult exposures. This is an appropriate dose-finding
strategy if E-R relationships are similar in adults and children. An assumption
of similar E-R relationships might be justified for some paediatric subgroups, but
not others. For example, Takahashi et al.174 concluded that whilst pubertal (12 to
18 years) and adult patients had similar response to long-term warfarin therapy,
differences existed in the pharmacodynamic response between pre-pubertal (1 to
11 years) patients versus pubertal and adult patients. If E-R relationships can be
assumed to be similar across age groups, it may be appropriate to make a complete
extrapolation of efficacy data from one age group to another, so that only dose-
exposure data are needed in the unstudied age group to identify doses producing
exposures efficacious in the studied age group.33,36 However, if E-R relationships
cannot be considered similar, a partial extrapolation approach36 may be consid-
ered, where dose-exposure and E-R data may be accrued in specified age groups
to establish differences in E-R relationships. Parkinson et al.193 developed a sig-
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moid Emax model for the relationship between dapagliflozin exposure and urinary
glucose excretion for adult and paediatric patents with type 2 diabetes mellitus.
After accounting for significant covariates (e.g. sex, race, baseline fasting plasma
glucose), further covariates were included for paediatric patients which failed to
improve model fit. The authors took this as evidence that adult and paediatric
patients had similar E-R relationships. Earp et al.194 used E-R modelling and
exposure matching analyses to estimate paediatric doses for esomeprazole for the
treatment of gastroesophageal reflux disease. The authors modelled E-R relation-
ships of intragastric pH for adults and children separately and concluded similarity
of E-R based on a visual inspection of fitted E-R relationships. In this chapter, a
more quantitative approach to evaluating differences between E-R relationships is
taken using sophisticated modelling approaches.
Age groups characterised by different E-R relationships can be considered as dis-
tinct subgroups. Lipkovich et al.195 review methods for the identification and
analysis of subgroups in clinical trials. Ondra et al.196 reviewed methods for de-
signing or analysing clinical trials that aim to investigate differences in treatment
effects across subgroups. In this chapter, we consider two model-based approaches
to quantify how E-R model parameters vary over a continuous age range: Bayesian
penalised B-splines,197 and model-based recursive partitioning (MOB)3,198 which
is used to fit model-based trees to bootstrapped samples of the E-R data. Based
on estimates of how E-R model parameters vary with age, we propose an ap-
proach to identify the age groups and exposure levels that define a dosing rule
which is optimal for targeting a certain level of response; definition of the dosing
rule is then completed by using the exposure levels and estimated dose-exposure
relationship to make dosing recommendations for each age group. The estimated
dose-exposure relationship is not considered in this thesis. Thomas et al. use MOB
to estimate patient subgroups with different dose-response curves, and apply this
method to data from a dose-finding trial. In this chapter, we focus on estimating
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age groups with different E-R relationships since in practice, when seeking to re-
late dose to response, a two-step process relating dose to exposure then exposure
to response is often adopted. For example, the ICH E4 guidance199 states that
E-R information can help identify a range of concentrations which likely lead to
a satisfactory response, which can in turn inform dose selection. While param-
eters of the dose-exposure relationship are expected to depend on age, for some
medicines parameters of the E-R relationship are expected to remain stable across
age groups. In such cases, the two-step modelling process can be advantageous
because it enables separate modelling of the dose-exposure and E-R relationships,
which allows for changes due to age to be captured in each relationship separately.
In a simulation study to compare the performance of the two-step and single stage
(dose-response) approaches to dose finding, Berges and Chen200 found that the
two-step approach resulted in more precise E-R model parameter estimation and
more accurate dose selection, though the authors show that the gain with the
two-step approach depends on properties of the drug, trial design features and
the response level being targeted. Hsu201 found that in scenarios with increased
intrinsic PK variability, E-R modelling has advantages for dose selection over dose-
response modelling, provided measurement error for exposures is small. As an
example of a two-stage approach to selecting a dosing rule, Schoemaker et al.202
developed a population PK model to describe the relationship between brivarac-
etam dose and plasma concentration in adults with partial onset seizures, and a
population pharmacokinetic-pharmacodynamic model to describe the relationship
between brivaracetam plasma concentration and daily seizure counts. The authors
then simulated from these models to estimate the relationship between dose and
response, enabling them to identify a dose range producing the maximum response.
This chapter proceeds as follows. Section 7.3 gives a motivating example while
Section 7.4 defines two E-R models. In Section 7.5, we introduce the methods that
will be used to estimate parameters of E-R relationships. Section 7.6 proposes an
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approach for using fitted E-R models to identify practical dosing rules for children.
We use simulation to evaluate the performance of E-R modelling approaches and
the operating characteristics of the dosing rule algorithm. The design of the sim-
ulation study is described in Section 7.7 and the results are presented in Section
7.8. An example illustrating how the E-R modelling approaches can be applied to
non-linear models is given in Section 7.9. The chapter concludes with a discussion
in Section 7.10.
7.3 Motivating example
We motivate the work that follows by considering the development of epilepsy
medicines for paediatric patients with partial onset seizures. Girgis et al.166 study
both monotherapy and adjunctive therapy with the anti-epileptic drug topiramate,
whilst Nedelman et al.38 consider adjunctive therapy with oxcarbazepine. For
adjunctive therapy, Girgis et al.166 and Nedelman et al.38 take response, Y =
log{Z + 110}, to be the log-transformed percent change from baseline in seizure
frequency (where Z is the percent change from baseline in seizure frequency).
The response, Y , is assumed to be normally distributed and a linear function
of exposure, measured by the average steady-state trough concentration (Cmin).
Girgis et al.166 and Nedelman et al.38 evaluate the similarity of E-R relationships
in adults and children on adjunctive therapy with the aim of justifying the use
of extrapolation to support the approval of monotherapy in children. The models
the authors use and parameter estimates provided by Girgis et al.166 will be used
to inform the design of realistic simulation scenarios.
7.4 Exposure-Response models
We start by considering a linear model for the relationship between exposure and
response. Suppose E-R data are available from a single study which recruited
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children aged 0 to 18 years and let Yi represent the response of subject i, for
i = 1, . . . , N . If the E-R relationship does not depend upon age, we could model
it as:
Yi = γ0 +
P∑
p=1
γpxpi + γCCi + i,
where Ci is a measure of drug exposure (such as Cmin), x1i, . . . , xPi are other
covariates influencing response (such as body weight), and i ∼ N(0, σ2) is a
random error term. We consider the situation where the E-R relationship may
differ between age groups, that is, γ0 and γC are functions of age (A):
Yi = γ0(Ai) +
P∑
p=1
γpxpi + γC(Ai)Ci + i. (7.1)
In Section 6.3 we will consider different approaches for parameterising γ0(Ai) and
γC(Ai).
The non-linear sigmoid Emax model is often used to represent the relationship
between exposure and response:











where for subject i, aged Ai years old, γ0(Ai) is the intercept, Emax(Ai) is the
maximum effect attributable to the drug, EC50(Ai) is the concentration of the drug
that produces half of the maximum effect, and δ(Ai) (the Hill parameter) governs
slope steepness. Here, four of the model parameters may potentially depend upon
age.
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7.5 Estimating the exposure-response relation-
ship
In this Section we describe three E-R modelling approaches that can be applied
when we assume that the E-R relationship follows model (7.1) with age-dependent
intercept and slope. These methods are: linear regression with categorical co-
variates for age groups; MOB and partially additive linear model (PALM) trees;
and Bayesian penalised B-splines. We also highlight where methods can be ap-
plied more generally with non-linear E-R models. A worked example illustrating
how each method can be applied to estimate a linear E-R relationship is given in
Appendix C.1.
7.5.1 Linear model fit with categorical age covariates
If we knew that the age groups defined by different E-R relationships were, (a0 =
0, a1], (a1, a2], . . . , (aH−1, aH = 18], we could define a linear model for the E-R
relationship which adjusts for a categorical age covariate:
Yi = γ0 +
P∑
p=1








where Ah is the interval (ah−1, ah]; 1Ah(Ai) is an indicator function (1 if Ai ∈ Ah, 0
otherwise); γA,2, . . . , γA,H are the main effects of the age groups; and γI,2, . . . , γI,H
are the interactions between age group and exposure. Fitting this model permits
estimation of age group specific intercepts and slopes. We include this simple model
as a benchmark for comparison with other more complex modelling approaches.
Unlike the other methods we consider, this approach requires that age groups be
pre-specified rather than estimating them from the data.
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7.5.2 MOB and PALM trees
Building on this simple model, MOB allows data to be split into groups based
on partitioning variables, with each subgroup characterised by its own parametric
model.198 We implement MOB using age as the only partitioning variable. The
MOB algorithm we use comprises the following steps:198 Fit a parametric model
to the dataset, estimating model parameters by minimising the objective func-
tion; test for whether the intercept and slope parameters significantly change over
age by using a generalized M-fluctuation test,198,203 which assesses whether the
scores of the model systematically deviate from 0 over age; partition the model
into two subgroups with respect to age by finding the value of age which minimises
an objective function segmented at this age split point; repeat the fitting, testing
and splitting procedure in each identified age group until no significant changes
are found in the intercept and slope parameters over age within each group. The
MOB algorithm198 can be implemented using the ‘mob’ function found in the ‘par-
tykit’ package2,198 in R.16 As MOB allows subgroups with any parametric model,
non-linear models (such as Emax models) are possible.
PALM trees are a variation of MOB, allowing for global parameters which remain
constant across subgroups, although PALM trees are restricted to generalised lin-
ear models (GLM) rather than any parametric model.3 For our linear model ex-
ample with outcome Yi and partitioning age variable Ai, PALM trees can contain
globally fixed linear effects γ1, . . . , γP for covariates x1i, . . . , xPi and subgroup-wise
varying linear effects γ0(Ai) and γC(Ai), as in equation (7.1). PALM trees use the
MOB algorithm described above to identify age groups with separate GLMs. In
order to allow for global parameters which do not change over the partitioned age
subgroups, an EM-type algorithm is used. This iterates between estimating the
global effects, γ1, . . . , γP , for the currently estimated PALM tree and estimating
the PALM tree (using the above algorithm) for a given set of global effect esti-
mates, γˆ1, . . . , γˆP . The algorithm can be implemented in R
16 using the ‘palmtree’
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function found in the ‘partykit’ package.2,3 We implement PALM trees with the
default tuning parameters, i.e. a significance level of 0.05 and no maximum tree
depth. An advantage of tree based methods is the easy to understand output:
each final partitioned subgroup of the tree represents an age group, with model
parameter estimates given for each group.
We implement MOB and PALM tree approaches using bootstrap aggregating204
to improve the accuracy and precision of age-specific E-R model parameters and
reduce overfitting. The E-R data are bootstrapped and each bootstrap sample
is used to fit a MOB or PALM tree. From each bootstrap tree fit, estimates of
age-specific model parameters (intercept and slope) can be evaluated for a grid
of ages covering the interval [0, 18] years. For each grid point in turn, we then
aggregate across the bootstrap samples and, applying linear interpolation to the
average age-specific parameter estimates, can thus obtain an estimate of the E-R
intercept or slope for any given age. The important aspect to note here is that no
parametric assumptions are made about the form of the relationship between each
model parameter and age. One disadvantage of this is that these relationships
cannot then be easily recorded in a closed form for future reference.
We fit linear E-R models using PALM trees in Section 7.7 because we also consider
the case of having an additional global covariate whose effect is independent of age,
which we present in Appendix C.3. In Section 7.9, we fit non-linear E-R models
using MOB.
7.5.3 Bayesian penalised B-splines
Splines define flexible regression models by joining smooth curves (differentiable
at every point) together at knot points.205 An E-R model parameter that can be
written as a smooth function of A, f(A), can be modelled as a spline. Here, we
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will consider the penalised B-splines developed by Eilers and Marx.197 B-splines
can be written as a linear combination of B-spline basis functions of degree d, that





A B-spline basis function of degree d consists of d + 1 polynomial curves of de-
gree d, each joined in sequence.197 The degree of the B-spline basis controls how
differentiable the spline is and can influence the smoothness of the spline. We
implement B-splines of degree 2 as in the examples we have considered we gain
little in terms of smoothness for the added complexity of using degree 3 B-splines.









βCjBj(Ai; d = 2).
J = 26 given our choice of degree and number of knots; five knots equally spaced
knots within each of the four ICH E11 age groups (not including pre-term newborn
infants), knots at each age group boundary, along with two external knots below
age zero and two above age 18. We use the function ‘splineDesign’ in the R package
‘splines’16 to construct our 26 B-spline basis functions. Further details of how the
B-spline basis functions are constructed can be found in Bowman and Evers.205
Note that for penalised B-splines, Eilers and Marx197 recommend using equidis-
tant knots and suggest that there are no gains to be made from using unequally
spaced knots, as the penalty smooths any sparse areas. However, we specify knots
using the prior information on potential age groupings that is contained in the
ICH E11 guidance document.23 By specifying an equal number of knot points on
each ICH E11 age group, knots are more densely spread across age ranges where
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model parameters are expected to change most rapidly with age.
For penalised B-splines, a roughness penalty is used to control the smoothness of
the estimated spline, rather than the choice of knot location and number.197 In a
Bayesian context, penalised B-splines are implemented placing random walk priors
on the B-spline coefficients.205,206 For example, to penalise differences between
adjacent B-spline coefficients, first-order random walk priors are used:
β0,j|β0,j−1 ∼ N(β0,j−1, τ 20 ), for j = 2, . . . , J
βC,j|βC,j−1 ∼ N(βC,j−1, τ 2C),
with β0,1 ∼ N(0, 100) and βC,1 ∼ N(0, 100). This penalises B-spline coefficients by
shrinking towards a common constant,205 which is desirable in our context since
we anticipate that there may be age ranges on which a model parameter is fairly
stable followed by periods of rapid change. We stipulate diffuse Inverse-Gamma(1,
0.005) priors for τ0 and τC , similar to Lang and Brezger (2004)
206 who place an
Inverse-Gamma prior on the variance of the random walk prior. We do not weight
τ 20 and τ
2
C by the distance between successive knot points, as suggested by Kneib
et al.,207 to allow larger prior variation when there are larger steps between knots.
This is because in our setting, we have purposefully placed knots closer together
over age intervals where the most rapid changes with age are anticipated.
We fit the Bayesian penalised B-splines model using Hamiltonian Monte Carlo,
calling Stan14 from R16 using the RStan package15 running three chains with a
default thinning rate of one for 3000 iterations, 1500 of which are discarded as
burn-in samples. Following equation (7.4), the posterior means of the B-spline
coefficients are multiplied by the B-spline basis functions to estimate the B-spline
for the respective E-R model parameter.
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Bayesian penalised B-splines are a very flexible modelling approach, with the ca-
pacity to be used to represent the E-R parameters of any parametric model for the
E-R relationship. The ability to write the relationship between E-R parameters
and age in a simple form, as in equation (7.4), means it is easy to record and
share the estimated relationship. However, Bayesian penalised B-spline models




We could use the modelling approaches described in Section 7.5 to derive per-
sonalised dosing recommendations tailored to a patient’s exact age. However, for
practical reasons, we seek to identify dosing rules based on wider age subgroups.
First, we derive target exposure levels for up to K age groups of children. For
practical reasons, K would likely be small, e.g. K = 5 in the ICH E11 guideline.23
When defining the target exposure for each age group, we would like to minimise
the difference between the expected response and a target response denoted by Y ∗.
For the epilepsy example, a 50% change in seizure frequency from baseline would
be an appropriate target response, so that Y ∗ = log(−50 + 110).
We derive dosing rules assuming the E-R model and parameter estimates are iden-
tical to the true model and parameter values. Given a proposed age grouping, let
Ck denote the target exposure for the kth age group (ak−1, ak] needed for a patient
aged (ak−1 +ak)/2 years to have expected PD response equal to Y ∗. Furthermore,
define Da = |E[Y | A = a, C = Ck] − Y ∗|. One approach would be to find the
dosing rule minimising the objective function F =
∫ 18
0
Da da, where rules min-
imising F minimise the total absolute difference between the expected response
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and Y ∗. F weights equally the performance of the dosing rule at every age. This
is undesirable in our context since if E-R model parameters do depend on age, it
may be reasonable to expect parameters to change rapidly over short intervals (i.e.
between 0 - 2 years) and remain fairly stable across the adolescent age range. Min-
imising F would favour rules which dose most ages effectively, where inaccurate
dosing over narrow age intervals would not be seriously penalised. However, our
aim is to ensure all ages are dosed appropriately. With this in mind, we choose


















where a∗1 < a
∗
2 < . . . < a
∗
P are fixed and pre-specified age boundaries and may
be based on regulatory guidance, such as the ICH E11 guideline23 or the NICHD
guideline.208 We define these boundaries in line with the NICHD guidelines. Find-
ing dosing rules which minimise G means that we give equal weight to the perfor-
mance of the dosing rule in a number of paediatric age groups considered as our
best prior guesses.
7.6.2 Identifying an optimal number of age groups in our
dosing rule
Define aK = (a0, . . . , aK) as the vector of age boundaries defining the optimal
dosing rule with K groups; CK as the vector of target exposures; and G∗K as the
minima of G for K age groups. Furthermore, let Kmax denote the maximum
number of age groups considered to be plausible or workable in practice, which
would be pre-specified based on feedback from clinicians. We use the following
algorithm to define a paediatric dosing rule:
1. Begin with K = 1 age group;
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2. For K age groups, search over configurations of aK to find the dosing rule
minimising GK ;
3. Save G∗K , a
∗
K , and C∗K ;
4. Repeat steps (2) and (3), successively increasing K by one until K = Kmax.
The minima G∗1, ..., G
∗
Kmax
can be compared to see if increasing K always produces
a worthwhile increase in the accuracy of the dosing rule. The optimum value of
K, balancing the trade-off between complexity and accuracy, is denoted by K∗.
In some scenarios, a more automated approach to selecting K∗ is possible. In
these cases, for each K = 1, ..., 5, we propose calculating the percentage difference
between G∗K+1 and G
∗
K . The value of K where the percentage change is less than
c = 25% is taken as K∗. The arbitrary choice of c used here is intended to illustrate
one possible approach and will be adopted in the simulation study described in
the next section.
7.7 Design of the simulation study
We performed a simulation study to explore the performance of the modelling
approaches described in Section 7.5 and the approach of Section 7.6 for defin-
ing dosing rules. We consider a range of data generation scenarios for the lin-
ear model described in Section 7.4. For the categorical age covariates model, we
follow the ICH E11 age groups to fix the age intervals A1 = (0, 28/365],A2 =
(28/365, 2],A3 = (2, 12] and A4 = (12, 18] of equation (7.3), across all scenarios of
the simulation study.
We simulate studies enrolling 25 subjects into each of four ICH E11 age groups,
(0, 28/365], (28/365, 2], (2, 12], (12, 18], excluding preterm newborn infants. Within
age group (ai−1, ai], the age of patient i is sampled from a Uniform(ai−1, ai) dis-
tribution. We consider 11 scenarios, as illustrated in Figures 7.1 and 7.2, for how
127
Figure 7.1: Plot showing how the intercept of the E-R model changes with age in
simulation scenarios 1-11.
E-R model parameters vary with age. More detail on these scenarios is provided
in Supplementary Tables C.1 and C.2, Supplementary Figure C.9 and Appendix
C.2. We only consider scenarios where the E-R intercept and slope change mono-
tonically with age, since these differences are most realistic in the context of the
epilepsy example.
We measure exposure by Cmin. Following Wadsworth et al.,
209 we sample log(Cmin)
from a N(log(2.94), 0.921) distribution, truncating samples above by log(17.27) to
avoid excessively high concentrations. We sample random errors from a N(0, 0.02)
distribution. These simulated values are used to generate patient responses, Yi,
according to equation (7.1). We simulate 1000 data sets for each scenario and
approach using the statistical software R.16
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Figure 7.2: Plot showing how the slope of E-R model changes with age in simula-
tion scenarios 1-11.
7.7.1 Evaluating different approaches to modelling the E-
R relationship
We use the following measures to compare the modelling approaches described in
Section 7.5. Define A as a grid of Q = 40000 equally spaced ages between 0 and
18 years. For each age, Aq ∈ A, we first measure how well each of the methods
has estimated the true intercept and slope parameters. We do this by comparing
the true parameters, γ0(Aq) and γC(Aq), with our estimates of the parameters,
γˆ
(m)
0 (Aq) and γˆ
(m)
C (Aq), based on simulated dataset m, for m = 1, . . . , 1000. For
simplicity, henceforth we will refer to a general E-R model parameter γ(m)(Aq) and
corresponding estimate γˆ(m)(Aq).
Let ̂E[γˆ(Aq)] = 1M
∑M
m=1 γˆ
(m)(Aq). We evaluate the average absolute bias (AAB),
Empirical Standard Deviation (ESD) and Empirical Mean Squared Error (EMSE)
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, for q = 1, . . . , Q.
Using the grids of AAB, ESD and EMSE values thus produced, we use Simpson’s
rule210,211 to calculate the integrated absolute bias, integrated empirical SD and
integrated empirical MSE for the E-R model parameter. These metrics can be
interpreted as overall measures of the accuracy, precision and MSE of an estimate
of the functional relationship between an E-R model parameter and age.
Similarly, let Yqj denote the response at age, Aq, and exposure, Cj ∈ C, where
C is a grid of J = 40000 equally spaced exposures between 0 and 18. We wish
to compare the estimated expected response at exposure level Cj, Eˆ(m)[Yqj] =
γˆ
(m)
0 (Aq) + γˆ
(m)
C (Aq)Cj, with the true expected response at Cj given by E[Yqj] =
γ0(Aq) + γC(Aq)Cj.
Let Ê[Yqj] = 1M
∑M

























These evaluations produce Q × J matrices of values for AAB, ESD, EMSE. For
each Cj, for j = 1, . . . , J , we then numerically integrate over age using Simpson’s
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rule, and then apply Simpson’s rule again to integrate over exposure to obtain the
integrated absolute bias, integrated empirical SD and integrated empirical MSE
for a patient’s expected response. These can be interpreted as overall measures of
the accuracy, precision and MSE of our estimate of the E-R relationship across a
continuum of ages.
7.7.2 Measuring the accuracy of dosing rules
Following the algorithm of Section 7.6, we find dosing rules comprising K =
1, . . . , 6 age groups, with associated target exposures and minimum objective func-
tion values. We want to assess the performance of this dosing rule identification
process in our simulation study. For each simulated dataset, m, we first take the
derived K ‘optimal’ age groups, (a
(m)
0 = 0, a
(m)




K = 18], and esti-
mates of corresponding target exposure levels, Cˆ
(m)
1 , . . . , Cˆ
(m)
K , and evaluate the
true expected response, at the target exposure levels, according to the simulation















, for q = 1, . . . , Q,
where A(m)k is the interval (a(m)k−1, a(m)k ] and 1A(m)k (Aq) is an indicator function, which
takes the value 1 if Aq ∈ A(m)k and 0 otherwise. This measure is the true expected
response, under the simulation model, implied by the estimated dosing rule. Com-
paring this to the target response will allow us to measure the accuracy of our
dosing rule. For each q = 1, . . . , Q and K = 1, . . . , Kmax we find YqK,diff, the











∣∣∣∣Eˆ [Y (m)qK ]− Y ∗∣∣∣∣ .
This measure can be interpreted as the accuracy of the K-group optimal dosing
rule at age Aq. As with Section 7.7.1, we calculate the integral of YqK,diff over
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age using Simpson’s integration. This measure gives an overall measure of the
accuracy of the K-group optimal dosing rule and allows us to evaluate how close
the true expected response (derived from the simulation model) is to the target
response when children are dosed according to the estimated optimal dosing rule.
We also consider how many of the simulated datasets would lead us to select a
dosing rule with K∗ = 1, . . . , Kmax groups according to the algorithm described in
Section 7.6.2, in order to evaluate the typical complexity of optimal dosing rules
and how this varies with the extent of differences between E-R model parameters
across age groups.
7.8 Results
Figures 7.3–7.5 plot the integrated absolute bias and integrated empirical SD of E-
R model parameter estimators for each modelling approach in each simulation sce-
nario. For estimates obtained fitting Bayesian penalised B-splines, bootstrapped
PALM trees, a single PALM tree and the linear model with categorical age covari-
ate, Supplementary Tables C.3–C.6, in Appendix C, present the integrated average
absolute bias, empirical SD (as shown in Figures 7.3–7.5) and empirical MSE (not
included in the chapter) of the estimated intercepts, slopes and expected response.
Comparing different modelling approaches within a scenario, Figures 7.3–7.5 sug-
gest that, in general, estimates of the functional relationship between the E-R
model intercept and slope parameters obtained via Bayesian penalised B-splines
are more accurate than estimates obtained using bootstrapped PALM trees. The
single PALM tree fit is outperformed by the bootstrapped PALM tree approach in
terms of both integrated absolute bias and empirical SD across most scenarios and
both parameters, suggesting that bootstrapping is a refinement to the single PALM
tree approach. As would be expected, the categorical covariate fit performs best





















































































































































Figure 7.3: Integrated absolute bias (blue circles) and integrated empirical SD (red
triangles) for the E-R model intercept. On the horizontal axis, ‘BS’ refers to the
Bayesian penalised B-splines approach, ‘Categorical’ the linear model adjusted for
a categorical age covariate, and ‘PALM’ and ‘singlePALM’ label the bootstrapped
PALM tree approach and single PALM tree, respectively.
rameters and expected response in scenario 1, where age groups E-R relationships
are most distinct and follow the categories suggested by the ICH E11 guidance,
excluding pre-term newborns.
Figure 7.6 compares the performance of dosing rules minimising GK under different
values of K, derived from E-R models fitted using different modelling approaches.
As the linear model adjusting for a categorical age covariate approach has fixed
age groups and the single PALM tree approach estimates specific age groupings,
results of the dosing rules optimisation are only presented for the Bayesian pe-
nalised B-splines and bootstrapped PALM tree approaches. Figure 7.6 shows that
overall both Bayesian penalised B-splines and bootstrapped PALM trees define
K-group dosing rules with a similar performance in getting the expected response
close to the target response under the true simulation scenarios. In most simula-



















































































































































Figure 7.4: Integrated absolute bias (blue circles) and integrated empirical SD (red
triangles) for the slope of the E-R model. On the horizontal axis, ‘BS’ refers to the
Bayesian penalised B-splines approach, ‘Categorical’ the linear model adjusting for
a categorical age covariate, and ‘PALM’ and ‘singlePALM’ label the bootstrapped
PALM tree approach and single PALM tree, respectively.
accuracy by refining the dosing rule further by allowing for additional age groups.
In most scenarios, as K increases either the true expected response (under the
simulation model and implied by the estimated dosing rule) better matches the
target response or there is little difference in the K-group dosing rules of both
modelling approaches.
Figure 7.7 shows the percentage of the simulations where the global optimum
dosing rule comprises K∗ age groups for various values of K∗ when dosing rules
are derived modelling the E-R relationship using Bayesian penalised B-splines or
bootstrapped PALM trees. It is important to note, however, that the ‘true’ dosing
rule age groups determined using the algorithm described in Section 7.6.2 may not
necessarily be the same as the true underlying E-R age groups, as if there are large
differences in expected response between underlying E-R age groups, a more opti-
























































































































































Figure 7.5: Integrated absolute bias (blue circles) and integrated empirical SD
(red triangles) for the expected response. On the horizontal axis, ‘BS’ refers to the
Bayesian penalised B-splines approach, ‘Categorical’ the linear model adjusting for
a categorical age covariate, and ‘PALM’ and ‘singlePALM’ label the bootstrapped
PALM tree approach and single PALM tree, respectively.
combining age groups with smaller changes. However, it is interesting to explore
the values of K∗ defining the global optimal dosing rules to assess their complex-
ity. Additionally, the complexity of the derived dosing rules will depend on the
quantitative threshold used to identify K∗ as described in Section 7.7.2; with a
different threshold, c, dosing rules with different K∗ may be chosen as optimal.
Optimal dosing rules minimising G are cautious, forming slightly more age groups
than the underlying E-R age groups.
Focusing on Bayesian penalised B-splines, we see from Figure 7.7 that in scenario
1, where larger differences are present in the underlying E-R model parameters,
the large majority (81.6%) of simulated datasets would lead to the investigator
selecting a global optimum dosing rule with K∗ = 4, as would the majority (54%)
of simulated datasets in scenario 3. This suggests that when underlying E-R re-
lationships across age groups become less distinct, dosing rules with smaller K∗
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Figure 7.6: Integrated absolute difference between the target response and true ex-
pected response when children are dosed according to the K group optimal dosing
rule. Results are shown for dosing rules obtained modelling the E-R relationship
using Bayesian penalised B-splines (solid blue line) and bootstrapped PALM trees
(dashed red line).
are selected. In scenario 4, the majority of simulated datasets would lead to the
investigator selecting global optimum dosing rules with K∗ = 4, although there is
a trend to larger K∗ compared with other scenarios. In scenario 5, where underly-
ing E-R model parameters do not depend on age a higher percentage of datasets
lead to the selection of a dosing rule defined by a smaller value of K∗ chosen.
Similar patterns are seen for the bootstrapped PALM trees approach in Figure
7.7. It seems that both bootstrapped PALM trees and the Bayesian penalised
B-splines approach are capable of identification of dosing rules with multiple age
groups when differences in the underlying E-R relationships across age groups are
large, but fewer are identified as differences diminish. For the single PALM tree
fit, for scenarios where larger differences are present in the underlying E-R model
parameters, as in scenarios 1 and 2, a single PALM tree often identifies dosing
rules with four groups; 96.9% and 94.6% would choose four groups, respectively.
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Figure 7.7: Percentage of 1000 simulations in which K∗, the optimal number of
age groups in the dosing rule, takes each value shown. K∗ is selected according to
the algorithm described in Section 7.6.2 for Bayesian penalised B-spline (blue) and
bootstrapped PALM tree (pink) approaches. The values of K∗ chosen by applying
the algorithm in Section 7.6.2 to the true underlying E-R relationships in each
scenario are shown by the yellow bars.
It is interesting to note, in not one scenario did a single PALM tree select a dosing
rule with K∗ > 4.
7.9 Extension to Emax model
We consider a simulated example informed by the data presented in Marshall
and Kearns,175 who model the relationship between cyclosporine concentration
and in vitro inhibitory effect on peripheral blood monocyte (PBM) proliferation
as a sigmoid Emax curve (7.2). We simulate responses for 41 subjects assigned
to one of four age groups: 10 infants (0–1 year); 12 children (1–4 years); 9 pre-
adolescents (4–12 years); and 10 adults (12–18 years). Data are generated such
that for each of the following concentrations of cyclosporine (6.25; 12.5; 25; 50;
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Figure 7.8: Fitted curves of the relationship between log base-10 transformed
cyclosporine concentrations and PBM proliferation based on frequentist two pa-
rameter Emax model fit for each of the four age groups considered. Fitted curves
are the solid lines and the points are simulated data.
100; 250; 500; 1000; and 5000 ng/mL) a patient was recruited from each age group
and the remaining patients in each age group (1 infant; 3 children; 1 adult) were
randomly assigned a concentration from this set. Within an age group, patients’
ages are assumed to follow a uniform distribution. In a deviation from Marshall
and Kearns,175 patient responses are simulated according to a hyperbolic Emax
model (setting δ(A) ≡ 1), although we follow the original publication to force a zero
intercept (γ0(A) ≡ 0). Patient responses are simulated setting the remaining EC50
and Emax model parameters equal to the age group specific parameter estimates
provided by Marshall and Kearns,175 and we assume a normally distributed random
error with mean zero and variance 15. We restrict attention to a hyperbolic Emax
model because estimates of age group specific Hill parameters are not reported
by Marshall and Kearns. Using these simulated data, we fitted a two parameter
Emax model separately to each age group. The four fitted curves are shown in
Figure 7.8.
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7.9.1 Bayesian penalised B-splines
We implement the Bayesian penalised B-splines model by running three Markov
chains (as in our simulation study), although now using a thinning rate of 3 and
9000 iterations, 4500 of which are discarded as burn-in samples. We adopt the
first-order random walk prior defined in Section 7.5.3 for the penalisation. We
found a great deal of sensitivity, in terms of convergence, to the choice of prior
for the standard deviation parameters of the random walk priors on the B-spline
coefficients of the Emax and EC50 parameters. This sensitivity was found when
using the Inverse-Gamma priors as used in Section 7.7. We would advise cau-
tion and appropriate checks to ensure posterior results are reliable. One should
check a priori the plausible range of values for these standard deviation parame-
ters, which would depend on the magnitude of the Emax and EC50 parameters.
Gamma(2, 1/A) priors, with A large (such as A = 10) are recommended by Chung
et al. (2013)212 and the Stan user guide213 as boundary-avoiding priors in hierarchi-
cal models for hierarchical standard deviation parameters. Placing Gamma(2, 0.1)
priors on these random walk prior standard deviation parameters allowed the two
parameter Emax model to fit well to the simulated data shown in Figure 7.8, with
the chains converging with Gelman-Rubin convergence diagnostic < 1.011 for all
parameters.
Figure 7.9 shows the fitted Bayesian penalised B-spline for the Emax and EC50
parameters over age, showing the median, 2.5th and 97.5th quantiles and the
parameter values reported by Marshall and Kearns175 (green dotted lines). The
fitted B-splines for both the EC50 and Emax parameters seem to follow closely to
the true underlying parameter values and, as can be seen from Figure 7.10a, the
underlying E-R relationships are accurately estimated. Figure 7.10a plots fitted
expected response against concentration in each of the four age groups. For each
age group, the fitted expected response is calculated by setting the Emax and EC50
parameters at values gained by evaluating the Emax and EC50 fitted B-splines at
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the mid-points of each age group.
7.9.2 Bootstrapped MOB
To implement the bootstrapped MOB approach, we used the ‘mob’ function in R
with a two parameter Emax model. Otherwise, the approach proceeds exactly as
the bootstrapped PALM trees approach described in Section 7.5.2. To incorporate
a two parameter Emax model in the ‘mob’ function, we built on code provided
by Thomas and Bornkamp,214 using the ‘nls’ function in R16 to specify the two
parameter Emax model.
Figure 7.9 shows the fitted bootstrapped MOB to the Emax and EC50 parameters
over age, showing the median, 2.5th and 97.5th quantiles over the bootstrapped
samples and the true parameter (green dotted lines). The fitted Emax and EC50
parameters do change with age. However, they are both quite far from the true
underlying values. When looking at Figure 7.10b we see that the model still fits
fairly well to the general shape of the data. However, in comparison to the Bayesian
penalised B-splines, Figure 7.10b highlights that there is worse separation between
the fitted E-R curves for different age groups across the whole concentration range
when using the bootstrapped MOB approach.
7.9.3 Deriving dosing rules
Following the procedure to derive optimal dosing rules described in Section 7.6,
Figure 7.11 provides a plot of the objective function values for dosing rules based on
both the Bayesian penalised B-splines and bootstrapped MOB approaches. Over-
all, the bootstrapped MOB approach has lower objective function values than
the Bayesian penalised B-splines approach. For both the bootstrapped MOB and
Bayesian penalised B-splines approaches two groups would almost certainly be




Figure 7.9: Plots of the Bayesian penalised B-spline and bootstrapped MOB fits
of (a) the Emax parameter and (b) the EC50 parameter. The median of each
parameter, with 2.5th and 97.5th quantiles, over the 1000 simulated bootstrap




Figure 7.10: Fitted relationships between log base-10 transformed cyclosporine
concentrations and PBM proliferation based on parameter estimates for the four
age groups obtained with (a) the Bayesian penalised B-spline approach and (b)
the bootstrapped MOB approach.
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Figure 7.11: Plot of the objective function values from the optimisation procedure
used to identify age groups for the Bayesian penalised B-splines approach (blue
line) and bootstrapped MOB (red line).
For two age groups, the optimal age groups defining the bootstrapped MOB dosing
rule would be 0 to 3.33 years and 3.33 to 18 years, with target exposures of
191.95 and 294.87, respectively. For the optimal age groups defining the Bayesian
penalised B-splines dosing rule would be 0 to 0.84 years and 0.84 to 18 years,
with target exposures of 110.36 and 446.04, respectively. It is interesting to note
how different the dosing rules are for these two methods: the bootstrapped MOB
rule stipulates a wider youngest age group, with larger target exposure levels than
the Bayesian penalised B-splines rule. However, overall the bootstrapped MOB
dosing rule has a lower maximum target exposure than the Bayesian penalised
B-splines dosing rule. This seems to be indicative of the larger differences for the
E-R relationships found when using the Bayesian penalised B-splines approach.
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7.10 Discussion
In this chapter we have considered several approaches to estimating if and how
E-R model parameters change over age in order to determine practical dosing rules
for distinct paediatric age groups. Our approaches concentrate on the relationship
between exposure and response, deriving target exposures for age groups. These
target exposures can then be used to identify dosing rules based on a separate
relationship between dose and exposure. We do not develop PK models relating
dose and exposure in this chapter, many methods exist to do this.215
We derive the target exposures of each age group by taking each age group mid-
point and finding the exposure level at which the expected response would be equal
to the target response. In reality, this may not actually be the optimal exposure
level over the whole age group. A more appropriate method may be to search for
age specific exposure levels at which the expected response would be equal to the
target response for each age over the whole age group, then calculate the expected
response over the whole age group using each of these potential target exposures.
The target exposure which minimises the absolute difference between the expected
response and the target response integrated over the age group would be a more
optimum target exposure level for that age group. This approach is computation-
ally more demanding making it unsuitable for our simulation study, but should be
quickly implemented for one dataset in practice.
Results of our simulation study of linear model scenarios suggest that the Bayesian
penalised B-splines and bootstrapped PALM tree approaches perform similarly
in terms of estimating changes in E-R model parameters over age, though the
integrated absolute bias and empirical SD is consistently lower in the Bayesian
penalised B-splines approach. Plots of the absolute difference between the true
expected response implied by proposed target exposures and the target response
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also suggest that for most scenarios both approaches perform similarly well, though
in some scenarios Bayesian penalised B-splines perform better than bootstrapped
PALM trees and vice versa. In fact, the Bayesian penalised B-splines approach
appears to outperform all other approaches in most scenarios; only the approach
using categorical covariates sometimes has lower integrated absolute bias, and even
then, only in some scenarios where the true underlying E-R models contain four






This thesis contains four papers placed in the area of extrapolating between popu-
lations, with a particular focus on paediatric clinical trials in an epilepsy context.
Chapter 3 detailed a systematic review of methodology for extrapolating between
‘source’ and ‘target’ populations and provides a detailed overview of extrapolation
approaches. The expert group meeting, discussed in Chapter 5, gave an insight
into the opinions of leading UK epilepsy experts regarding extrapolation in the de-
velopment of drugs to treat epilepsy. This led to the conclusion that these experts
felt a partial extrapolation of adult efficacy data and a limited extrapolation of
adult safety data would be appropriate for drugs treating paediatric focal epilep-
sies, and that a single combined drug development program in adults and children
2 years and older could be suitable.
Our discussion with clinical experts regarding the acceptability of extrapolation
in epilepsy medicine development motivated our development of a quantitative
framework for informing extrapolation decisions in paediatric medicine develop-
ment given in Chapter 6 and Chapter 7 investigating how PK-PD relationships
146
change with age in order to define practical dosing rules.
Our quantitative framework to inform extrapolation decisions in the paediatric
population highlights the potential gains from utilising existing data, along with
expert prior opinion, for the decision making process regarding appropriate levels
of extrapolation. The prior probability of an extrapolation assumption provides
valuable information which can be leveraged to determine a future course of action
with regards to extrapolation: a low probability would be strong evidence that a
separate drug development programme is required; a high probability may be suf-
ficient evidence to state that PK-PD relationships between adults, adolescents and
younger children are similar enough that complete extrapolation of efficacy data is
suitable; whilst a moderate probability could be incorporated into some decision
theoretic approach to determine how worthwhile a future study in younger chil-
dren would be, given existing information.
When trialling the prior elicitation schemes that lead to our final elicitation proto-
col in Chapter 6, several interesting issues were found. Some of our trial schemes
began by asking for histograms of the average response (rather than the expert’s
best guess at the average response), which experts found to be particularly dif-
ficult. Experts had difficulty determining where they wanted to centre the his-
togram, with all four experts who trialled such a scheme underestimating what
they felt the average response should be in children; all elicited histograms were
centred closer to zero response than experts expected. This led to the elicitation
of the expert’s best guess at the average response line first, using this to mark on
the histograms where experts would expect to centre. We also had a version of the
histograms where experts clicked the plot to add blocks to chosen bins. This was
a very simple and more interactive approach which was well received, however,
choice of block size and quantity (in terms of how much probability each block
was worth) became an issue; one expert wanted to spread their probability further
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than was possible given the number of chips available. As such, we changed to
allowing experts to place specific quantities in each bin.
Chapter 7 describes model-based approaches to deriving practical dosing rules for
paediatric age groups. The Bayesian penalised B-splines and bootstrapped MOB
or PALM tree approaches estimate the relationship between PK-PD model pa-
rameters and a continuous age variable. This essentially gives us the potential
for completely personalised dosing recommendations over the whole age range. In
practice, however, such personalised dosing would likely be impossible; the prac-
tical difficulties of clinicians needing to have access to an algorithm to give dosing
recommendations for a specific age and the investment in terms of time, money
and the need for a wide (perhaps even continuous) range of dosing formulations are
just a few reasons. Hence, the benefit of forming practical dosing rules for a few
distinct age groups, deriving age groups by optimising based on a sum of weighted
integrals (over age) of the difference between expected and target response.
8.2 Limitations
As mentioned in Chapter 3, one limitation of the systematic review is that we
focussed on just four application areas: paediatric drug development; use of his-
torical data in contemporary clinical trials; bridging trials extrapolating efficacy
data between ethnic groups or geographic regions; and the use of short-term data
to support inferences on long-term outcomes. As a result, we may have missed
other relevant methods, such as in approaches for borrowing information across
species.
With our focus group meeting of epilepsy experts, we perhaps could have gained a
broader view of the place of extrapolation in paediatric medicine development for
epilepsy by speaking to experts with different backgrounds. For example, perhaps
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pharmacologists and pharmacometricians could have offered a different perspec-
tive on the appropriateness of extrapolation.
One limitation of our approach for the prior elicitation scheme in Chapter 6, is that
only certain shapes are possible for the credibility intervals around the expert’s
opinion regarding the distribution of the average response of younger children. This
is due to the BVN assumption for the bias priors; in Section 6.4.2 it can clearly
be seen that the variance of the distribution of the expected response for younger
children, conditional on the existing adult and adolescent data, is a quadratic in
dose where the quadratic coefficient is a variance and can therefore only be a non-
negative real number. This stops us from being able to achieve a shape for the
credibility interval which could be described to an expert as “more confidence in
the response at low and high doses, but more uncertainty at moderate doses”; this
is a belief that one clinical collaborator suggested might be how experts would
feel, as they suggested that the middle part of the dose range may not be as well
explored or understood.
For our Bayesian penalised B-spline approach to estimate the relationship between
PK-PD model parameters and age, there can be a great deal of sensitivity to the
choice of prior distribution for the random walk prior standard deviation param-
eter. In practice, one would want to explore sensitivity to the choice of prior to
ensure confidence in the results.
8.3 Further work
An interesting extension of our systematic review in Chapter 3 would be to have
a single consistent extrapolation example to compare as many of the methods
identified as possible. It may be that several examples would be needed within
groupings of methods i.e. where specific data types and distributional assumptions
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have been made which would conflict between methods. Additionally, given the re-
cent increased interest in extrapolation approaches, such as the EMA extrapolation
framework,34,35 it may be worthwhile to update this review with new methodology
proposed in the literature since our paper (beyond 31st January 2014).
With regards to the proposed joint drug development program in Chapter 5, it
may be interesting to quantify the potential gains (such as in terms of patient
recruitment, cost and development time) from considering joint recruitment of
adults and children, with standard practice in paediatric trials of epilepsy.
Future work from the paper in Chapter 6 could be to consider extensions to
more complex PK-PD models, such as the non-linear Emax model. However,
this could be quite a challenging endeavour as the increased complexity would cas-
cade throughout the entire approach. For example, considering extending to the
Emax model, the comparison between adults and younger children would then be
based on parameters of the Emax model (intercept, Emax, ED50; Hill parameter
if considering Sigmoid Emax model) and corresponding bias parameters. With
potentially four bias parameters, a bivariate Normal distribution would no longer
be an appropriate model for these parameters. Careful thought and clinical collab-
oration would be required to develop an elicitation scheme that would best capture
expert belief under this more complex model. Even if an appropriate prior elicita-
tion scheme could be developed to elicit expert opinion for the expert’s best guess
at the average response in younger children, and some measure of uncertainty, it
would be more difficult to derive estimates for the underlying bias parameters and
would require careful thought on modelling assumptions. Additionally, our prior
probability of an extrapolation assumption would likely need to consider more ex-
posure levels than placebo and some other level; with the non-linear nature of the
Emax model, matching similar PK-PD relationships between adults and younger
children may want to take in to account some moderate exposure level, such as
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the EC50, along with placebo and a higher exposure level.
As discussed, the prior probability of the extrapolation assumption holding could
be incorporated into some Bayesian decision theoretic approach. Future work to
develop such an approach to determine how worthwhile a future study would be,
would be valuable. Future studies of adults and younger children could also be
conducted according to an adaptive design, updating this prior probability of an
extrapolation assumption holding at interim analyses to potentially provide early
stopping in favour of extrapolation.
At present, we have simply assumed dose-proportionality and a direct one-to-one
relationship between dose and exposure when translating the elicited expert opin-
ion to a prior distribution for the bias parameters of our PK-PD model for a
future study of adults and younger children. As mentioned in Chapter 6, existing
PK studies may be available to determine whether an assumption of dose propor-
tionality is appropriate and to estimate the proportionality constant, or to assess
whether some other relationship holds. If existing data are not available, it could
be interesting further work to establish a scheme to elicit the expert opinion of
pharmacologists (see the approach of Whitehead et al.216) regarding the relation-
ship between dose and exposure.
For future work, a more comprehensive testing of the prior elicitation scheme would
be ideal. Clearly, to really demonstrate how well this approach could work, a real-
world practical application would be desirable, though perhaps a well designed
simulation study with strong clinical input would suffice. At present, although
the scheme has been trialled with experts, each testing session only had a short
window of time (between 10 to 30 minutes). In practice, one would want to have a
full day session with initial elicitation training, detailed presentation of the prob-
lem requiring elicitation and plenty of time to run through the elicitation scheme
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with individuals. Additionally, if behavioural aggregation of the elicited opinion
was chosen to derive a consensus prior, time would need to be allocated for dis-
cussion of individual opinion amongst the group of experts to arrive at a final
joint bias prior distribution. When elicitation schemes were being trialled, some
adult neurologists felt unable to answer the questions due to feeling they did not
have enough understanding or experience with the paediatric population to give
meaningful answers. This may make behavioural aggregation an ideal approach
to deriving consensus opinions; adult experts can still bring the knowledge they
do have, whilst taking on board the expertise of their paediatric neurology peers
when agreeing to a consensus prior. However, given the amount of information we
elicit (especially with the three histograms), this behavioural aggregation could be
a very time consuming process. If this approach were not felt to be appropriate
due to the complexity of the elicitation scheme, mathematical aggregation could
be considered as an alternative.
An extension to the work in Chapter 7, could be to consider other objective func-
tions for the optimisation procedure, perhaps based on eliciting expert opinion on
where age groupings are most likely to exist. At present, our objective function
uses age groupings suggested by guidance documents. Whilst using guidance doc-
uments appears to be a very reasonable approach, it may be possible that age
groups could stray from this and if this difference may be suggested by experts in
advance, gains could be made when optimising groups to establish dosing rules.
Currently, the approaches considered in Chapter 7 derive optimal age groups based
on an assumption that the estimated relationship between PK-PD parameter and
age is true; future work could perhaps look at incorporating the uncertainty in the
estimated relationship.
Further, in our approach we find practical dosing rules by using a continuous
optimisation method over age, however, we could instead search for optimal age
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groupings over a grid of possible age boundaries. This would allow the incorpo-
ration of practical restrictions into the design of the search grid, such as setting
a minimum width of any age groups or ensuring age boundaries are in terms of
practical units of age (e.g. months or years). Additionally, this would ensure the
identification of the global optimum across the age grid chosen. We tested this
approach, however, the computation time dramatically increases as the number of
age groups increases (even over a small age grid of equally spaced years), making
this infeasible for our simulation study. It may be possible to find a computa-
tionally quicker approach to evaluate this grid search optimisation in a simulation
study, but given time constraints we felt the continuous optimisation approach was
sufficient. For future work it may be worthwhile to explore this grid optimisation
in more detail.
8.4 Wider application
Whilst the focus of this thesis has been the extrapolation of efficacy data from
adults to the paediatric population, many of the approaches could generalise to
other areas. This is clearly demonstrated by the systematic review of methods for
extrapolating between ‘source’ and ‘target’ populations, where extrapolation from
adults to children was only one of four areas explored.
For example, our quantitative framework for informing extrapolation decisions in
Chapter 6 could be extended to any homogenous populations where existing data
already exists for two groups and expert opinion can be sought for the similarity
between an existing group and some new ‘target’ population. This approach would
work across finer paediatric age groupings, extending to geriatrics, considering dif-
ferences across related conditions, indications or drugs with similar mechanisms of
action, and informing extrapolation decisions across geographic regions.
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The focus group meeting should also provide clear evidence that seeking the opin-
ion of subject leaders regarding the place of extrapolation in a specific area of drug
development can be worthwhile. Expert opinion can potentially lead to pragmatic
approaches to extrapolate across populations, as is the case with our joint drug
development paradigm.
This thesis has aimed to demonstrate how utilising existing historical data and
expert opinion can be useful to focus and prioritise paediatric drug development
research, and hopefully more broadly across other areas of drug development.
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This section contains the following three appendices:
A.1: Systematic review search strategy;
A.2: Data extraction form used to record relevant information from articles iden-
tified by the systematic review;
A.3: Search strategy for software implementing methods identified by the system-
atic review.
In addition, file “Appendix D Spreadsheet.xlsx” contains Appendix D.
Appendix D: For each method this file lists the following information: a) the cita-
tion number (as listed in the main text) and bibliographic details of the paper from
which the method was extracted; b) a short description of the method; c) whether
the method is Bayesian or frequentist; and d) whether software is available to im-
plement the method and what statistical language this is written in (i.e., R, Win-
BUGS etc). Appendix D can be found at: http://www.research.lancs.ac.uk/
portal/en/publications/-(8911844e-2638-4dec-a844-8b842f034168).html
173
A.1 Systematic review search strategy
Below are listed the search terms used to perform three searches of the Web of
Science SCI-EXPANDED database.
Search 1: Paediatric clinical trials and bridging trials extrapolating efficacy across
ethnic groups or regions combined into one search
(TS=( (bridging OR "borrow* strength" OR extrapolat* OR synthesize) AND
(p$ediatric OR child* OR ethnic OR region* OR geotherapeutic* OR centre
OR center) AND (trial* OR "bridging stud*") )) AND (WC=(Biology OR
Mathematical & Computational Biology OR Mathematics, Applied OR Mathematics,
Interdisciplinary Applications OR Medical Informatics OR Medicine,
Research & Experimental OR Pediatrics OR Statistics & Probability))
Search 2: Historical controls in clinical trials
(TS=( ("historical control*" OR "historical information" OR "historical data")
AND (trial*) )) AND (WC=(Biology OR Mathematical & Computational Biology OR
Mathematics, Applied OR Mathematics, Interdisciplinary Applications OR
Medical Informatics OR Medicine, Research & Experimental OR Pediatrics OR
Statistics & Probability))
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Search 3: Using short-term endpoints to support inferences about treatment effects
on long-term endpoints
(TS=( (short-term endpoint OR short-term end point OR biomarker OR
surrogate endpoint OR surrogate end point) AND (long-term endpoint OR
long-term end point) AND (trial*) )) AND (WC=(Biology OR Mathematical &
Computational Biology OR Mathematics, Applied OR Mathematics,
Interdisciplinary Applications OR Medical Informatics OR Medicine,
Research & Experimental OR Pediatrics OR Statistics & Probability))
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A.2 Data extraction form used to record rele-














Repeat of Paper?  
 
1. What is the source population?  
e.g. adult, original region. 
 
2. What is the target population?  
e.g. paediatric, new region. 
 
 
3. Does the method assume a homogenous target population?  
 
4. Is the question to be addressed based on, 
 
4.1. Comparison of interventions 
 







5. Specific example of setting? 
 
5.1. Paediatric clinical trials. 
 
5.2. Using short-term endpoints to support inferences  
about treatment effects on long-term endpoints. 
 
5.3. Historical controls in clinical trials. 
 
5.4. Bridging trials extrapolating efficacy across ethnic  
groups / regions / centres. 
 
 
6. Does the method require data from a source population? 
 
7. Does the method require data from a target population? 
 
 




















8. What type of relevant data is required? 









9. What is the form of the required data? 
 (can pick multiple)   Source  Target 
 






9.4. Ordered categorical 
 
9.5. Unordered categorical  
 
9.6. Count data 
 
10. What quality of data does the method require / can the method accommodate? 
      Source  Target 
 
10.1. High (RCT) 
 
10.2. Medium (observational studies) 
 
10.3. Low (Case reports) 
 









11. Is the method Bayesian and / or Frequentist? 
 


































12. Extrapolation process: Inferences regarding differences between source and target population 
(e.g. are Exposure-Response curves similar in adult and paediatric populations) 
 
12.1. Are data collected to generate hypotheses about differences  If no, go to 14 
between the source and target populations? 
 
12.2. Are these data from the source and target populations?   If no, go to 12.3 
 












13. Details of the statistical model used for Q12. 
 






































14. Extrapolation process: Inferences about key parameter in target population (i.e. efficacy 
parameter in target population) 
 
14.1. From the conclusion of Q12, are the source and    go to 14.2. 
target populations assumed to be similar?      
 
 
14.2. For inference on the target population, are inferences: 
 
14.2.1. made in the source population only?      If yes, go to 14.3 
 
14.2.2. made in the target population only?      If yes, leave comments, go to 15. 
 
14.2.3. made in both the source and target      If yes, go to 14.4. 
populations? 
 







14.3. Are key parameters of interest assumed to be     Leave comments, go to 15. 







14.4. Are inferences about key parameters in the target population to be based on: 
 
14.4.1. An overall model for the data from the       If yes, go to 14.5. 
    source and target populations? 
 
14.4.2. concurrent data from the target population?       If yes, go to 14.6. 
 
14.4.3. Weighted test of source and target.        If yes, go to 15. 
 
14.5. In the overall model, 
 
14.5.1. Are key parameters  in source and target populations 
    assumed to be the same? 
   
14.5.2. Are nuisance parameters (e.g. variances) in source  
    and target populations assumed to be the same? 
 




















14.6. How is the method borrowing strength from data in the source population? 
 
14.6.1. Creation of informative prior? 
14.6.2. Use of point prior? 
14.6.3. Informal supportive analysis?  






15. Details of the statistical model used for Q14. 
 









































A.3 Search strategy for software implementing
methods identified by the systematic review.
We searched for software implementing methods identified by the systematic review
in the following ways:
1. By checking whether code was listed in the paper proposing the method
(either in the main text, an Appendix, or on-line supplementary material).
We also recorded whether it was stated in the paper that code is available
from the authors upon request.
2. By checking the references of each paper for companion software papers.
3. By checking papers listed by Web of Science as having cited the original
article to see whether these included companion software papers.
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Appendix B
Online supplementary material to
accompany Chapter 6.
Below is the online supplementary material provided for the
manuscript “A proposal for a quantitative framework to in-
form extrapolation decisions in children” by Wadsworth I,
Hampson LV, Jaki T, Sills GJ, Marson AG and Appleton R
This document contains the following appendices:
B.1: Screen captures of the Shiny app developed for prior elicitation
of expert opinion;
B.2: Additional plots of the probability of the extrapolation assump-
tion holding for scenarios 2, 5 and 6;
B.3: Supplementary tables ST1 - ST13.
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B.2 Additional plots of the probability of the ex-
trapolation assumption holding
Figure B.9: (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of ± 1 standard deviations of the mean, when the true PK-PD
relationships in adults and adolescents follows model S2. (b) Median PK-PD
curves for adults, adolescents and younger children following model S2, along with
lower bounds of 90% empirical credibility intervals for the median response in
younger children resulting from the expert bias prior E1 when its variance matrix
is unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are calculated
conditioning on the true values of the adult and adolescent PK-PD parameters.
Similarity bounds at placebo and the EC90 given by criteria (11) and (12) are also
shown.
193
Figure B.10: (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of ± 1 standard deviations of the mean, when the true PK-PD
relationships in adults and adolescents follows model S5. (b) Median PK-PD
curves for adults, adolescents and younger children following model S5, along with
lower bounds of 90% empirical credibility intervals for the median response in
younger children resulting from the expert bias prior E1 when its variance matrix
is unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are calculated
conditioning on the true values of the adult and adolescent PK-PD parameters.
Similarity bounds at placebo and the EC90 given by criteria (11) and (12) are also
shown.
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Figure B.11: (a) Average probability of the extrapolation assumption under bias
prior E1, with bars of ± 1 standard deviations of the mean, when the true PK-PD
relationships in adults and adolescents follows model S6. (b) Median PK-PD
curves for adults, adolescents and younger children following model S6, along with
lower bounds of 90% empirical credibility intervals for the median response in
younger children resulting from the expert bias prior E1 when its variance matrix
is unscaled; or scaled by a factor of 0.5 or 2. Credibility intervals are calculated
conditioning on the true values of the adult and adolescent PK-PD parameters.





Table B.1: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and
the interaction between age and exposure - Low between-trial heterogeneity 1 of 2
Low between-trial heterogeneity
γA γI
mean SD MSE mean SD MSE
N = 30 Truth: 0 Truth: 0
H = 2 0.0013 0.0481 0.0227 -0.0018 0.1065 0.0056
H = 3 0.0022 0.0126 0.0083 0 0.0010 0.0005
H = 4 0.0021 0.0114 0.0064 0.0010 0.0231 0.0042
H = 5 -0.0002 0.0060 0.0047 0.0010 0.0046 0.0007
H = 10 -0.0018 0.0026 0.0020 0.0002 0.0013 0.0002
H = 20 -0.0007 0.0011 0.0009 -0.0006 0.0031 0.0002
N = 170 Truth: 0 Truth: 0
H = 2 0.0002 0.0054 0.0031 0.0002 0.0002 0.0001
H = 3 0.0011 0.0030 0.0020 0.0001 0.0001 0.0001
H = 4 -0.0003 0.0021 0.0017 0.0004 0.0001 0.0001
H = 5 0.0017 0.0015 0.0013 0.0001 0.0001 0
H = 10 -0.0002 0.0007 0.0007 0.0001 0 0
H = 20 0.0007 0.0003 0.0003 -0.0001 0 0
N = 30 Truth: 0.0569 Truth: 0.0056
H = 2 0.0637 0.0320 0.0160 0.0030 0.0054 0.0012
H = 3 0.0560 0.0139 0.0091 0.0045 0.0017 0.0007
H = 4 0.0551 0.0081 0.0057 0.0058 0.0006 0.0004
H = 5 0.0615 0.0061 0.0042 0.0049 0.0004 0.0002
H = 10 0.0551 0.0026 0.0022 0.0064 0.0010 0.0002
H = 20 0.0576 0.0011 0.0010 0.0058 0.0002 0.0001
N = 170 Truth: 0.0569 Truth: 0.0056
H = 2 0.0578 0.0055 0.0029 0.0058 0.0002 0.0001
H = 3 0.0576 0.0030 0.0020 0.0060 0.0001 0.0001
H = 4 0.0584 0.0021 0.0015 0.0053 0.0001 0
H = 5 0.0561 0.0015 0.0013 0.0058 0.0001 0
H = 10 0.0577 0.0007 0.0006 0.0056 0 0
H = 20 0.0563 0.0003 0.0003 0.0058 0 0
N = 30 Truth: 0.1108 Truth: 0.0103
H = 2 0.1057 0.0269 0.0128 0.0114 0.0026 0.0010
H = 3 0.1093 0.0128 0.0075 0.0093 0.0010 0.0005
H = 4 0.1141 0.0082 0.0055 0.0097 0.0006 0.0003
H = 5 0.1098 0.0060 0.0043 0.0106 0.0004 0.0002
H = 10 0.1123 0.0025 0.0020 0.0100 0.0001 0.0001
H = 20 0.1096 0.0011 0.0010 0.0103 0.0001 0.0001
N = 170 Truth: 0.1108 Truth: 0.0103
H = 2 0.1106 0.0054 0.0029 0.0103 0.0002 0.0001
H = 3 0.1108 0.0031 0.0022 0.0102 0.0001 0.0001
H = 4 0.1105 0.0020 0.0015 0.0105 0.0001 0
H = 5 0.1107 0.0015 0.0012 0.0105 0.0001 0
H = 10 0.1129 0.0007 0.0006 0.0102 0 0
H = 20 0.1113 0.0003 0.0003 0.0104 0 0
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Table B.2: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and
the interaction between age and exposure - Low between-trial heterogeneity 2 of 2
Low between-trial heterogeneity
γA γI
mean SD MSE mean SD MSE
N = 30 Truth: 0.2105 Truth: 0.0175
H = 2 0.2185 0.0726 0.0195 0.0141 0.0055 0.0014
H = 3 0.2102 0.0126 0.0073 0.0180 0.0010 0.0005
H = 4 0.2093 0.0081 0.0055 0.0172 0.0006 0.0003
H = 5 0.2155 0.0059 0.0042 0.0163 0.0004 0.0002
H = 10 0.2121 0.0026 0.0019 0.0171 0.0009 0.0002
H = 20 0.2101 0.0014 0.0011 0.0175 0.0011 0.0001
N = 170 Truth: 0.2105 Truth: 0.0175
H = 2 0.2084 0.0054 0.0030 0.0178 0.0002 0.0001
H = 3 0.2115 0.0031 0.0019 0.0175 0.0001 0.0001
H = 4 0.2107 0.0021 0.0016 0.0176 0.0001 0
H = 5 0.2085 0.0016 0.0013 0.0175 0.0001 0
H = 10 0.2108 0.0007 0.0006 0.0175 0 0
H = 20 0.2116 0.0003 0.0003 0.0175 0 0
N = 30 Truth: 0.0569 Truth: 0.0137
H = 2 0.0601 0.0457 0.0140 0.0083 0.1246 0.0244
H = 3 0.0605 0.0127 0.0072 0.0132 0.0010 0.0005
H = 4 0.0564 0.0084 0.0055 0.0141 0.0009 0.0003
H = 5 0.0553 0.0061 0.0045 0.0137 0.0025 0.0003
H = 10 0.0564 0.0024 0.0021 0.0136 0.0001 0.0001
H = 20 0.0566 0.0013 0.0010 0.0142 0.0014 0.0001
N = 170 Truth: 0.0569 Truth: 0.0137
H = 2 0.0558 0.0055 0.0034 0.0137 0.0002 0.0001
H = 3 0.0545 0.0030 0.0022 0.0138 0.0001 0.0001
H = 4 0.0589 0.0021 0.0015 0.0134 0.0001 0.0001
H = 5 0.0572 0.0015 0.0012 0.0135 0.0001 0
H = 10 0.0560 0.0007 0.0006 0.0137 0 0
H = 20 0.0577 0.0003 0.0003 0.0136 0 0
N = 30 Truth: 0.0569 Truth: 0.0274
H = 2 0.0506 0.0412 0.0187 0.0281 0.0049 0.0018
H = 3 0.0607 0.0125 0.0073 0.0268 0.0010 0.0005
H = 4 0.0597 0.0082 0.0054 0.0268 0.0006 0.0003
H = 5 0.0618 0.0102 0.0055 0.0282 0.0064 0.0024
H = 10 0.0558 0.0025 0.0021 0.0278 0.0007 0.0001
H = 20 0.0563 0.0011 0.0011 0.0276 0.0001 0.0001
N = 170 Truth: 0.0569 Truth: 0.0274
H = 2 0.0558 0.0053 0.0031 0.0276 0.0002 0.0001
H = 3 0.0573 0.0030 0.0021 0.0272 0.0001 0.0001
H = 4 0.0574 0.0020 0.0016 0.0276 0.0001 0
H = 5 0.0565 0.0015 0.0011 0.0273 0.0001 0
H = 10 0.0567 0.0007 0.0006 0.0275 0 0
H = 20 0.0574 0.0003 0.0003 0.0275 0 0
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Table B.3: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and




mean SD MSE mean SD MSE
N = 30 Truth: 0 Truth: 0
H = 2 0.0039 0.0269 0.0156 0.0003 0.0027 0.0012
H = 3 -0.0019 0.0201 0.0119 0.0005 0.0166 0.0030
H = 4 0.0007 0.0090 0.0073 -0.0005 0.0019 0.0005
H = 5 0.0025 0.0062 0.0056 0.0001 0.0004 0.0003
H = 10 -0.0028 0.0027 0.0028 0 0.0024 0.0003
H = 20 0.0016 0.0012 0.0013 -0.0003 0.0001 0.0001
N = 170 Truth: 0 Truth: 0
H = 2 0.0018 0.0063 0.0052 0.0006 0.0002 0.0002
H = 3 0 0.0039 0.0033 0.0001 0.0001 0.0001
H = 4 0.0019 0.0029 0.0027 -0.0002 0.0001 0.0001
H = 5 0.0002 0.0023 0.0022 0 0.0001 0.0001
H = 10 0.0007 0.0011 0.0012 -0.0001 0 0
H = 20 -0.0005 0.0006 0.0005 0.0002 0 0
N = 30 Truth: 0.0569 Truth: 0.0056
H = 2 0.0525 0.0307 0.0175 0.0059 0.0040 0.0015
H = 3 0.0523 0.0134 0.0108 0.0072 0.0011 0.0006
H = 4 0.0539 0.0090 0.0067 0.0066 0.0023 0.0005
H = 5 0.0583 0.0063 0.0054 0.0057 0.0011 0.0004
H = 10 0.0564 0.0028 0.0026 0.0061 0.0023 0.0003
H = 20 0.0562 0.0014 0.0013 0.0050 0.0040 0.0007
N = 170 Truth: 0.0569 Truth: 0.0056
H = 2 0.0552 0.0063 0.0053 0.0059 0.0002 0.0002
H = 3 0.0587 0.0040 0.0037 0.0064 0.0001 0.0001
H = 4 0.0559 0.0029 0.0026 0.0058 0.0001 0.0001
H = 5 0.0584 0.0023 0.0021 0.0058 0.0001 0.0001
H = 10 0.0556 0.0011 0.0011 0.0056 0 0
H = 20 0.0572 0.0006 0.0005 0.0057 0 0
N = 30 Truth: 0.1108 Truth: 0.0103
H = 2 0.1154 0.0322 0.0190 0.0093 0.0041 0.0024
H = 3 0.1089 0.0132 0.0107 0.0095 0.0011 0.0006
H = 4 0.1067 0.0087 0.0074 0.0105 0.0006 0.0004
H = 5 0.1112 0.0063 0.0052 0.0108 0.0006 0.0003
H = 10 0.1115 0.0027 0.0026 0.0098 0.0002 0.0001
H = 20 0.1103 0.0013 0.0013 0.0101 0.0002 0.0001
N = 170 Truth: 0.1108 Truth: 0.0103
H = 2 0.1110 0.0063 0.0058 0.0105 0.0002 0.0002
H = 3 0.1124 0.0040 0.0038 0.0105 0.0001 0.0001
H = 4 0.1126 0.0030 0.0027 0.0100 0.0001 0.0001
H = 5 0.1129 0.0023 0.0022 0.0099 0.0001 0.0001
H = 10 0.1114 0.0011 0.0011 0.0099 0 0
H = 20 0.1105 0.0006 0.0006 0.0103 0 0
199
Table B.4: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and




mean SD MSE mean SD MSE
N = 30 Truth: 0.2105 Truth: 0.0175
H = 2 0.2099 0.0256 0.0155 0.0179 0.0025 0.0014
H = 3 0.2110 0.0135 0.0087 0.0174 0.0011 0.0006
H = 4 0.2086 0.0085 0.0077 0.0180 0.0006 0.0004
H = 5 0.2101 0.0066 0.0053 0.0167 0.0068 0.0011
H = 10 0.2105 0.0028 0.0025 0.0177 0.0004 0.0001
H = 20 0.2092 0.0013 0.0013 0.0176 0.0001 0.0001
N = 170 Truth: 0.2105 Truth: 0.0175
H = 2 0.2126 0.0063 0.0057 0.0172 0.0002 0.0002
H = 3 0.2098 0.0039 0.0036 0.0173 0.0001 0.0001
H = 4 0.2110 0.0030 0.0028 0.0175 0.0001 0.0001
H = 5 0.2128 0.0023 0.0024 0.0179 0.0001 0.0001
H = 10 0.2091 0.0011 0.0011 0.0174 0 0
H = 20 0.2103 0.0006 0.0006 0.0174 0 0
N = 30 Truth: 0.0569 Truth: 0.0137
H = 2 0.0500 0.0269 0.0161 0.0149 0.1033 0.0012
H = 3 0.0560 0.0132 0.0100 0.0142 0.0011 0.0006
H = 4 0.0564 0.0095 0.0069 0.0142 0.0040 0.0007
H = 5 0.0567 0.0068 0.0056 0.0138 0.0011 0.0003
H = 10 0.0548 0.0027 0.0026 0.0140 0.0002 0.0001
H = 20 0.0576 0.0022 0.0016 0.0138 0.0012 0.0001
N = 170 Truth: 0.0569 Truth: 0.0137
H = 2 0.0574 0.0064 0.0056 0.0142 0.0002 0.0002
H = 3 0.0593 0.0040 0.0038 0.0138 0.0001 0.0001
H = 4 0.0576 0.0029 0.0028 0.0140 0.0001 0.0001
H = 5 0.0551 0.0023 0.0022 0.0135 0.0001 0.0001
H = 10 0.0580 0.0011 0.0010 0.0136 0 0
H = 20 0.0572 0.0006 0.0005 0.0134 0 0
N = 30 Truth: 0.0569 Truth: 0.0274
H = 2 0.0621 0.0304 0.0174 0.0297 0.0243 0.0067
H = 3 0.0496 0.0192 0.0123 0.0297 0.0196 0.0059
H = 4 0.0564 0.0089 0.0070 0.0279 0.0012 0.0004
H = 5 0.0594 0.0072 0.0053 0.0277 0.0011 0.0003
H = 10 0.0587 0.0029 0.0027 0.0269 0.0028 0.0003
H = 20 0.0558 0.0012 0.0012 0.0276 0.0001 0.0001
N = 170 Truth: 0.0569 Truth: 0.0274
H = 2 0.0598 0.0063 0.0052 0.0275 0.0002 0.0002
H = 3 0.0569 0.0039 0.0039 0.0276 0.0001 0.0001
H = 4 0.0541 0.0029 0.0029 0.0274 0.0001 0.0001
H = 5 0.0563 0.0023 0.0021 0.0276 0.0001 0.0001
H = 10 0.0583 0.0011 0.0011 0.0275 0 0
H = 20 0.0571 0.0006 0.0006 0.0272 0 0
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Table B.5: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and




mean SD MSE mean SD MSE
N = 30 Truth: 0 Truth: 0
H = 2 -0.0081 0.1871 0.0474 0.0018 0.0098 0.0022
H = 3 0.0028 0.0148 0.0112 -0.0008 0.0127 0.0015
H = 4 0.0004 0.0089 0.0084 0.0007 0.0006 0.0005
H = 5 0.0019 0.0075 0.0060 -0.0014 0.0099 0.0018
H = 10 0.0044 0.0029 0.0032 -0.0002 0.0002 0.0002
H = 20 -0.0007 0.0014 0.0016 0.0003 0.0001 0.0001
N = 170 Truth: 0 Truth: 0
H = 2 -0.0050 0.0070 0.0084 -0.0005 0.0002 0.0002
H = 3 -0.0016 0.0046 0.0055 -0.0003 0.0001 0.0002
H = 4 -0.0030 0.0036 0.0039 0.0005 0.0001 0.0001
H = 5 0.0015 0.0030 0.0030 0 0.0001 0.0001
H = 10 0.0009 0.0015 0.0015 0.0002 0 0
H = 20 0.0001 0.0008 0.0007 -0.0001 0 0
N = 30 Truth: 0.0569 Truth: 0.0056
H = 2 0.0590 0.0481 0.0199 0.0037 0.0123 0.0016
H = 3 0.0602 0.0138 0.0113 0.0046 0.0011 0.0006
H = 4 0.0528 0.0088 0.0081 0.0060 0.0008 0.0004
H = 5 0.0560 0.0071 0.0065 0.0058 0.0015 0.0004
H = 10 0.0543 0.0029 0.0033 0.0060 0.0002 0.0002
H = 20 0.0566 0.0017 0.0018 0.0024 0.0221 0.0108
N = 170 Truth: 0.0569 Truth: 0.0056
H = 2 0.0542 0.0070 0.0075 0.0062 0.0002 0.0002
H = 3 0.0537 0.0055 0.0051 0.0060 0.0056 0.0003
H = 4 0.0595 0.0037 0.0039 0.0057 0.0001 0.0001
H = 5 0.0560 0.0030 0.0030 0.0052 0.0001 0.0001
H = 10 0.0564 0.0016 0.0016 0.0058 0 0
H = 20 0.0566 0.0008 0.0008 0.0057 0 0
N = 30 Truth: 0.1108 Truth: 0.0103
H = 2 0.1194 0.0549 0.0204 0.0078 0.0060 0.0015
H = 3 0.1095 0.0134 0.0115 0.0116 0.0011 0.0006
H = 4 0.1171 0.0090 0.0090 0.0093 0.0009 0.0004
H = 5 0.1096 0.0067 0.0060 0.0105 0.0005 0.0003
H = 10 0.1093 0.0030 0.0030 0.0108 0.0005 0.0002
H = 20 0.1107 0.0014 0.0015 0.0102 0.0001 0.0001
N = 170 Truth: 0.1108 Truth: 0.0103
H = 2 0.1065 0.0072 0.0070 0.0108 0.0002 0.0002
H = 3 0.1070 0.0048 0.0052 0.0096 0.0001 0.0001
H = 4 0.1101 0.0038 0.0039 0.0102 0.0001 0.0001
H = 5 0.1109 0.0030 0.0030 0.0104 0.0001 0.0001
H = 10 0.1135 0.0016 0.0015 0.0102 0 0
H = 20 0.1123 0.0008 0.0008 0.0104 0 0
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Table B.6: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and




mean SD MSE mean SD MSE
N = 30 Truth: 0.2105 Truth: 0.0175
H = 2 0.2055 0.1025 0.0333 0.0192 0.0085 0.0024
H = 3 0.2168 0.0134 0.0111 0.0160 0.0015 0.0007
H = 4 0.2127 0.0101 0.0079 0.0157 0.0010 0.0004
H = 5 0.2088 0.0066 0.0066 0.0183 0.0016 0.0004
H = 10 0.2143 0.0029 0.0033 0.0177 0.0002 0.0001
H = 20 0.2096 0.0014 0.0014 0.0173 0.0001 0.0001
N = 170 Truth: 0.2105 Truth: 0.0175
H = 2 0.2045 0.0070 0.0083 0.0180 0.0002 0.0002
H = 3 0.2121 0.0049 0.0053 0.0179 0.0002 0.0002
H = 4 0.2117 0.0036 0.0041 0.0171 0.0001 0.0001
H = 5 0.2133 0.0030 0.0029 0.0169 0.0001 0.0001
H = 10 0.2065 0.0016 0.0017 0.0176 0 0
H = 20 0.2112 0.0008 0.0008 0.0173 0 0
N = 30 Truth: 0.0569 Truth: 0.0137
H = 2 0.0615 0.0432 0.0236 0.0090 0.0775 0.0184
H = 3 0.0566 0.0132 0.0100 0.0144 0.0011 0.0006
H = 4 0.0495 0.0087 0.0081 0.0143 0.0007 0.0004
H = 5 0.0583 0.0067 0.0069 0.0123 0.0065 0.0010
H = 10 0.0550 0.0031 0.0034 0.0134 0.0022 0.0004
H = 20 0.0592 0.0014 0.0017 0.0136 0.0002 0.0001
N = 170 Truth: 0.0569 Truth: 0.0137
H = 2 0.0575 0.0071 0.0078 0.0142 0.0002 0.0002
H = 3 0.0565 0.0049 0.0056 0.0137 0.0002 0.0002
H = 4 0.0603 0.0037 0.0038 0.0139 0.0001 0.0001
H = 5 0.0565 0.0030 0.0032 0.0137 0.0001 0.0001
H = 10 0.0569 0.0016 0.0015 0.0138 0 0
H = 20 0.0581 0.0008 0.0008 0.0136 0 0
N = 30 Truth: 0.0569 Truth: 0.0274
H = 2 0.0573 0.1333 0.1001 0.0350 0.2044 0.0318
H = 3 0.0585 0.0138 0.0120 0.0269 0.0011 0.0007
H = 4 0.0517 0.0141 0.0096 0.0304 0.0324 0.0056
H = 5 0.0563 0.0067 0.0072 0.0277 0.0005 0.0004
H = 10 0.0555 0.0029 0.0031 0.0277 0.0007 0.0002
H = 20 0.0561 0.0019 0.0016 0.0275 0.0006 0.0001
N = 170 Truth: 0.0569 Truth: 0.0274
H = 2 0.0529 0.0074 0.0074 0.0267 0.0002 0.0002
H = 3 0.0572 0.0048 0.0055 0.0272 0.0001 0.0001
H = 4 0.0593 0.0037 0.0040 0.0269 0.0001 0.0001
H = 5 0.0570 0.0030 0.0030 0.0274 0.0001 0.0001
H = 10 0.0583 0.0015 0.0017 0.0275 0 0
H = 20 0.0553 0.0008 0.0007 0.0275 0 0
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Table B.7: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and
the interaction between age and exposure - Very high between-trial heterogeneity
1 of 2
Very high between-trial heterogeneity
γA γI
mean SD MSE mean SD MSE
N = 30 Truth: 0 Truth: 0
H = 2 0.0047 0.0636 0.0339 0.0029 0.1632 0.0143
H = 3 0.0013 0.0221 0.0162 -0.0024 0.0313 0.0130
H = 4 -0.0016 0.0093 0.0103 0.0004 0.0009 0.0005
H = 5 0.0047 0.0070 0.0078 -0.0010 0.0011 0.0004
H = 10 0.0013 0.0032 0.0043 0.0004 0.0002 0.0002
H = 20 0.0026 0.0017 0.0022 0.0003 0.0008 0.0001
N = 170 Truth: 0 Truth: 0
H = 2 0 0.0082 0.0106 -0.0001 0.0003 0.0003
H = 3 0.0020 0.0057 0.0071 0.0004 0.0002 0.0002
H = 4 0.0021 0.0046 0.0059 -0.0005 0.0001 0.0002
H = 5 -0.0032 0.0040 0.0045 -0.0004 0.0001 0.0001
H = 10 0.0005 0.0021 0.0023 -0.0003 0.0001 0.0001
H = 20 0.0009 0.0011 0.0011 0.0002 0 0
N = 30 Truth: 0.0569 Truth: 0.0056
H = 2 0.0649 0.0903 0.0268 0.0051 0.0126 0.0015
H = 3 0.0567 0.0141 0.0146 0.0053 0.0016 0.0007
H = 4 0.0538 0.0114 0.0107 0.0090 0.0213 0.0054
H = 5 0.0548 0.0072 0.0080 0.0061 0.0008 0.0004
H = 10 0.0550 0.0042 0.0043 0.0066 0.0067 0.0017
H = 20 0.0583 0.0017 0.0020 0.0051 0.0001 0.0001
N = 170 Truth: 0.0569 Truth: 0.0056
H = 2 0.0500 0.0083 0.0112 0.0064 0.0002 0.0003
H = 3 0.0568 0.0060 0.0073 0.0052 0.0002 0.0002
H = 4 0.0584 0.0048 0.0054 0.0054 0.0001 0.0002
H = 5 0.0542 0.0038 0.0042 0.0061 0.0001 0.0001
H = 10 0.0555 0.0022 0.0023 0.0057 0.0001 0.0001
H = 20 0.0566 0.0011 0.0012 0.0055 0 0
N = 30 Truth: 0.1108 Truth: 0.0103
H = 2 0.1113 0.0290 0.0250 0.0113 0.1037 0.0017
H = 3 0.1115 0.0145 0.0135 0.0077 0.0102 0.0024
H = 4 0.1145 0.0093 0.0102 0.0093 0.0007 0.0005
H = 5 0.1089 0.0069 0.0079 0.0107 0.0006 0.0004
H = 10 0.1122 0.0033 0.0041 0.0098 0.0002 0.0002
H = 20 0.1140 0.0017 0.0019 0.0104 0.0015 0.0002
N = 170 Truth: 0.1108 Truth: 0.0103
H = 2 0.1135 0.0080 0.0111 0.0101 0.0002 0.0003
H = 3 0.1107 0.0060 0.0075 0.0110 0.0002 0.0002
H = 4 0.1084 0.0046 0.0053 0.0096 0.0001 0.0002
H = 5 0.1120 0.0039 0.0043 0.0112 0.0001 0.0001
H = 10 0.1119 0.0021 0.0022 0.0102 0.0001 0.0001
H = 20 0.1116 0.0011 0.0011 0.0104 0 0
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Table B.8: Means, empirical standard deviations and mean squared error over the
1000 replications of each scenario’s meta-analysis results for the effects of age and
the interaction between age and exposure - Very high between-trial heterogeneity
2 of 2
Very high between-trial heterogeneity
γA γI
mean SD MSE mean SD MSE
N = 30 Truth: 0.2105 Truth: 0.0175
H = 2 0.2122 0.0300 0.0258 0.0168 0.0030 0.0015
H = 3 0.2074 0.0137 0.0140 0.0164 0.0011 0.0008
H = 4 0.2080 0.0108 0.0103 0.0195 0.0116 0.0015
H = 5 0.2106 0.0071 0.0082 0.0162 0.0080 0.0011
H = 10 0.2144 0.0032 0.0035 0.0170 0.0002 0.0002
H = 20 0.2107 0.0017 0.0019 0.0176 0.0001 0.0001
N = 170 Truth: 0.2105 Truth: 0.0175
H = 2 0.2137 0.0080 0.0108 0.0172 0.0002 0.0003
H = 3 0.2106 0.0060 0.0077 0.0173 0.0002 0.0002
H = 4 0.2163 0.0048 0.0054 0.0177 0.0001 0.0002
H = 5 0.2098 0.0039 0.0046 0.0179 0.0001 0.0001
H = 10 0.2113 0.0021 0.0024 0.0171 0.0001 0.0001
H = 20 0.2087 0.0011 0.0011 0.0177 0 0
N = 30 Truth: 0.0569 Truth: 0.0137
H = 2 0.0601 0.0582 0.0283 0.0145 0.0052 0.0020
H = 3 0.0575 0.0141 0.0144 0.0140 0.0011 0.0008
H = 4 0.0568 0.0093 0.0095 0.0140 0.0007 0.0005
H = 5 0.0504 0.0073 0.0080 0.0159 0.0069 0.0021
H = 10 0.0562 0.0033 0.0039 0.0145 0.0002 0.0002
H = 20 0.0595 0.0017 0.0020 0.0133 0.0001 0.0001
N = 170 Truth: 0.0569 Truth: 0.0137
H = 2 0.0546 0.0082 0.0109 0.0144 0.0002 0.0003
H = 3 0.0566 0.0061 0.0071 0.0136 0.0002 0.0002
H = 4 0.0570 0.0048 0.0053 0.0134 0.0001 0.0002
H = 5 0.0559 0.0040 0.0045 0.0140 0.0001 0.0001
H = 10 0.0581 0.0021 0.0022 0.0139 0.0001 0.0001
H = 20 0.0569 0.0011 0.0011 0.0136 0 0
N = 30 Truth: 0.0569 Truth: 0.0274
H = 2 0.0513 0.0428 0.0275 0.0287 0.0044 0.0019
H = 3 0.0606 0.0136 0.0138 0.0258 0.0012 0.0008
H = 4 0.0596 0.0093 0.0107 0.0273 0.0007 0.0005
H = 5 0.0576 0.0072 0.0082 0.0284 0.0196 0.0045
H = 10 0.0593 0.0034 0.0040 0.0275 0.0002 0.0002
H = 20 0.0588 0.0017 0.0021 0.0274 0.0001 0.0001
N = 170 Truth: 0.0569 Truth: 0.0274
H = 2 0.0619 0.0082 0.0111 0.0268 0.0002 0.0003
H = 3 0.0558 0.0059 0.0077 0.0273 0.0002 0.0002
H = 4 0.0559 0.0047 0.0055 0.0276 0.0001 0.0002
H = 5 0.0584 0.0039 0.0046 0.0272 0.0001 0.0001
H = 10 0.0569 0.0021 0.0021 0.0275 0.0001 0.0001
H = 20 0.0562 0.0011 0.0011 0.0272 0 0
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Table B.9: Means and empirical standard deviations over the 1000 replications of
each scenario’s probability of the extrapolation assumption holding - Low between-
trial heterogeneity
Low between-trial heterogeneity
mean SD mean SD
Scenario 1 N = 30 N = 170
H = 2 0.170 0.073 0.387 0.068
H = 3 0.236 0.079 0.451 0.065
H = 4 0.286 0.079 0.479 0.057
H = 5 0.330 0.082 0.506 0.048
H = 10 0.437 0.069 0.548 0.032
H = 20 0.512 0.045 0.572 0.021
Scenario 2 N = 30 N = 170
H = 2 0.152 0.070 0.327 0.083
H = 3 0.207 0.078 0.368 0.078
H = 4 0.250 0.085 0.397 0.074
H = 5 0.279 0.081 0.415 0.069
H = 10 0.360 0.073 0.445 0.053
H = 20 0.412 0.059 0.461 0.039
Scenario 3 N = 30 N = 170
H = 2 0.122 0.064 0.236 0.085
H = 3 0.156 0.069 0.254 0.085
H = 4 0.174 0.073 0.267 0.076
H = 5 0.192 0.074 0.273 0.073
H = 10 0.236 0.069 0.284 0.057
H = 20 0.268 0.055 0.292 0.042
Scenario 4 N = 30 N = 170
H = 2 0.056 0.040 0.083 0.052
H = 3 0.058 0.041 0.077 0.043
H = 4 0.061 0.039 0.076 0.042
H = 5 0.061 0.040 0.076 0.037
H = 10 0.064 0.033 0.070 0.025
H = 20 0.064 0.025 0.068 0.018
Scenario 5 N = 30 N = 170
H = 2 0.137 0.064 0.277 0.089
H = 3 0.178 0.070 0.308 0.086
H = 4 0.211 0.077 0.323 0.081
H = 5 0.236 0.082 0.335 0.079
H = 10 0.296 0.079 0.354 0.061
H = 20 0.330 0.066 0.363 0.045
Scenario 6 N = 30 N = 170
H = 2 0.108 0.055 0.165 0.079
H = 3 0.129 0.065 0.171 0.075
H = 4 0.144 0.069 0.168 0.071
H = 5 0.151 0.071 0.172 0.064
H = 10 0.163 0.070 0.168 0.052
H = 20 0.165 0.063 0.168 0.038
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Table B.10: Means and empirical standard deviations over the 1000 replications
of each scenario’s probability of the extrapolation assumption holding - Moderate
between-trial heterogeneity
Moderate between-trial heterogeneity
mean SD mean SD
Scenario 1 N = 30 N = 170
H = 2 0.163 0.077 0.347 0.096
H = 3 0.227 0.085 0.409 0.087
H = 4 0.269 0.089 0.436 0.080
H = 5 0.313 0.088 0.466 0.072
H = 10 0.416 0.080 0.523 0.047
H = 20 0.493 0.053 0.555 0.032
Scenario 2 N = 30 N = 170
H = 2 0.144 0.073 0.303 0.106
H = 3 0.188 0.082 0.341 0.109
H = 4 0.238 0.093 0.373 0.099
H = 5 0.267 0.094 0.385 0.093
H = 10 0.346 0.088 0.432 0.074
H = 20 0.404 0.070 0.451 0.053
Scenario 3 N = 30 N = 170
H = 2 0.115 0.068 0.219 0.104
H = 3 0.152 0.081 0.241 0.105
H = 4 0.172 0.084 0.257 0.100
H = 5 0.187 0.085 0.267 0.098
H = 10 0.235 0.085 0.285 0.080
H = 20 0.264 0.070 0.292 0.061
Scenario 4 N = 30 N = 170
H = 2 0.057 0.048 0.088 0.075
H = 3 0.060 0.046 0.086 0.065
H = 4 0.064 0.052 0.083 0.059
H = 5 0.065 0.048 0.077 0.052
H = 10 0.066 0.042 0.077 0.039
H = 20 0.068 0.031 0.072 0.026
Scenario 5 N = 30 N = 170
H = 2 0.132 0.072 0.252 0.112
H = 3 0.175 0.085 0.283 0.109
H = 4 0.209 0.089 0.301 0.102
H = 5 0.227 0.091 0.321 0.100
H = 10 0.287 0.091 0.344 0.080
H = 20 0.324 0.079 0.362 0.062
Scenario 6 N = 30 N = 170
H = 2 0.102 0.064 0.158 0.096
H = 3 0.129 0.075 0.168 0.097
H = 4 0.139 0.080 0.173 0.091
H = 5 0.148 0.082 0.169 0.081
H = 10 0.164 0.082 0.169 0.065
H = 20 0.168 0.071 0.172 0.050
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Table B.11: Means and empirical standard deviations over the 1000 replications of
each scenario’s probability of the extrapolation assumption holding - High between-
trial heterogeneity
High between-trial heterogeneity
mean SD mean SD
Scenario 1 N = 30 N = 170
H = 2 0.154 0.081 0.316 0.113
H = 3 0.212 0.087 0.373 0.104
H = 4 0.255 0.093 0.410 0.098
H = 5 0.295 0.093 0.434 0.084
H = 10 0.398 0.085 0.501 0.060
H = 20 0.482 0.061 0.543 0.040
Scenario 2 N = 30 N = 170
H = 2 0.142 0.080 0.280 0.118
H = 3 0.189 0.087 0.319 0.115
H = 4 0.227 0.092 0.345 0.113
H = 5 0.257 0.099 0.374 0.105
H = 10 0.337 0.095 0.413 0.084
H = 20 0.399 0.076 0.444 0.067
Scenario 3 N = 30 N = 170
H = 2 0.112 0.075 0.217 0.117
H = 3 0.142 0.086 0.247 0.121
H = 4 0.166 0.091 0.252 0.116
H = 5 0.187 0.094 0.256 0.106
H = 10 0.231 0.089 0.274 0.091
H = 20 0.261 0.077 0.285 0.069
Scenario 4 N = 30 N = 170
H = 2 0.058 0.052 0.098 0.088
H = 3 0.064 0.057 0.089 0.078
H = 4 0.067 0.056 0.091 0.075
H = 5 0.067 0.055 0.085 0.064
H = 10 0.066 0.050 0.084 0.051
H = 20 0.070 0.035 0.074 0.033
Scenario 5 N = 30 N = 170
H = 2 0.128 0.076 0.236 0.120
H = 3 0.172 0.089 0.273 0.120
H = 4 0.205 0.096 0.287 0.114
H = 5 0.222 0.100 0.306 0.110
H = 10 0.279 0.101 0.333 0.091
H = 20 0.319 0.088 0.352 0.070
Scenario 6 N = 30 N = 170
H = 2 0.096 0.065 0.165 0.112
H = 3 0.121 0.077 0.172 0.112
H = 4 0.138 0.085 0.174 0.108
H = 5 0.142 0.085 0.172 0.097
H = 10 0.165 0.092 0.171 0.080
H = 20 0.171 0.078 0.173 0.060
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Table B.12: Means and empirical standard deviations over the 1000 replications
of each scenario’s probability of the extrapolation assumption holding - Very high
between-trial heterogeneity
Very high between-trial heterogeneity
mean SD mean SD
Scenario 1 N = 30 N = 170
H = 2 0.141 0.085 0.273 0.128
H = 3 0.199 0.098 0.332 0.125
H = 4 0.245 0.103 0.367 0.111
H = 5 0.280 0.101 0.396 0.102
H = 10 0.379 0.095 0.466 0.074
H = 20 0.464 0.072 0.520 0.053
Scenario 2 N = 30 N = 170
H = 2 0.131 0.086 0.253 0.133
H = 3 0.177 0.095 0.287 0.128
H = 4 0.208 0.102 0.322 0.124
H = 5 0.239 0.105 0.340 0.120
H = 10 0.325 0.104 0.392 0.100
H = 20 0.386 0.088 0.433 0.079
Scenario 3 N = 30 N = 170
H = 2 0.108 0.077 0.201 0.132
H = 3 0.140 0.090 0.222 0.131
H = 4 0.159 0.094 0.247 0.129
H = 5 0.182 0.108 0.240 0.120
H = 10 0.224 0.101 0.269 0.101
H = 20 0.252 0.089 0.282 0.084
Scenario 4 N = 30 N = 170
H = 2 0.061 0.062 0.097 0.098
H = 3 0.071 0.072 0.099 0.094
H = 4 0.069 0.068 0.090 0.081
H = 5 0.072 0.068 0.094 0.080
H = 10 0.070 0.058 0.085 0.057
H = 20 0.069 0.041 0.078 0.044
Scenario 5 N = 30 N = 170
H = 2 0.114 0.081 0.222 0.133
H = 3 0.156 0.091 0.257 0.130
H = 4 0.190 0.104 0.273 0.125
H = 5 0.209 0.101 0.284 0.121
H = 10 0.268 0.109 0.319 0.110
H = 20 0.315 0.097 0.347 0.085
Scenario 6 N = 30 N = 170
H = 2 0.097 0.074 0.157 0.123
H = 3 0.125 0.087 0.167 0.122
H = 4 0.132 0.091 0.172 0.120
H = 5 0.152 0.098 0.173 0.107
H = 10 0.163 0.098 0.175 0.091
H = 20 0.168 0.085 0.177 0.070
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Table B.13: Means and empirical standard deviations of the average ESS over the
1000 replications - Model 1
mean SD mean SD
Low between-trial heterogeneity N = 30 N = 170
H = 2 5.425 2.312 13.504 1.043
H = 3 7.648 2.601 17.093 1.266
H = 4 9.465 2.588 19.122 1.278
H = 5 11.394 2.503 20.478 1.084
H = 10 16.482 1.899 22.821 0.621
H = 20 20.305 1.127 23.828 0.444
Moderate between-trial heterogeneity N = 30 N = 170
H = 2 5.226 2.294 13.102 1.140
H = 3 7.549 2.577 16.305 1.663
H = 4 9.146 2.581 18.199 1.712
H = 5 11.038 2.394 19.487 1.557
H = 10 15.986 1.866 21.924 1.089
H = 20 19.807 0.997 23.292 0.576
High between-trial heterogeneity N = 30 N = 170
H = 2 5.206 2.345 12.932 1.151
H = 3 7.361 2.568 15.815 1.834
H = 4 9.176 2.567 17.544 2.138
H = 5 10.534 2.574 18.644 2.146
H = 10 15.555 1.856 21.252 1.360
H = 20 19.493 1.095 22.749 0.718
Very high between-trial heterogeneity N = 30 N = 170
H = 2 5.260 2.294 12.596 1.121
H = 3 7.232 2.546 15.197 2.229
H = 4 8.894 2.545 16.571 2.562
H = 5 10.466 2.489 17.534 2.588
H = 10 15.148 1.808 20.023 1.817
H = 20 19.039 1.28 21.936 0.902
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Appendix C
Online supplementary material to
accompany Chapter 7.
Below is the supplementary material for Chapter 7: “Exposure-
response modelling approaches for determining optimal dos-
ing rules in children” by Wadsworth I, Hampson LV, Jaki
T, Bornkamp B
This document contains the following appendices:
C.1: Worked example of methods;
C.2: Simulation scenarios in detail;




C.1 Worked example of methods
This appendix aims to give an illustration of the output that would
be seen from fitting each of the methods in Section 7.5 to a single
set of simulated data. For each of the approaches we estimate the
relationship between intercept or slope and age. For i = 1, . . . , 100
subjects, we simulate the response as:
Yi =

5.1− 0.010Ci + i, for Ai ∈ (0, 4]
4.8− 0.035Ci + i, for Ai ∈ (4, 10]
4.4− 0.075Ci + i, for Ai ∈ (10, 14]
3.9− 0.125Ci + i, for Ai ∈ (14, 18]
where the Ci exposure values are simulated as in Section 7.7 follow-
ing Wadsworth et al.209 and the i are random errors simulated from
a normal distribution with mean 0 and variance 0.02. The Ai age
values are simulated from four Uniform distributions such that there
are 25 subjects in each of four age groups: 0 to 4 years; 4 to 10 years;
10 to 14 years; and 14 to 18 years.
First, the linear model with categorical covariates as shown in Sec-
tion 7.5.1 is fitted to the simulated example data. Using the true age
groups to define A1i, . . . , AHi (the age groups used for the categorical
covariates), the following intercepts and slopes are estimated in turn
for each of the four age groups: intercept estimates are 5.13, 4.80,
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4.42 and 3.84; and slope estimates are -0.010, -0.031, -0.080 and -
0.120.
Now, we fit a single PALM tree model as described in Section 7.5.2.
Figure C.1 shows the results of a PALM tree fitted to simulated data;
this is standard output from the ‘partykit’ package.2,3 Four nodes
(here, age groups) have been found in the following age groupings: 0
to 3.89 years; 3.89 to 9.94 years; 9.94 to 14.00 years; and 14.00 to 18
years. Other than 0 and 18 (fixed based on the paediatric popula-
tion), the age group bounds are observed age values from the data;
were there an age data point less than 4, but closer to 4 than 3.89,
this age boundary could be even closer to the truth. Regardless,
these age groups are very close to the true age groups and estimate
the underlying PK-PD parameters well also. For each age group in
turn, the intercepts are 5.13, 4.80, 4.42 and 3.84 and the slopes are
-0.010, -0.031, -0.080 and -0.120. For this data, this model gives
identical estimates to the linear model with categorical covariates,
to six decimal places.
We then extend to the bootstrapped PALM trees also described in
Section 7.5.2. Figure C.2 presents plots of the bootstrapped PALM
fits of intercept and slope parameters over age constructed by fol-
lowing the approach given in Section 7.5.2. We plot the relationship
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Figure C.1: Example to demonstrate the structure of a single PALM tree fitted to
simulated data, produced from the ‘partykit’ package.2,3
between intercept or slope against age using the bootstrap averaged
median, 2.5th and 97.5th quantiles at a continuum of ages from 0 to
18 years, also highlighting the true underlying intercept/slope val-
ues by green dashed lines. The 2.5th and 97.5th quantile lines are
asymmetric as the distribution (over the bootstrap samples) of the
intercept / slope values is asymmetric at many age values from 0 to
18.
Next, we apply the B-splines approach described in Section 7.5.3.
Figure C.3 presents plots of the median, 2.5th and 97.5th quantiles of
the posterior distributions of the intercept/slope parameters at each




Figure C.2: (a) Plot of the the intercept parameter over age from the bootstrapped
PALM fit to the simulated example data, showing the median intercept, with
2.5th and 97.5th quantiles, over the 1000 simulated bootstrap samples and true
parameter values given by the green dotted lines. (b) Plot of the the slope
parameter over age from the bootstrapped PALM fit to the simulated example
data, showing the median slope, with 2.5th and 97.5th quantiles, over the 1000
simulated bootstrap samples and true parameter values given by the green dotted
lines.
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Figure C.3: (a) Plot of the the intercept parameter over age from the B-spline
fit to the simulated example data, showing the median intercept with 2.5th and
97.5th quantiles and true parameter values given by the green dotted lines. (b)
Plot of the the slope parameter over age from the B-spline fit to the simulated
example data, showing the median slope with 2.5th and 97.5th quantiles and true
parameter values given by the green dotted lines.
216
C.2 Simulation scenarios in detail
In terms of how the E-R model parameters change over age, we
consider 11 scenarios for data generation:
1. Step function relates how E-R model parameters change over
age, following ICH guidance document age groupings with sub-
stantial differences between E-R model parameter values in each
age group;
2. E-R model parameters have a less steep linear transition be-
tween age groups, with parameter values and age groups the
same as scenario 1;
3. E-R model parameter values have same change over age as in
scenario 2, though now age groups parameter values are more
similar between age groups to more closely resemble what might
be observed in reality;
4. Step function relates how E-R model parameters change over
age, as in scenario 1, but now there is a deviation from the ICH
age groups so that there are more distinct age groups amongst
younger children, following NICHD groupings;
5. E-R model parameters constant over all age groups;
217
6. E-R model parameters have a constant linear decrease over the
whole age range;
7. Intercept term as in scenario 3, slope term constant over age as
in scenario 6;
8. Intercept term constant over age as in scenario 6, slope term as
in scenario 3;
9. Same as scenario 3, though now the true age groups will be 0
to 6 months, 6 months to 3 years, 3 years to 11 years, 11 years
to 18 years;
10. Same as scenario 3, though now the true age groups will be 0
to 2 year, 2 year to 6 years, 6 years to 14 years, 14 years to 18
years;
11. Same as scenario 3, though now the true age groups will be 0
to 8 years, 8 years to 12 years, 12 years to 16 years, 16 years to
18 years.
C.3 Inclusion of additional covariate
For all scenarios in Chapter 7, the response has been modelled as
in equation (7.1) without additional covariates x1i, . . . , xPi. In this
appendix, the data are generated such that there is a relationship
between response and an additional covariate.
218
Figure C.4: Plots for the supplementary scenario showing (1) the true underlying
E-R relationship; (2) how the intercept of the E-R model changes with age; (3)
how the slope of the E-R model changes with age.
Assume we have data on body weight, xw, which is modelled as a
linear function of age; the linear relationship we use, xw = 3A+ 7, is
based on the use of weight estimation in paediatrics (1 to 13 years,
inclusive) suggested by Luscombe et al.,217 though other suggested
weight/age relationships exist. We assume that, like age, this co-
variate has an effect on response. However, as body weight here is
largely explained by age it feels more natural to regress body weight
against age and to consider the effect of the fitted residuals, rw, in the
model, essentially, what effect of body weight on response remains
after adjusting for age. We simulate the response in this example by
having the body weight residuals, rw (which have a standard normal
distribution), included in the simulation model as follows:
Yi = γ0(Ai) + 0.4rw + γC(Ai)Ci + i. (C.1)
When fitting the model, we consider two approaches: one approach
where body weight has been observed and the residuals are included
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Figure C.5: Directed acyclic graph illustrating the causal relationships between
age, observed/unobserved covariates and response.
in the model; and a variation where the effect of the body weight
residuals still exists, though body weight is now an unobserved co-
variate and not included in the model. The directed acyclic graph
shown in Figure C.5 aims to visualise this causal relationship. For
this second modelling approach, we seek to identify how the meth-
ods cope when there is an effect that we are unable to observe and
control for. We will therefore fit the models in Section 7.5 to this
scenario, modelling the PD response in two ways.
Comparing the panels in Figures C.6 representing the supplementary
scenario with and without rw, it is clear that when the additional co-
variate is included in the simulation model, but not included in the
analysis model, all approaches do not perform as well at estimating
the underlying relationship between age and the exposure-response
model slope or intercept parameters. However, the B-splines ap-
proach again seems to perform better than the other approaches in
terms of accuracy and precision.
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Figure C.6: Integrated absolute bias (blue circles) and integrated empirical SD
(red triangles) for (1) E-R model intercept; (2) E-R model slope; (3) expected
response. On the horizontal axis, ‘BS’ refers to the Bayesian penalised B-splines
approach, ‘Categorical’ the linear model adjusted for a categorical age covariate,
and ‘PALM’ and ‘singlePALM’ label the bootstrapped PALM tree approach and
single PALM tree, respectively. Panels display the supplementary scenario with
and without the additional covariate in the analysis model.
Figure C.7 shows that when the additional covariate is not included
in the analysis model, the accuracy of the K-group optimal dosing
rule is lower and the true expected response (derived from the sim-
ulation model when children are dosed according to the estimated
optimal dosing rule) is further from the target response, for both
the bootstrapped PALM trees and Bayesian penalised B-splines ap-
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Figure C.7: Integrated absolute difference between the target response and true
expected response when children are dosed according to the K group optimal
dosing rule, for the supplementary scenario. Results are shown for dosing rules
obtained modelling the E-R relationship using Bayesian penalised B-splines (solid
blue line) and bootstrapped PALM trees (dashed red line).
Figure C.8: Percentage of 1000 simulations in which K∗, the optimal number of
age groups in the dosing rule, takes each value shown. K∗ is selected according
to the algorithm described in Section 7.6.2 for Bayesian penalised B-spline (blue)
and bootstrapped PALM tree (pink) approaches. The values of K∗ chosen by
applying the algorithm in Section 7.6.2 to the true underlying E-R relationships
in the supplementary scenario are shown by the yellow bars.
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proaches. However, the Bayesian penalised B-splines approach does
seem to provide better accuracy than the bootstrapped PALM trees.
Figure C.8 shows that when the additional covariate is included in
the analysis model, the majority of simulated datasets would lead to
the investigator selecting a global optimum dosing rule with K∗ = 4,
especially for the Bayesian penalised B-splines approach.
C.4 Supplementary tables
Table C.1: True E-R model parameter values for age groupings in scenarios 1 to 5
Simulation scenario
Parameter Age group 1 & 2 3 4 5
γ0
0 to 28 days 4.85 4.60 4.60 4.50
28 days to 1 year 4.65 4.55 4.52 4.50
1 to 2 years 4.65 4.55 4.44 4.50
2 to 6 years 4.45 4.50 4.35 4.50
6 to 12 years 4.45 4.50 4.27 4.50
12 to 18 years 4.25 4.45 4.20 4.50
γE
0 to 28 days -0.045 -0.040 -0.035 -0.050
28 days to 1 year -0.055 -0.045 -0.045 -0.050
1 to 2 years -0.055 -0.045 -0.055 -0.050
2 to 6 years -0.065 -0.050 -0.065 -0.050
6 to 12 years -0.065 -0.050 -0.075 -0.050
12 to 18 years -0.075 -0.055 -0.085 -0.050
223
Table C.2: True E-R model parameter values for age groupings in scenarios 6 to
8.
Simulation scenario
Parameter Age group 6 7 8
γ0
0 to 28 days 4.700 – 4.698 4.60 4.50
28 days to 1 year 4.698 – 4.680 4.55 4.50
1 to 2 years 4.680 – 4.660 4.55 4.50
2 to 6 years 4.660 – 4.580 4.50 4.50
6 to 12 years 4.580 – 4.460 4.50 4.50
12 to 18 years 4.460 – 4.340 4.45 4.50
γE
0 to 28 days -0.050 – -0.050 -0.050 -0.040
28 days to 1 year -0.050 – -0.052 -0.050 -0.045
1 to 2 years -0.052 – -0.053 -0.050 -0.045
2 to 6 years -0.053 – -0.059 -0.050 -0.050
6 to 12 years -0.059 – -0.068 -0.050 -0.050
12 to 18 years -0.068 – -0.077 -0.050 -0.055
Table C.3: Average absolute bias, empirical standard deviation (ESD) and empir-
ical mean squared error (EMSE) for the estimated B-spline intercept/slope over
age curve, integrated over age for each scenario considered.
Intercept Slope Expected response
Scenario Bias ESD EMSE Bias ESD EMSE Bias ESD EMSE
1 0.831 0.811 0.063 0.110 0.132 0.001 21.994 21.214 2.672
2 0.720 0.790 0.045 0.103 0.125 0.001 18.879 20.195 1.927
3 0.496 0.557 0.022 0.091 0.113 0.001 14.058 16.574 1.152
4 0.644 0.726 0.036 0.122 0.145 0.001 20.405 21.440 2.355
5 0.339 0.421 0.010 0.074 0.093 0.000 10.381 13.254 0.675
6 0.571 0.706 0.030 0.100 0.126 0.001 15.568 18.994 1.439
7 0.526 0.544 0.024 0.087 0.103 0.001 12.501 15.018 0.934
8 0.346 0.434 0.011 0.083 0.100 0.001 11.940 14.354 0.877
9 0.526 0.580 0.024 0.090 0.113 0.001 14.175 16.622 1.159
10 0.557 0.611 0.027 0.097 0.123 0.001 14.946 17.706 1.305
11 0.570 0.578 0.029 0.093 0.117 0.001 14.950 17.128 1.280
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Table C.4: Average absolute bias, empirical standard deviation (ESD) and em-
pirical mean squared error (EMSE) for the estimated bootstrapped PALM inter-
cept/slope over age curve, integrated over age for each scenario considered.
Intercept Slope Expected response
Scenario Bias ESD EMSE Bias ESD EMSE Bias ESD EMSE
1 0.811 0.875 0.063 0.129 0.162 0.002 21.690 23.930 2.905
2 0.763 0.860 0.052 0.125 0.157 0.001 20.588 23.762 2.473
3 0.553 0.668 0.027 0.103 0.130 0.001 16.089 19.138 1.514
4 0.702 0.810 0.043 0.130 0.156 0.002 22.774 24.781 2.987
5 0.392 0.508 0.014 0.076 0.098 0.001 9.690 12.429 0.596
6 0.759 0.845 0.051 0.116 0.145 0.001 21.741 23.790 2.662
7 0.573 0.694 0.029 0.092 0.118 0.001 13.359 16.536 1.041
8 0.437 0.548 0.017 0.093 0.111 0.001 12.668 14.691 0.997
9 0.564 0.682 0.028 0.103 0.130 0.001 16.379 19.371 1.551
10 0.583 0.715 0.030 0.104 0.131 0.001 16.786 20.444 1.634
11 0.593 0.711 0.032 0.105 0.132 0.001 16.923 19.635 1.733
Table C.5: Average absolute bias, empirical standard deviation (ESD) and empiri-
cal mean squared error (EMSE) for the estimated single PALM tree intercept/slope
over age step function curve, integrated over age for each scenario considered.
Intercept Slope Expected response
Scenario Bias ESD EMSE Bias ESD EMSE Bias ESD EMSE
1 0.821 1.051 0.076 0.142 0.183 0.002 21.921 28.674 3.548
2 0.856 1.086 0.073 0.143 0.181 0.002 23.066 29.816 3.434
3 0.689 0.825 0.041 0.116 0.148 0.001 21.454 25.290 2.514
4 0.942 1.117 0.078 0.166 0.205 0.003 32.076 37.016 5.766
5 0.340 0.446 0.011 0.069 0.088 0.0004 8.686 11.151 0.480
6 1.070 1.174 0.097 0.141 0.179 0.002 31.382 34.460 5.209
7 0.760 0.905 0.048 0.097 0.129 0.001 16.499 20.326 1.490
8 0.391 0.512 0.015 0.106 0.111 0.001 15.696 15.713 1.472
9 0.711 0.848 0.043 0.118 0.150 0.001 22.087 25.688 2.645
10 0.742 0.896 0.048 0.119 0.149 0.001 22.596 26.905 2.858
11 0.689 0.837 0.044 0.116 0.149 0.001 20.588 24.893 2.607
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Table C.6: Average absolute bias, empirical standard deviation (ESD) and empir-
ical mean squared error (EMSE) for the estimated intercept/slope over age step
function curve based on the categorical covariates model approach, integrated over
age for each scenario considered.
Intercept Slope Expected response
Scenario Bias ESD EMSE Bias ESD EMSE Bias ESD EMSE
1 0.645 0.819 0.037 0.133 0.172 0.002 16.881 21.832 1.868
2 0.729 0.837 0.048 0.138 0.177 0.002 19.589 22.973 2.419
3 0.648 0.807 0.037 0.134 0.170 0.002 17.299 21.917 1.910
4 0.837 0.889 0.062 0.165 0.200 0.003 26.975 25.637 4.257
5 0.657 0.823 0.038 0.135 0.172 0.002 17.434 22.263 1.929
6 0.996 0.904 0.086 0.162 0.198 0.002 29.114 25.421 4.722
7 0.664 0.827 0.039 0.137 0.179 0.002 17.761 23.049 2.094
8 0.651 0.821 0.037 0.137 0.176 0.002 17.628 22.626 2.020
9 0.708 0.845 0.044 0.141 0.180 0.002 19.509 23.098 2.398
10 0.776 0.851 0.054 0.150 0.186 0.002 23.047 23.907 3.179
11 0.765 0.867 0.051 0.152 0.190 0.002 22.264 24.177 2.971
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C.5 Supplementary plot
Figure C.9: True underlying E-R relationships for scenarios 1 to 5, 7 and 8, as
described in Appendix C.2.
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